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ABSTRACT

ZIRCONIUM-89: RADIOCHEMISTRY AND LIGAND DEVELOPMENT TOWARD
IMPROVED PET APPLICATIONS
by
Melissa Ann Deri

Advisors: Professor Lynn C. Francesconi & Professor Jason S. Lewis

Antibodies are attractive targeting vectors for positron emission tomography (PET) based
imaging agents due to their high affinity and selectivity to a variety of biological targets.
Creating such imaging agents requires a radionuclide with suitable decay characteristics. This
role has been filled by zirconium-89 which has a 78.41 h half-life that ideally matches the multiday biological half-life of IgG antibodies.
However, the use of a radiometal necessitates the use of a bifunctional chelator to bind
the metal and conjugate to the antibody. For 89Zr this has been the purview of various derivatives
of desferrioxamine B (DFO); however, the observed uptake of radioactivity in the bones of mice
is evidence of in vivo release of 89Zr4+. A more robust chelator designed specifically around the
chemistry of Zr4+ could eliminate the release of the bone-seeking 89Zr4+ cation in vivo and thus
make for a safer, more effective PET tracer with reduced dose to non-target tissues.
The investigation of alternative ligands will be described with an emphasis on the lead
compound: a hydroxypyridinone based chelator — 3,4,3-(LI-1,2-HOPO) or HOPO. The
iv

evaluation of the chelator itself will be detailed leading to the development of a bifunctional
derivative — p-SCN-Bn-HOPO — that can be applied within the world of PET imaging.
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CHAPTER 1: INTRODUCTION
This chapter is an adaptation of published work, and is reproduced in part, from Deri, M. A.;
Zeglis, B. M.; Francesconi, L. C.; Lewis, J. S. PET Imaging with 89Zr: From Radiochemistry to
the Clinic. Nucl. Med. Biol. 2013, 40, 3-14, Copyright 2012 Elsevier Inc.

1.1:

Introduction
The exquisite specificity and affinity of antibodies have made them extremely attractive

candidates for cancer therapeutics and drug delivery agents.1 Consequently, over the past two
decades, considerable effort has been invested into the construction and development of
antibody-based imaging agents as companion diagnostics for the characterization, treatment
planning, and treatment monitoring of cancer.2 Positron emission tomography (PET) is a
quantitative, non-invasive, whole-body imaging technique which provides excellent sensitivity
and high resolution images for medical applications.3, 4 It is an extremely valuable clinical tool in
the practice of personalized medicine and for monitoring tumor response following therapy. The
combination of antibody-based targeting and PET-based imaging is known as immunoPET and
is a powerful formula for highly selective, highly sensitive imaging agents.
Importantly, one of the most fundamental principles in the construction of effective
antibody-based nuclear imaging agents is matching the physical half-life of the radioisotope to
the pharmacokinetic half-life of the immunoglobulin.5 Generally, intact antibodies have
relatively slow pharmacokinetics, often requiring multiple days to reach their optimal
biodistribution within the body. As a result, up until just a few years ago, the exigency of
matching physical and biological half-lives has led 111In, 99mTc, 67Ga, 86Y, 64Cu, and 124I  with
1

half-lives of 2.80 d, 6.0 h, 3.26 d, 14.74 h, 12.70 h, and 4.18 d, respectively  to be the most
often employed radioisotopes for antibody-based nuclear imaging agents.6
Each of these isotopes, however, possesses characteristics that ultimately limit their
suitability for clinical antibody-based imaging.

64

Cu, for example, has been employed

successfully as a radiolabel for antibodies in numerous pre-clinical studies in rodents, but its 12.7
h half-life is ultimately too short to prove effective under the slower pharmacokinetic conditions
of imaging in humans.7-10 Y-86 likewise possesses a half-life that is too short for human imaging
and also adds the limitations of sub-optimal decay characteristics and difficult radionuclide
production and purification protocols. I-124, in contrast, has a near ideal half-life for antibodybased imaging and has thus long been the radionuclide of choice for immunoPET.11, 12 However,
the expense of the isotope, its relatively low resolution due to the high energy of its positrons,
and the significant dehalogenation of 124I-labeled antibodies in vivo combine to limit its ultimate
clinical potential. Finally, while

111

In and

67

Ga also boast favorable physical half-lives and

behavior for antibody-based applications, they emit gamma rays rather than positrons, which
place them in the world of SPECT imaging. The inherent limitations of SPECT relative to its
higher resolution and quantitative cousin, PET, have resulted in a far greater interest in the
clinical translation of immunoPET agents. Tc-99m, of course, combines the aforementioned
limitations of SPECT imaging with a half-life that is regarded as too short for antibody imaging.
The desire to find a more suitable radioisotope for antibody-based imaging has been the
driving force behind the tremendous surge in research into

89

Zr-based imaging in recent years,

largely pioneered by the laboratories of Elisabeth de Vries and Guus van Dongen in the
Netherlands, among others.13-16 Indeed,

89

Zr has almost ideal physical characteristics for

antibody-based imaging, with a half-life of 78.4 h and a relatively low positron energy of
2

395.5 keV, and its advantages over the alternatives are manifold: its physical half-life is better
suited to antibody-based imaging than that of 64Cu or 86Y, particularly in the clinic; it is safer to
handle, cheaper to produce, more stable in vivo, and residualizes in tumors far more effectively
124

than

I; additionally, its emission of positrons rather than single photons allows for higher

resolution, quantitative imaging.17, 18 Taken together, these characteristics have spurred the rise
of

89

Zr from obscure positron-emitting radiometal less than ten years ago to what is fast

becoming the isotope of choice for both pre-clinical and clinical immunoPET imaging. It is also
important to note that while antibodies represent perhaps the most significant and promising
application of

89

Zr, the isotope may also prove extremely useful with other types of targeting

vectors, particularly nanoparticles with slow pharmacokinetics and peptides for which longer
imaging studies may prove informative.
In the following pages, we hope to provide a comprehensive review of the rapidly
growing field of 89Zr-based PET imaging. It would be remiss not to mention that other excellent
reviews on

89

Zr currently exist in the literature written by Vugts and van Dongen at Vrije

University in the Netherlands and Severin and Nickles at the University of Wisconsin.19, 20 Our
more comprehensive review stands apart from these, however, as the former focuses primarily
on

89

Zr radiochemistry while the latter primarily addresses conjugation methodologies. In the

following pages, we will strive to cover a wide range of topics, ranging from 89Zr production and
purification to the design and bioconjugation of chelators for

89

Zr to the most recent clinical

imaging studies. Ultimately, it is our hope that this review will provide an in-depth portrait of the
current state of the field, illustrate both the successes and limitations of 89Zr-based imaging, help
identify specific areas that are in need of additional research, and, in so doing, prove useful to the
scientist new to the field and veteran investigator alike.
3

1.2:

Decay Characteristics
Any discussion of PET imaging with

of the decay of the isotope17,

21-24

.

89

89

Zr must necessarily begin with the fundamentals

Zr decays with a half-life of 78.41 h via both positron

emission and electron capture to an intermediate 89mY state which in turn decays to stable 89Y via
a gamma ray emission (909 keV) with a half-life of 15.7 s (Figure 1.1). The relatively low
translational energy of the emitted positrons, 395.5 keV, results in high image resolution, and the
energy disparity between the 511 keV photons and the 909 keV prevents the latter from
interfering with the detection of the coincident photons. Importantly, the suitability of the
decay characteristics for imaging markedly contrasts with

124

89

Zr

I, which emits much higher energy

positrons (687 and 974 keV) and also emits a number of photons with energies within 100-150
keV of the positron-created 511 keV 18. Both phenomena combine to grant 89Zr noticeably better
resolution than its halogen competitor.
1.3:

Production and Purification
89

Zr has been produced on a cyclotron via both the

89

Y(p,n)89Zr and

89

Y(d,2n)89Zr

reactions.17, 20, 22, 25-27 In both cases, these routes provide the added advantage of employing a 89Y
metal target that is commercially available, non-reactive, and in 100% natural abundance, which
drives down costs and precludes the need for cumbersome recycling of the target. For the
deuterium reaction, a minimum beam energy of 5.6 MeV is required.27 In practice, the proton
reaction is the much more popular of the two and typically employs proton beams at or above 14
MeV, though early reports employed beams of 13 MeV. In both cases, the avoidance of the
isotopic impurity 88Zr by inadvertent (p, 2n) or (d, 3n) reactions, respectively, poses a particular
concern, for both

88

Zr (t1/2 = 83.4 d) and its daughter

88

Y (t1/2 = 106 d) are potentially

complicating impurities.26, 27
4

Figure 1.1. (A) A simplified decay scheme of 89Zr; (B) Some salient decay characteristics of
89
Zr; (C) Photograph of the custom-made water-cooled solid-target assembly for the TR19/9
cyclotron used at Memorial Sloan Kettering Cancer Center; (D) A static 10 minute PET image
recorded by using a Derenzo phantom, with corresponding hole diameters in mm. (C) and (D)
are modified and reprinted from Holland, et al. Nuclear Medicine and Biology 2009; 36:729-39.

5

The isolation and purification of

89

Zr have been subjects of considerable interest.

Methods ranging from solvent extraction to anion exchange chromatography have been
employed, though weak cation exchange chromatography using hydroxamate-modified resin has
emerged as the method of choice 22, 25, 27-29. Using this method, the 89Zr is loaded onto a column
of hydroxamate resin in 2 M HCl, washed with additional 2 M HCl and metal-free water, and
eluted in a 1.0 M oxalic acid solution that can then be employed for radiolabeling reactions. As a
practical example of the techniques for production and purification described above, at our
institution, Memorial Sloan Kettering Cancer Center in New York City, 89Zr is produced via the
89

Y(p,n)89Zr reaction using a

89

Y thin-foil target (99% purity, 0.1 mm width) using a 15 MeV

proton beam and a 10 angle of incidence to the target. Using these conditions and the
hydroxamate resin purification methodology described above,

89

Zr oxalate is produced reliably

and reproducibly in high specific activity (470–1195 mCi/mmol) and radionuclidic purity
(>99.99%).17
1.4:

Zirconium Chemistry
As we progress, a fundamental understanding of the aqueous chemistry of zirconium is

critical, both to better evaluate the coordinative relationship between the zirconium cation and its
chelator and to provide insight into the possible behavior of the metal if it were released from its
chelate in vivo.
1.4.1:

Basics

Zirconium is a group IV metal, which exists primarily as a +4 ion in aqueous solution.
This Zr4+ cation is a relatively large, highly-charged ion which typically forms coordination
complexes with high coordination numbers, and, as a ‘hard’ cation, typically prefers anionic
oxygen donors.30 The effective ionic radius of the Zr4+ cation with a coordination number of
6

eight is 0.84 angstroms.31 The complexity of aqueous zirconium chemistry has led to somewhat
limited study of the area. Oxides and hydroxides of zirconium exhibit very poor solubility in
water, less than 10-8 M, as well as pH-dependent changes in speciation. At very low pH, less than
zero, zirconium forms polynuclear species upon hydrolysis, while under slightly less acidic
conditions, between zero and two, mononuclear hydrolysis species predominate. However,
around pH two, the solubility of the zirconium species decreases and precipitation can occur.32
Even at very low pH, delicate equilibria exist between different polynuclear zirconium species
and slight changes in pH can lead to aggregation.33 In contrast to the zirconium hydroxide
species, Zr4+ salts of halides, perchlorate, and sulfate are soluble in acidic solution. 30
Outside of its radioisotopic applications that form the focus of this review, zirconium is
heavily used in ceramics, some of which are used in medical prosthetic applications, in the form
of zirconia or ZrO2.34 Additionally, due to the low neutron capture cross section of zirconium,
its metal alloys are used for cladding in nuclear reactors. However, the predominant use of
zirconium in chemistry is in the application of organometallic catalysis including olefin
metathesis35, ring-opening polymerizations36, aminoalkene hydroamination37, and other
reactions.38-40 For different catalytic and waste separation purposes, a number of different
zirconium coordination complexes have been studied, however, in the context of the construction
of

89

Zr-labeled bioconjugates for PET, only a handful of stable, aqueous, bio-compatible

complexes are appropriate.
1.4.2:

Chelation

The foundation of any biomolecular PET tracer lies in the formation of a stable
radiometal chelate. To date, a number of different aqueous chelators have been employed with

7

zirconium (Figure 1.2), of which desferrioxamine B (DFO) has become by far the most
successful and oft-employed.
Prior to the development of any specialized ligands for Zr4+, the majority of research into
the coordination chemistry of Zr employed some of the most commonly used bifunctional
chelates: ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA),
and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Crystal structures have
been obtained for Zr-EDTA 41 and Zr-DTPA 6, and a solution structure has been obtained in the
case of Zr-DOTA using NMR methodologies

42

. Despite the differences in chelators, each

structure indicates a coordination number of eight. EDTA binds zirconium through two nitrogen
atoms, four oxygen atoms, and two exogenous water molecules, whereas both DTPA and DOTA
coordinate the metal using solely the constituent atoms of the ligand: three nitrogens and five
oxygens for DTPA and four of each atom for DOTA. The log K values for thermodynamic
stability constants are reported as 29.4 for Zr-EDTA at 25oC in water and an ionic strength of 0.1
and 35.8 for Zr-DTPA at 20oC at water and an ionic strength of 0.23, but remain unreported for
Zr-DOTA.43 The higher thermodynamic stability of Zr-DTPA is most likely due to the fact that
DTPA coordinatively saturates the Zr4+, in contrast to EDTA which requires two exogenous
water molecules to complete the coordination sphere. Despite this, an attempt to radiolabel an
antibody using DTPA as the chelator resulted in less than 0.1% successful labeling.44
A different tactic for finding chelators came from the study of siderophores or natural
iron-chelating molecules produced by bacteria. The most prominent chelator of Zr4+ currently
employed, desferrioxamine (DFO), is an example of a hexadentate, bifunctional siderophore with
three hydroxamate groups for chelating metals and a primary amine tail which can be modified
for

conjugation

to

a

biomolecule.

Investigations

in

the

1960s

involving

the
8

Figure 1.2. The ligand structure, coordination scheme, and experimental structure of some
commonly-employed chelators for Zr4+ and their complexes with the metal.

9

reprocessing of nuclear fuel found that zirconium had an affinity for hydroxamic acid groups,
displaying stability constants of β1=2.7×1012 and β2=1.2×1024 with respect to benzohydroxamic
acid.45 It follows, then, that the presence of the hydroxamate groups in DFO would make it a
suitable and effective chelator for Zr4+, and indeed, the success of the vast majority of 89Zr-based
PET imaging is a testament to the value of DFO as a chelate. In one of the earliest investigations
into the utility of

89

Zr as a PET radionuclide, Meijs and co-workers reported that DFO exhibits

rapid and efficient labeling with a 1:1 ratio of metal to chelate and demonstrates good stability
with regard to demetallation, releasing less than 0.2% of the metal in serum after 24 hours.46
Further evaluation of the complex by Holland and coworkers utilizing density functional theory
(DFT) models Zr-DFO as an octadentate complex combining the six binding oxygens of DFO
with two additional water molecules. Also, stability studies over longer periods of time indicated
that still less than 2% demetallation occurs after seven days in serum.47 Unfortunately, thus far,
neither physical structural studies nor thermodynamic stability constants have been reported for
Zr-DFO.
While DFO is by far the most widely used zirconium chelator and behaves reasonably
well in vivo, there is a growing school of thought that an even better ligand could be designed
and synthesized. The most basic argument here is that zirconium favors octadentate coordination
and the DFO ligand itself only offers hexadentate chelation. As discussed above, DFT modeling
of DFO and Zr4+ that suggests two water molecules are bound to the zirconium in addition to
DFO reinforces this idea. A ligand that incorporates all eight binding sites for Zr4+ should benefit
from the preorganization of the coordination environment and thus should demonstrate superior
stability compared to DFO when complexed with 89Zr. However, initial experiments with ligands
such as EDTA, DTPA, and DOTA illustrated that these ligands, despite achieving higher
10

coordination numbers, form complexes with lower stability compared to DFO.43, 44 While not
proven, the reduction in stability in these cases is likely due to the additional chelation arising
from nitrogen atoms, rather than the oxygen donors preferred by the oxophilic Zr4+cation.
Ultimately, it is believed that the ideal solution for stable Zr4+ chelation would be a ligand that is
both octadentate and oxygen-rich. More specifically, catechols, hydroxypyridinones, and
hydroxamates are likely candidates for promising binding groups. The design, synthesis, and
evaluation of novel, high-stability Zr4+ ligands is a topic ripe for investigation.
1.5:

Conjugation Chemistry
With the selection of a targeting vector and radiometal-chelate pair comes the necessity

for a method to covalently link the units together. In the case of 89Zr, the overwhelming majority
of bioconjugates have utilized DFO as the chelator, so that will be the focus of the following
discussion. The conjugation of DFO to an antibody or other construct has been achieved in a
variety of ways: exploiting thiol linkages, amide couplings, and even click chemistry (Figure
1.3). Taken together, these conjugation techniques are based most frequently on the reaction of
an activated bifunctional chelator with a lysine or cysteine residue of the protein.
1.5.1:

Early work

Some of the earliest work of attaching DFO to an antibody comes not from the zirconium
literature, but rather from past work on

67

Ga-based radiopharmaceuticals. In these cases,

conjugation was accomplished by modifying both the primary amine of a lysine residue on an
antibody and the amine tail of DFO with hetero-bifunctional agents and then joining the units
together.48 For example, the modification of each piece with N-succinimidyl-3-(2-pyridyldithio)
propionate

(SPDP)

allows

for

the

formation

of

a

disulfide

linkage

and

11

Figure 1.3. Schematic of some common DFO conjugation strategies.
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N-(6-maleimidocaproyloxy)succinimide (EMCS) can be used to attach a maleimide functionality
to DFO which could then be connected to a thiolated antibody. Alternatively, a homobifunctional agent such as glutaraldehyde can be used to connect the antibody and chelate in one
step. This method, however, comes with the risk of the antibody linking to itself and forming
polymers instead of creating one to one antibody-chelate complexes.48 With the advent of 89Zr as
a radionuclide for PET imaging came an increased interest in DFO-antibody conjugation. At this
time, the notion of attaching hetero-bifunctional agents to both the antibody and DFO was still
prevalent, but now two different agents were used, namely N-succinimidyl-S-acetylthioacetate
(SATA) to append the antibody and succinimidyl 4-(N-maleimidomethyl)cyclohexane- 1 carboxylate (SMCC) to modify DFO. These two structures could then be combined through the
formation of a succinimide ring-thioether bond.49 However, it was later shown that such a
linkage was unstable at physiological pH.50
1.5.2:

Lysine methods

A major breakthrough was made by Verel and coworkers with the introduction of a new
conjugation method utilizing an activated 2,3,5,6-tetrafluorophenol (TFP) ester of DFO that
could be coupled to the unmodified, native lysine side-chains of an antibody. This involves a five
step procedure which includes the extension of DFO with succinyl anhydride, the protection of
the ligand’s hydroxamate groups with Fe(III), the formation of the activated TFP ester,
conjugation to the unmodified antibody, and removal of the iron to free the chelate for
radiolabeling.29 Conjugation in this manner with Fe-coordinated TFP-N-succinylDFO (N-sucDFO) offers a reliable procedure to form a stable linkage without the need to pre-modify the
antibody with its own bifunctional moiety and has to date been the most prevalent conjugation
method used in preclinical

89

Zr PET imaging. More recently, Perk and Vosjan et al. introduced
13

an even simpler method using a p-isothiocyanatobenzyl-bearing DFO (DFO-Bz-NCS). This
commercially available chelate can be attached to the lysine residues of an unmodified antibody
in one step, forming a stable thiourea linkage between chelator and biomolecule.51, 52 In only the
few years that the isothiocyanate derivative has been available, it has been gaining popularity
due to its simplicity. However, it is not a perfect solution, primarily due to the water insolubility
of the p-isothiocyanatobenzyl-DFO precursor, which requires more finesse than the
straightforward N-suc-DFO chemistry.
1.5.3:

Thiol methods

A significant concern with regard to the lysine-based conjugation methodologies is that
nonspecific attachment of a chelator to an antibody has the potential to hinder immunoreactivity
by attaching the chelate at an antigen-binding site. In response to this problem, increasing
attention has been dedicated to the development of site-specific conjugation strategies using
engineered cysteine residues. In the most prevalent example of this approach, the thiol-reactive
DFO derivatives bromoacetyl-desferrioxamine (DFO-Bac), iodoacetyl-desferrioxamine (DFOIac) and maleimidocyclohexyl-desferrioxamine (DFO-Chx-Mal) were constructed and then
attached to cysteine residues designed into non-bioactive sites on an antibody. Both DFO-Bac
and DFO-Iac attach to the cysteine through nucleophilic substitution reactions, whereas DFOChx-Mal undergoes a Michael addition with the residue. The resulting radiolabeled antibodies
were found to be stable and demonstrated imaging characteristics analogous to the lysine-linked
complexes. In the models tested, however, no significant advantage in immunoreactivity was
demonstrated for site-specific conjugation.53
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1.5.4:

Click methods

Very recently, the use of click chemistry has emerged as a specialized conjugation
method to expand the scope of 89Zr PET imaging possibilities. A click strategy using an inverse
electron demand Diels-Alder reaction between the strained dienophile norbornene and 3-(4benzylamino)-1,2,4,5-tetrazine has been harnessed by coupling a norbornene functionality to
lysine residues of an antibody and attaching a tetrazine to DFO. The benefit of this type of click
chemistry is that it allows for modularity, allowing researchers to switch out different chelatorradiometal pairs or different antibodies while still maintaining the same overall conjugation
methodology.54 Another click-based strategy attempted to take advantage of the Staudinger
ligation between azides and phosphines for use in pre-targeting experiments by reacting azidemodified antibodies with phosphine-containing radiometal-chelate complexes such as 89Zr-DFOphosphine. Unfortunately however, the Staudinger ligation was found thus far to be incompatible
in vivo.55
1.5.5:

Choosing a Conjugation Strategy

With such a variety of methods, it becomes important to select a conjugation method that
fits the task at hand. In most cases, the N-suc-DFO or DFO-Bz-NCS methods are more than
adequate, and while the most commonly used conjugation method is currently the N-succinylDFO TFP ester, one would expect that the already increasing use of the p-isothiocyanate method
will only become more widespread due to the fact that it is a more rapid and facile method and it
employs commercially available starting materials. More specialized situations, however, may
call for other routes. For example, the site specific system is particularly appropriate in cases
where the loss of immunoreactivity is a concern, and the click methodology may prove
beneficial where modularity is desired. As the field continues to expand and 89Zr-based imaging
15

moves further into the mainstream, it is hoped that new methodologies will be developed that
may combine the convenience of a commercially available starting materials with some of the
benefits of the other systems.
1.6:

Zirconium Biochemistry
Moving from the test tube to the body, the behavior of free Zr4+ within biological systems

has been studied in order to gauge the safety of using

89

Zr as a PET tracer as well as to better

understand the fate of the radionuclide in the case of metabolism of parts of the
radiopharmaceutical. This is especially important in the case of zirconium because of the high
affinity of Zr4+ for bone.
1.6.1:

Biodistribution

The normal composition of the human body includes small amounts of zirconium found
in fat, liver, and gall bladder tissue, as well as trace amounts in the brain. Excretion of zirconium
from food and water intake is thought to involve the hepatobiliary system and results in
hepatobiliary, rather than urinary, excretion.34 The fate of non-dietary zirconium, however, is
less straightforward and depends upon the chemical speciation of the metal cation as well as
perhaps the organism into which it is administered.
An example of the clearance mechanism and rate varying between species can be seen
when Zr4+ is complexed by citrate. In rats, 80-90% of Zr-citrate is rapidly excreted in the urine
within 24 hours56, while in mice, only 30% of Zr-citrate was cleared within 24 hours.57 In an
early study of 89Zr-citrate in man, activity was only found in the plasma of blood and zirconium
was shown bound to serum proteins. This study, however, showed low urinary excretion of the
activity.58
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When a complex, such as Zr-chloride, is poorly defined or understood, its biological
behavior is often unclear as well. For example, one study found that Zr-chloride accumulates in
the liver, which suggests it is in a colloidal form17, while another study using a different
preparation method of Zr-chloride showed no accumulation in soft tissue.57 More stable
complexes lead to more straightforward biodistribution data. Zr-phosphate does not demonstrate
significant clearance from the body, but instead collects in the liver and spleen most likely due to
precipitation.57 Zr-DFO is cleared extremely quickly through the kidneys and can be excreted
through the urine in a matter of minutes.17, 49
Overall, the key to consistent biodistribution and fast, dependable clearance largely rests
on the stability and control of the complexation. The stable, organized chelation of Zr-DFO
exhibits clear, predictable biological behavior, while the complicated and uncertain speciation of
lower denticity complexes leads to problematic or complex biological behavior.
1.6.2:

Bone uptake

Zirconium is a bone seeker and so, when not tightly bound to a chelate, accumulates
preferentially in bone in both rats59,

60

and mice57,

61

. This is a particularly important

consideration in the nuclear medicine community, as the accumulation of high levels of
bone during clinical scans may act as a dose-limiting characteristic of

89

89

Zr in

Zr PET agents. A

comparison of bone uptake from different zirconium species demonstrates that as the denticity
and stability of the complexes increases, the bone uptake decreases since the osteophilic Zr4+
cation is not released. In practice, this trend translates to the highest bone uptake observed upon
the injection of Zr-chloride, followed by Zr-oxalate, then Zr-citrate, and lastly Zr-DFO with
significantly less bone uptake (Figure 1.4). Notably, Zr-phosphate does not show considerable
bone uptake comparatively. Additionally, the bone marrow is responsible for much less than one
17

Figure 1.4. (A) Biodistribution of radioactivity at 6 days post-injection following i.v.
administration of various chemical form of 89Zr in female NIH Swiss mice (n ≥ 3; note the axis
break). Reprinted with permission from Abou, et al. Nuclear Medicine and Biology
2011;38:675-81. (B) PET images showing maximum intensity projection of 89Zr-oxalate at 24 h
after intravenous administration and dynamic PET images of 89Zr-DFO at 1 and 4 min after
injection. Adapted with permission from Holland, et al. Journal of Nuclear Medicine 2010; 51:
1293-300.
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percent (0.1%) of the activity of the bone, while the calcified tissue comprises the bulk of the
zirconium uptake with 33% concentrated in the epiphyses.57 Since free Zr4+ is responsible for the
observed bone uptake, a more stable chelate for zirconium should further limit the observed bone
activity. It is worth noting that early clinical trials with

89

Zr do not demonstrate the extent of

bone uptake exhibited in preclinical images.
1.7:

Preclinical Applications
In the past decade, the use of 89Zr for small animal PET imaging has become increasingly

widespread and a considerable amount of work has been undertaken at a variety of different
institutions (Table 1.1). By far the most prevalent use of
antibodies due to the favorable match up of the half-life of

89

89

Zr lies in the radiolabeling of

Zr and the circulation time of IgG

antibodies.
1.7.1:

ImmunoPET

The ability to image a radiolabeled antibody several days after its injection allows for
vastly improved image contrast due to decreased background signal. As a residualizing isotope,
89

Zr remains inside cells once the antibody-antigen complex is internalized, allowing activity to

accumulate and concentrate in tumors while non-localized activity clears from the body,
ultimately resulting in high contrast images. An analysis of each of the individual preclinical
studies would, of course, be outside of the scope of this chapter; instead, we will provide a few
interesting examples to demonstrate the utility of 89Zr in different areas of the preclinical arena.
The potential use of

89

Zr immunoPET to monitor and predict the effectiveness of therapy has

been demonstrated by Nagengast and co-workers in ovarian cancer using 89Zr-bevacizumab and
the HSP90 inhibitor NVP-AUY922.62 HSP90 inhibition has an antiangiogenic effect and leads to
a downstream reduction in the secretion of VEGF which, as this work shows, can be effectively
19

Targeting Moiety

Target

Type of cancer

Conjugation
Method

References

Cetuximab

EGFR

Multiple

N-suc-DFO

63-66

Bevacizumab

VEGF

Squamous cell head and neck
carcinoma, ovarian, breast

N-suc-DFO

64, 67-69

Trastuzumab

HER2

Breast, ovarian

N-suc-DFO

23, 62, 69, 70

J591

PSMA

Prostate

N-suc-DFO

47 71

cmAb U36

CD44v6

Head and neck squamous
cell carcinoma

N-suc-DFO

72, 73

5A10

fPSA

Prostate

N-suc-DFO

60

cG250

MN/CA IX

Renal cell carcinoma

N-suc-DFO

74

R1507

IGF-1R

Triple-Negative Breast

N-suc-DFO

75

Fresolimumab

TGF-b

Multiple

N-suc-DFO

76

DN30

Met

Gastric, head and
Neck

N-suc-DFO

77

7E11

PSMA

Prostate

N-suc-DFO

78

hRS7

EGP-1

Prostate

N-suc-DFO

79

Panitumumab

HER1

Colorectal

DFO-Bz-NCS

80

TRC105

CD105

Breast

DFO-Bz-NCS

66

Anti-B220

B cells

Unspecified

DFO-Bz-NCS

81

E48 and 323/A3

Unspecified
surface antigens

Head and neck squamous
cell carcinoma

SATA/SMCC
thioether

61

(aHGF)-Nanobodies

HGF

Glioma

DFO-Bz-NCS

82

Ranibizumab (Fab)

VEGF-A
isoforms

Ovarian

N-suc-DFO

83

cG250-F(ab9)2

CAIX

Head and neck carcinoma

N-suc-DFO

84

Peptides

c(RGDfK) with and
w/o PEG

Integrin αvβ3

Breast

DFO-Bz-NCS

85

Nanomaterials

Albumin

n/a

Prostate

N-suc-DFO

86

resin microspheres
and SIR-Spheres

n/a

Liver

n/a

87

nanocolloidal
albumin

n/a

Head and Neck

DFO-Bz-NCS

88

Dextran
Nanoparticles

macrophages

Colon

DFO-Bz-NCS

89

Colon adenocarcinoma

N-suc-DFO

90

Antibodies

Antibody
fragments

Single wall carbon VE-cad based on
nanotube
attached antibody
E4G10

Table 1.1. Summary of pre-clinical imaging studies using 89Zr-based imaging agents.
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imaged with

89

Zr-bevacizumab. The decrease in

89

Zr-bevacizumab uptake in A2780 xenografts

after treatment with NVP-AUY922 corresponds to the decrease in VEGF levels due to HSP90
inhibition, as confirmed by in vitro experiments (Figure 1.5). Additionally, no such change in
uptake was found with CP70 tumors which are known to not respond to AUY922 therapy.
Hence,

89

Zr-bevacizumab acts as an early biomarker for the effectiveness of HSP90 inhibition

and allows for in vivo visualization and quantification of early antiangiogenic tumor response.67
One recent study demonstrating immediate clinical relevance for castration-resistant prostate
cancer was conducted by Ulmert, Evans, and colleagues, who developed a

89

Zr-labeled 5A10

antibody targeting free prostate specific antigen (fPSA) that was shown to be able to track
intratumoral androgen receptor (AR) signaling due to testosterone levels or pharmacological
triggers such as antiandrogen MDV3100 (Figure 1.6).91 The clinical importance of PSA levels
and the changes thereof has been thoroughly investigated and the ability to non-invasively
monitor these changes in the tumor environment could prove greatly beneficial. 89Zr-5A10 is not
only able to provide diagnostic imaging of a tumor, but can be used to trace disease progression
and evaluate treatment response. Additionally, and importantly, in contrast to clinically used
radiotracers such as

99m

Tc-MDP or 18F-NaF, 89Zr-5A10 was able to differentiate cancerous bone

metastases from normal bone repair. The ability of this radiotracer to evaluate therapeutic effects
and AR-driven tumor activity on the level of individual lesions could be of great value
clinically.60
1.7.2:

Non-Antibody Applications

While immunoPET applications make up the majority of the literature regarding

89

Zr-

based PET imaging, there is also a growing amount of research into the development of

89

Zr-

labeled nanomaterials. One such study consists of nanoparticles made up of cross-linked, short
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Figure 1.5. Representative transversal and coronal small animal PET images of 89Zrbevacizumab obtained before treatment of A2780 (A) and CP70 (B) xenografts (left) and after
NVP-AUY922 treatment (right). Images were obtained at 144 h after injection of 89Zrbevacizumab. Tumor is indicated by arrow. Reprinted with permission from Nagengast, et al.
Journal of Nuclear Medicine 2010; 51: 761-767.
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Figure 1.6. 89Zr-5A10 detects pharmacologic inhibition of AR in vivo Left: representative
transverse and coronal PET slices of intact male mice bearing LNCaP-AR xenografts on the right
flank and imaged with 89Zr-5A10 24 hours post-injection after manipulation with a subcutaneous
testosterone pellet or a daily oral gavage of vehicle or MDV3100 for 7 days. Arrows indicate
the position of the tumor (T) and the murine liver (L). Right: region-of-interest analysis of the
tumors from the PET study shows statistically significant changes in tumor-associated 89Zr5A10. *P , 0.01 compared with vehicle. **P , 0.05 compared with vehicle. Error bars represent
the standard deviation from mean. Reprinted with permission from Ulmert, et al. Cancer
Discovery 2012; 2(4): OF1–OF8.
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chain dextran that were conjugated to p-isothiocyanate DFO for radiolabeling with

89

Zr. These

dextran nanoparticles (DNPs) are used as imaging probes for macrophages as they are engulfed
by mononuclear phagocytic cells. The optimal DNPs tested had an average diameter of 13
nanometers and were surface modified through succinylation to achieve a blood half-life of 3.9
hours. The 89Zr-labeled DNPs were used to image and quantitate tumor-associated macrophages
(TAMs) in mice with colon carcinoma xenografts. The resulting PET images showed significant
tumor uptake and histology confirmed the co-localization of TAMs and the 89Zr-labeled DNPs at
the microscopic level. This methodology represents a step forward in the imaging and
understanding of macrophage and inflammation levels associated with cancer and is expected to
be helpful in several applications including the evaluation of cancer therapies using
antimacrophage strategies.89
1.7.3: Challenges
As a longer-lived medical radionuclide, one of the principal concerns regarding the use of
89

Zr in the clinic is the substantial radiation dose received by patients compared to shorter-lived

nuclides. However, as long as the radiotracer clears the healthy tissue as expected, the prevailing
viewpoint is that the increased diagnostic value is worth the additional dose. Along these lines, a
notable issue with

89

Zr PET imaging preclinical mouse models is the uptake in bones. The

release of osteophilic Zr4+ in vivo leads to accumulation of the cation in the bone, which can
often be seen in the resulting images. Biodistribution results commonly show up to 10% injected
dose per gram activity in the bone. Localization of radioactivity in the bone is disadvantageous
due to the resulting increased dose to the bone marrow. As discussed earlier, the development of
a more favorable zirconium chelate may be the key to reducing this issue.
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1.8:

89

Zr-Based Imaging in the Clinic

Despite the youth of the field, the tremendous success of 89Zr-based radiopharmaceuticals
in pre-clinical imaging studies with rodent models has led to the rapid clinical translation of a
number of 89Zr-labeled antibodies. In 2013, all of the published clinical investigations with 89Zrlabeled antibodies had been performed in the Netherlands; however, since then the rapid advent
of 89Zr-based immunoPET has led to a surge of new clinical trials throughout Europe, the United
States, and most recently, Australia.92 Due to the abundance of recent investigations, we have
summarized them in Table 1.2 while a more detailed discussion is included for four specific
89

Zr-labeled antibody conjugates:

89

Zr-J591.44, 93-97 The selected studies include three of the oldest and most established clinical

investigations of

89

Zr and the first

89

89

Zr-cmAb-U36,

89

Zr-trastuzumab,

89

Zr-ibritumomab, and

Zr clinical trial here at Memorial Sloan Kettering Cancer

Center.
The first report of a clinical study employing a

89

Zr-labeled antibody was published in

2006 by Börjesson, et al., investigating the safety and diagnostic value of 89Zr-cmAb U36 for the
imaging of CD44v6-positive head and neck tumors.94 In the study, twenty patients with head and
neck squamous cell carcinoma (HSNCC) underwent 89Zr-cmAb U36 immunoPET along with CT
and/or MRI. The patients received 75 MBq of the

89

Zr-labeled conjugate, corresponding to 10

mg of the antibody, and were imaged up to 144 h after injection of the radiopharmaceutical. The
authors report that the conjugate was safe (only two of twenty patients developed an antichimeric
antibody response), and all primary tumors were detected as well as lymph node metastases in 18
of 25 positive levels (Figure 1.7). Significantly, the lymph nodes that were missed were
determined to be small, contain relatively little tumor tissue, and were often also missed by CT
or MRI, resulting in the sensitivity of the immunoPET for lymph node metastases (72%) being
25

Antibodies

Compound

Type of Disease

Number of Trials
& Status

Zr-bevacizumab

Breast Cancer, Neuroendocrine
Cancer, Renal Cell Carcinoma,
Von Hippel-Lindau Disease,
Hemangioblastoma,
Pheochromocytoma, & Multiple
Myeloma

6 Completed.
1 Recruiting,
1 Unknown

Stage IV Cancer, & Colorectal
Cancer

1 Completed,
2 Recruiting

EphA2 Positive Cancer

1 Recruiting

Zr-GC1008

Glioma

1 Completed

Zr-girentuximab

Renal Cell Carcinoma

1 Recruiting

Zr-GSK2849330

HER3-Positive Solid Tumors

1 Recruiting

Zr-J591

Prostate Cancer,
& Glioblastoma

1 Active, not
recruiting,
1 Recruiting

Zr-MMOT0530A

Ovarian & Pancreatic

1 Completed

Bladder, Non Small Cell Lung, &
Breast Cancer

2 Not yet
recruiting

89

Zr-MSTP2109A

Prostate Cancer

1 Recruiting

89

Zr-panitumumab

9

89

Zr-cetuximab

89

Zr-DS-8895a

89
89
89

89

89

89

Zr-MPDL3280A

Neoplasms

1 Recruiting

89

Glioblastoma

1 Withdrawn

89

Neoplasms

1 Completed

Breast Cancer, & Esophagogastric
Cancer

1 Completed,
7 Recruiting

Prostate, & EphA2 Positive Cancer

1 Withdrawn,
3 Recruiting

Zr-RO5323441
Zr-RO5429083

89

Zr-trastuzumab

Minibodies

89

Zr-IAB2M

Table 1.2. Summary of 89Zr-based imaging agents involved in clinical trials currently registered
with the U. S. National Institutes of Health.92
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Figure 1.7. ImmunoPET images with 89Zr-cmAb U36 of head and neck cancer patient with a
tumor in the left tonsil (large arrow) and lymph node metastases (small arrows) at the left (level
II and III) and right (level II) side of the neck. Images were obtained 72 hours post-injection. A:
sagittal image; B: axial image; and C: coronal image. Reprinted with permission from Borjesson,
et al. Clinical Cancer Research 2006; 12: 2133-40.
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comparable if not better to that of CT/MRI (60%). Further, the authors found that in a subset of
the patients (n = 6), imaging with 89Zr-cmAb U36 gave comparable results to imaging with 18FFDG.
In a later report from the same group, both the radiation dosimetry and potential for 89ZrcmAb-U36 quantification were studied.93 Here, the authors report that the PET-based
quantification of activity in the left ventricle of the heart agreed quite well with values obtained
from blood samples; likewise, good correlation between PET- and biopsy-derived values was
also observed for tumor uptake. Taken together, these data suggest that 89Zr-cmAb-U36 may be
used to quantitatively assess antibody biodistribution, thereby helping to differentiate patients
with high and low tumor uptake and in turn aiding in treatment planning. In the same study, the
authors determined that the mean effective dose of the immunoPET was 0.53 ± 0.03 mSv/MBq
in men and 0.66 ± 0.03 mSv/MBq in women, resulting in an average dose of approximately 40
mSv for the patients in the study receiving 74 mBq. This, of course, is high and could certainly
limit the repeated application of

89

Zr-immunoPET, though the authors reasonably argue that

subsequent studies employing different doses and more modern PET scanners can reduce the
dose.
Soon after the first-in-man reports of

89

Zr-cmAb-U36, an overlapping group of

researchers from the VU Medical Center published a pilot study investigating the use
ibritumomab tiuxetan for monitoring and predicting the biodistribution of

90

89

Zr-

Y-ibritumomab

tiuxetan (Zevalin®) in patients with relapsed or refractory low-grade B-cell non-Hodgkin’s
lymphoma.44 The authors report that co-injected

89

Zr- and

88

Y-ibritumomab tiuxetan have very

comparable biodistributions, despite a few small differences, particularly liver and bone uptake.
As a result, they conclude that

89

Zr-ibritumomab tiuxetan is well-suited to predict
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90

Y-ibritumomab tiuxetan dosimetry. More recently, a complementary study has been published

illustrating that immunoPET scout scans
radioimmunotherapy with

90

with

89

Zr-ibritumomab tiuxetan prior to

Y-ibritumomab tiuxetan can be used to effectively and accurately

predict the biodistribution of the

90

Y-labeled antibody and the dose-limiting organ during

therapy, a development which could aid significantly in patient selection and dose
optimization.95
In 2010, researchers at the University of Groningen published an investigation into the
use of

89

Zr-trastuzumab for imaging Her2-positive lesions in patients with metastatic breast

cancer.96, 98 In the study, the patients (n = 14 total) were divided into three groups that received
10 or 50 mg of trastuzumab for antibody-naïve patients or 10 mg for patients on trastuzumab
treatment. It was found that for the trastuzumab-naïve patients, a 50 mg dose of 89Zr-trastuzumab
was required for effective imaging, while a 10 mg dose was sufficient for patients on
trastuzumab treatment. The

89

Zr-trastuzumab produced excellent images, with high spatial

resolution and good signal-to-noise ratio as well as high tumor uptake. It also allowed for the
observation of metastatic lesions in the liver, lung, bone, and brain (Figure 1.8). The uptake in
brain lesions was particularly interesting, especially because of the common belief in the poor
penetration of trasuzumab through the blood brain barrier. The authors report that most favorable
imaging times were 4-5 d after injection of the radiopharmaceutical, and while a full study
between imaging modalities was not conducted, the immunoPET results generally correlated
well with complementary imaging with CT, MRI, and bone scans. Finally, and importantly, the
radiation dose to patients was significantly attenuated in this study compare to the

89

Zr-cmAb-

U36 investigations: patients received 37 MBq 89Zr-trastuzumab for an average dose of 20 mSv.
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Figure 1.8. Examples of fusion images from 89Zr-Trasutuzmab PET and MRI scans. (a) In a
vertebral metastasis seen on MRI but unapproachable for biopsy, HER2 status was revealed by
89
Zr-trastuzumab uptake on PET imaging. (b) Example of HER2-positive brain lesion undetected
by conventional scans, revealed by 89Zr-trastuzumab PET imaging, and subsequently confirmed
by MRI. Arrows indicate lesions. Reprinted with permission from Dijkers, et al. Journal of
Nuclear Medicine 2009; 50: 974-81.
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More recently, Memorial Sloan Kettering Cancer Center has started its own clinical
investigation of

89

Zr-based probes. The first of these focuses on the use of

89

Zr-DFO-huJ591

(89Zr-J591) for the detection of prostate-specific membrane antigen-positive lesions in castrateresistant prostate cancer patients.97 The pilot study results were very promising: the

89

Zr-J591

displays high spatial resolution in addition to uptake both in primary tumors and distant
metastases (Figure 1.9) and led to a full Phase I/II study. In a study of fifty patients, injected
with 5 mCi of the radioimmunoconjugate and imaged with whole body PET/CT,

89

Zr-J591 was

found to be comparable to current modalities for detecting soft tissue lesions, but highly
advantageous for bone metastases. Overall,

89

Zr-J591 had an accuracy of 95.2% (20/21) for

osseous lesions and 60% (15/25) for soft tissue lesions. With this superior detection of bone
metastases,

89

Zr-J591 is not only a promising clinical compound, but will also serve as a

benchmark for comparison with other PSMA targeting imaging agents for application in prostate
cancer.
1.9:

Conclusions
In the preceding pages, we have hoped to illustrate to the reader both the depth and

breadth of the research in the rapidly expanding field of

89

Zr-based PET imaging, with

investigations ranging from basic metal coordination chemistry to on-going clinical trials.
Indeed, the field is proceeding at such an exciting pace that important contributions to our
knowledge of

89

Zr-PET will no doubt be made between the writing of this manuscript and its

ultimate publication. Yet despite the manifold successes, much work is yet to be done as this
field grows and matures. In particular, we believe that particular emphasis should be placed on
five areas: (A) the synthesis and evaluation of novel chelators with fast coordination kinetics and
high kinetic and thermodynamic stability in order to address the observed in vivo release of
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Figure 1.9. 18F-FDG (13.2 mCi), 18F-NaF (10.2 mCi), and 89Zr-DFO-J591 (4.8 mCi) sagittal
PET images of a 56 year-old male with castrate-resistant prostate cancer. Images courtesy of Drs.
N. Pandit-Taskar, J. Carrasquillo, M. Morris, and S.M. Larson, MSKCC.
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89

Zr4+ and its subsequent mineralization in the bone; (B) the development of mild, modular, and

site-specific bioconjugation strategies with which to attach DFO to antibodies; (C) the expansion
of

89

Zr-based PET imaging from antibodies to other targeting vectors with suitable

pharmacokinetics; (D) the advancement of our understanding of the metabolism of 89Zr4+-labeled
compounds and the fate of free

89

Zr4+ in vivo; and finally, but perhaps most important, (E) the

performance of direct comparison studies between 89Zr-labeled antibodies and antibodies labeled
with other relevant isotopes in both pre-clinical models and a clinical environment to allow for
the quantitative and comprehensive comparison between

89

Zr-immunoPET and its competitor

modalities.
As these issues are addressed, new 89Zr-labeled radiopharmaceuticals are developed, and
new pre-clinical and clinical studies are performed, we believe that 89Zr-based PET imaging will
continue to progress, expand to involve new disciplines and address different pathologies, and
ultimately take an extremely important place at the forefront of medical imaging.
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CHAPTER 2: PHYSICAL, CHEMICAL, AND BIOLOGICAL INSIGHTS INTO
89

ZR-DFO AND THE STUDY OF SMALL MOLECULE 89ZR COMPLEXES

This chapter is an adaptation of unpublished work from Deri, M. A.; Abou, D. S.; Ramos, N. E.;
Carlin, S. S.; Francesconi, L. C.; Lewis, J. S. 2013.

2.1:

Introduction
While considerable work has utilized DFO to radiolabel larger targeting moieties, 1,2,3,4

insufficient effort has focused on the understanding of 89Zr-labeled small molecules or 89Zr-DFO
itself. Delineating this chemistry is becoming increasingly important to probe the chelation
chemistry of Zr and in developing novel bifunctional chelators for use in

89

Zr-mAb PET

studies.5,6 This will necessitate not only the development of methodology to prepare and analyze
small molecule

89

Zr-ligand complexes, but a fuller understanding of the

89

Zr-DFO complex

itself, both chemically and biologically, as a basis for comparison for future applications.
In order to address the first of these needs, we have herein developed a radiolabeling method
using an oxalate-free, colloidal solution of

89

Zr. This approach makes it possible to purify

radiolabeled small molecules such as 89Zr-DFO utilizing classic chromatographic methods which
are unable to provide sufficient separation when using the standard method of radiolabeling with
89

Zr-oxalate. Furthermore, we have endeavored to more fully characterize the Zr-DFO complex

with both traditional macroscopic chemical techniques and radioanalytical techniques. The
methodology to efficiently monitor the radiolabeling of small molecule ligands is essential to the
investigation of possible alternative chelators.

34

One of the limitations of PET is the inability to differentiate an intact radiotracer from its
radiometabolites. The signal always comes from the radioactive atom, whether it is still part of
the original molecule or not. This phenomenon is particularly relevant when the

89

Zr-labeled

mAb or immunocomplex is internalized in tumor cells7,8 leading to possible radiotracer
metabolism. Among others, two conceivable metabolic products of
89

89

Zr-DFO-mAbs are 1) free

Zr, released from DFO, which binds serum proteins and is known to exhibit bone-seeking

properties9 and 2) the intact

89

Zr-DFO complex which is rapidly excreted within 20 min when

injected in healthy mice.1 However, little is known about the behavior of

89

Zr-DFO when

administered in tumor-bearing mice, particularly the fate of the radiotracer within the tumor
microenvironment. With this in mind, a particular focus on the pharmacokinetics of 89Zr-DFO in
tumor-bearing mice is presented herein to interrogate the biological behavior of
Additionally, more comprehensive characterization of

89

89

Zr-DFO.

Zr-DFO complex and the development

of appropriate HPLC methods could prove beneficial for metabolic analysis of future

89

Zr-DFO

conjugates.
2.2:

Results and discussion
The ideal preparation of 89Zr-labeled small molecules would fulfill a few basic conditions

(1) it should provide fast radiolabeling under mild conditions; (2) it should allow for quick and
easy monitoring of the radiolabeling without wasting product; and (3) it should allow for the
separation of desired product from any starting materials or side products. In order to achieve
this balance, we have investigated novel radiolabeling techniques as well as improved
characterization and analytical methods. Additionally, once the 89Zr-DFO complex was produced
and characterized, we evaluated its interaction with tumor cells in vitro and behavior in healthy
and tumor-bearing mice in vivo.
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2.2.1:

Radiolabeling

Radiolabeling of monoclonal antibodies with
using a solution of

89

89

Zr is generally achieved in high yields

Zr-oxalate which has been neutralized to pH 7.10 One challenge of this

approach is the renal toxicity of calcium-oxalate crystals in patients,11 which necessitates the
removal of any lingering oxalate contaminations post-radiolabeling. Traditionally, this approach
relies on the great size discrepancy between

89

Zr-oxalate and the radiolabeled immunoconstruct

for purification and analysis. It is, however, difficult to apply the same methodology when
radiolabeling small molecules with

89

Zr because the final product is not sufficiently larger than

the starting materials. To achieve this goal, we faced challenges in the choice of appropriate
chromatographic techniques including: (1) compatibility with the high oxophilicity of

89

Zr and

(2) ability to separate free 89Zr from complexes and small molecules.
RP-HPLC was excluded due to severe retention (up to 100%) of free or weakly chelated
89

Zr by the stationary phase constituted of C18-coated silica. In comparison, the cross-linked

dextran gel used in size exclusion chromatography (SEC) exhibited weaker

89

Zr retention, and

thus represented a compatible option for analysis of 89Zr-labeled molecular tracers. However, the
separation of neutralized

89

Zr-oxalate from

89

Zr-DFO by SEC was poor with a significant

overlapping of the two peaks (Figure 2.1a), thus limiting the ability to isolate and purify
individual species produced using 89Zr-oxalate for radiolabeling.
We overcame this limitation by utilizing an alternative starting species of
free

89

Zr was prepared from a strong acidic digestion of

89

89

Zr wherein

Zr-oxalate resulting, after saline

dissolution, in a colloidal polymeric solution herein called “89Zr-colloid”.9 The colloidal nature
of 89Zr-colloid was confirmed with dynamic light scattering (Figure 2.1b). 89Zr-colloid and 89ZrDFO were successfully separated based on size retention. 89Zr-colloid was eluted earlier (elution
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Figure 2.1. (a) SEC (Sephadex G-25) of 89Zr -colloid separated from 89Zr -DFO, enabling the
monitoring of the radiolabeling efficiency, whereas neutralized 89Zr-oxalate presented poor
separation from 89Zr-DFO; (b) Dynamic light scattering report of 89Zr -colloid indicating the
average diameter at various solvation times. Notice the non-assigned (N/A) values after 25 min
due to a dramatic increase in particle size (> 5 µm); (c) Radiolabeling of DFO with 89Zr-colloid
at pH 2 depicts a single peak characteristic of labeling completion; Radiolabeling of DFO at pH
4 shows two peaks indicative of partial radiolabeling.
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volume < 5 mL) than

89

Zr-DFO (elution volume > 5 mL) further indicating the colloidal nature

of 89Zr-colloid as compared to 89Zr-DFO, a single molecule moiety (Figure 2.1a).
Starting from

89

Zr-colloid allowed for the monitoring of the radiolabeling of DFO using

SEC. Now the excess free

89

Zr-colloid was substantially larger than the

89

Zr-DFO product

resulting in appreciable separation. Through SEC analysis, the radiolabeling of DFO was shown
to be only partial when the pH of the solution was higher than 2, whereas complete chelation was
observed when the labeling was conducted at ~pH 2 (Figure 2.1c). This observation suggests
that the polymeric 89Zr-colloid is likely increasing in size concomitantly with pH increase.12 The
same trend results from increasing solvation time as demonstrated by DLS. Combined, these two
factors lead to the precipitation of the radiometal and thus reduce the potential radiolabeling
yield. This indicates that this radiolabeling approach is most likely only compatible with ligands
that are stable under acidic conditions. This pH requirement also eliminates the possibility of
adapting this radiolabeling method to antibody applications which would not tolerate the low pH.
Given the renal toxicity associated with calcium-oxalate crystals,11 the ability to eliminate
oxalate contaminations makes SEC a great purification technique when combined with the
colloidal based

89

Zr radiolabeling of DFO. However, SEC is not ideal for in situ reaction

monitoring since it requires a substantial amount of compound for ease of analysis and takes
several steps which would be time consuming and inconvenient to repeat at multiple time points.
In contrast, radio-ITLC can be carried out on sub-microliter samples and completed in just a few
minutes which makes it well suited for reaction monitoring. Yet, there was no established
method suitable for analyzing small molecule 89Zr complexes.
Traditionally, the radiolabeling of 89Zr-DFO-mAb complexes is monitored via radio-TLC
using ITLC-SG strips and 50 mM EDTA at pH 5 as the mobile phase. The

89

Zr-DFO-mAb
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complexes remain at the origin, while free

89

Zr is taken up by EDTA in the mobile phase and

migrates along the ITLC strip. Unfortunately, when the 89Zr-DFO complex is analyzed in such a
way, it does not result in a single clean peak. Instead it gives a broad, indistinct result. This led to
the exploration of other stationary and mobile phases to find conditions compatible with small
89

Zr-ligand complexes. We evaluated ITLC-SG, ITLC-SA, and cellulose stationary phases in

combination with EDTA, citric acid, and water mobile phases. Of the conditions tested, ITLCSA strips run in 50 mM EDTA was found to give the cleanest separation of 89Zr-DFO remaining
at the origin and free

89

Zr being taken up by the EDTA and migrating with the solvent front

(Figure 2.2). A close second was ITLC-SA strips run in 0.5 M citric acid13 which gave similar
separation, but with a broader signal for the free 89Zr since it likely forms multiple species when
chelated by the citric acid eluant. All radio-ITLC methods discussed were evaluated with
oxalate as the starting material because

89

89

Zr-

Zr-colloid unavoidably sticks at the origin and makes

such analysis impractical. Just as SEC was poorly matched to 89Zr-oxalate, ITLC was unsuitable
for 89Zr-colloid.
2.2.2:

Characterization

In order to verify the identity of the complex, 89Zr-DFO was analyzed via HPLC against
Zr-DFO and DFO standards. Non-radioactive Zr-DFO (structure confirmed by NMR and MS,
Figures A.2.1 & A.2.2) and DFO were respectively detected at 8.3 min and 9.5 min by UV
absorbance at 210 nm (Figure 2.3a). Radioactive detection of 89Zr-DFO indicated a single peak
at 8.5 min consistent with the UV detection of the non-radioactive analogue (taking into account
the small time delay due to the sequential placement of the UV and radioactive detectors; Figure
2.3b). Upon the injection of

89

Zr-DFO, there is no appreciable UV peak for the complex;

however this is as expected due to the tracer level (picomolar) concentration of the complex.
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Figure 2.2. Radio-ITLC analysis of 89Zr-DFO complex and free 89Zr-oxalate using ITLC-SA
strips and 50 mM EDTA at pH 5. The 89Zr-DFO complex remains at the origin while the free
89
Zr is taken up by the EDTA in the mobile phase and carried to the solvent front.
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Figure 2.3. RP-HPLC analysis of (a) the separation of non-radioactive Zr-DFO from DFO as
seen by UV absorbance and (b) 89Zr-DFO radiolabeling mixture with UV and radioactive
detection. The UV signal corresponds to excess, unlabeled DFO. Analysis was carried out on a
C18 RP-HPLC column at a flow rate of 1 mL/min with an increasing gradient from 10 to 100%
MeCN in water over a 20 min acquisition time (all solvents contained 0.1% TFA).
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Instead, an intense UV peak was read at 9.5 min indicating the presence of excess non-metallated
DFO due to low specific activity of

89

Zr-DFO (1.5 µCi/mg). Accordingly, the presented HPLC

method may be utilized to evaluate a relative specific activity of the radiocomplex by examining
the amount of free ligand observed. This HPLC methodology may also be suitable for further
utilization to identify 89Zr-DFO-mAb metabolites in the context of in vivo studies.
The hydrophilicity of 89Zr-DFO was then evaluated measuring the distribution coefficient
(log D). The log D at pH 7.4 was found to be -2.33±0.02 using an extraction between 1-octanol
and PBS. This value indicated the poor solubility of 89Zr-DFO at pH 7.4 in 1-octanol which is in
agreement with the known 2+ positive charge of
hydrophilicity of

89

89

Zr-DFO.

6, 9

It predicts the extreme

Zr-DFO, corresponding to the low protein affinity and rapid in vivo renal

clearance observed in the rest of this study.14
2.2.3:

In vitro studies

Incubation of 89Zr-DFO in serum protein for 1 h at room temperature was carried out in
order to assess the stability of the radiocomplex. The samples were analyzed using SEC with UV
detection at 280 nm as well as gamma counting of the collected fractions (Figure 2.4). Although
the retention time of

89

Zr-DFO overlaps with the elution of a small subsection of lower

molecular weight serum proteins, the retention time observed by HPLC of 89Zr-DFO before and
after protein incubation remained unchanged (Figure A.2.4).

89

Zr-DFO is therefore inert to

serum proteins showing no binding affinity in contrast to free 89Zr.15 Moreover, the incubation of
89

Zr-DFO with SW1222 tumor cells shows no internalization and a negligible affinity for tumor

cells and membranes as compared to

89

Zr-radiolabeled A33 antibody (89Zr-DFO-A33),16 here

used as a positive control (Figure A.2.5).
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Figure 2.4 89Zr-DFO was incubated with mouse serum proteins for 1 h at room temperature and
then analyzed using SEC with UV detection at 280 nm (solid line) and radioactive detection
(dashed line). The radioactive peak corresponding to 89Zr-DFO was eluted in the 1 KDa
molecular weight range, consistent with the molecular weight of 89Zr-DFO (647 Da). The three
lines represent triplicate samples.
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2.2.4:

In vivo studies

With an understanding of the chemistry of Zr-DFO in hand, we endeavored to probe the
behavior of the complex in vivo in both healthy and tumor-bearing mice.
2.2.4.1:
89

Dynamic imaging

Zr-DFO was retro-orbitally injected in healthy and tumor-bearing mice directly on the

PET imaging bed. Dynamic PET images were obtained for each animal for the first 20 min postinjection. The reconstructed PET images (Figure 2.5), as well as the time activity curve (Figure
2.6), initially indicated an elevated level of radioactivity in the blood and heart which then
decreased from 15 to 10 %ID/g between 2 to 4 min in both healthy and tumor-bearing mice.
From 6 to 20 min, the radioactivity rapidly migrated to the kidneys and bladder.

89

Zr-DFO was

almost completely renally excreted within 20 min p.i. with a negligible bone uptake (<2% ID/g
for both groups), indicating the stability of the radiocomplex within the 20 min residency time in
the body.
As illustrated by the PET images (Figure 2.5), it is possible to visualize the tumors
throughout the study, however we achieved poor tumor-to-background ratios and low tumor-toblood ratios (Figure 2.7). Nevertheless, while the accumulation of radioactivity in the heart
decreased over the 20 min, the amount of radioactivity in the tumor increased, until the two
levels stabilized at approximately the same activity (3 %ID/g) for the final 7 min of the study.
A difference in the distribution of the radioactivity in the tumor was observed throughout the
study and is particularly noticeable in the axial PET slices (Figure 2.5). Interestingly, a ring
shaped structure was observed at early time points (2-10 min), illustrating blood delivery by
surrounding vessels and consistent with the tumor-to-blood ratio of about 1. Subsequently, at 16
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15.0

0.0
%ID/g

Figure 2.5. Selected coronal and axial slices of 89Zr-DFO (150 µCi/animal) dynamic PET scans,
from 2 to 20 min p.i. of retro-orbitally injected mice (NCRNU-M female) bearing SW1222
tumors. Initially, the radioactivity is heterogeneously distributed in the tumor (indicated by an
arrow) showing a ring-shaped structure, characteristic of a necrotic core. After 14 min, the
distribution in the tumor changed to a disc-shaped structure.
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Figure 2.6. Time activity curve of the accumulation of radioactivity in: the hearts of tumorbearing mice (square); the hearts of healthy mice (dashed line); and the tumors (triangle).
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Figure 2.7. Organ-to-blood ratio of radioactivity distribution 22 min after intravenous injection
of 89Zr-DFO in SW1222 inoculated mice and healthy mice indicative of blood delivery in each
organ, except kidney and bladder due to renal clearance of the radiocomplex (Tu: tumor; Mu:
muscle; He: heart; Lu: Lung; Bo: bone; Ki: kidney; Blad: bladder).
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to 20 min p.i., the distribution of the radioactivity in the tumor changes, with higher levels of
radioactivity filling in the core of the tumor.
2.2.4.2:

Biodistribution

Healthy and tumor-bearing mice showed comparable organ distribution of radioactivity
(Table A.3.1). There were no notable differences and the tumor did not act as a sufficient sink of
activity to change the in vivo behavior of the complex. The tumor uptake of 89Zr-DFO was quite
low, only achieving a tumor to blood ratio of about 1 (Figure 3.7).
2.2.4.3:

Histology

Histology and autoradiography of the excised SW1222 tumors (22 min p.i.) further
confirmed that most of the radioactivity was localized in the tumor core (Figure 3.8). The
microscopic analysis showed the distribution of the radioactivity to be opposite that of the
Hoechst and CD31 stained tissues. In areas of high perfusion and vascularization indicated by
Hoechst (blue) and CD31 (red) staining respectively,17 the radioactivity was absent. Hematoxylin
and eosin staining (H&E), revealed the tumor composition to be heterogeneous, with the core
mostly constituted of collagen and fibrotic wire (stained in pink by eosin), likely indicative of a
necrotic core, surrounded by a well-perfused and densely vascularized cellular tissue. Since 89ZrDFO did not get internalized by SW1222 tumor cells, as here demonstrated in vitro, the
radioactivity was likely non-specifically trapped in the tumor necrotic core, resulting in a slower
kinetic clearance than the other organs and viable tissues. A similar phenomenon has been
reported when using Gd-DTPA, a blood perfusion probe for magnetic resonance imaging, where
a slower clearance of the tracer has been observed in necrotic tumor tissue.18
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Figure 2.8: Autoradiography and histology of SW1222 tumor section harvested 22 min p.i.; a)
blue staining corresponds to Hoechst highlighting the blood perfusion; the red staining matches
with CD31 indicating the presence of blood vessels. b) hematoxilin and eosin staining
differentiating viable from necrotic tissue; c) overlay of a+b; d) 89Zr autoradiography overlapped
with c. 89Zr-DFO accumulated in the tumor necrotic core underlining a slower clearance from the
necrotic tissue as compared to well-perfused, viable tissue.
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2.3:

Conclusions
Using a colloidal preparation of

89

Zr, an oxalate-free radiolabeling methodology was

developed and optimized to overcome the existing challenges of radiolabeling small molecules
with

89

Zr. This approach combined with optimized SEC and HPLC methods considerably

facilitated the monitoring, separation, and purification of

89

Zr-DFO. In vitro studies showed the

inertness of the radiocomplex to serum proteins or cells. A detailed pharmacokinetic evaluation
in a tumor-bearing murine model demonstrated the rapid excretion of 89Zr-DFO. No meaningful
differences were found between the in vivo behavior in healthy or tumor bearing mice.
Interestingly, a particularly slow clearance of the radiocomplex from the necrotic area of the
tumor was observed as compared to viable tissues, which provided information on the tumor
quality. This characteristic of

89

Zr-DFO may be useful for non-invasively assessing the

heterogeneity of a tumor through PET imaging.
In brief, a novel, technical method is here presented for the preparation, characterization,
and purification of small molecule
depth evaluation of

89

89

Zr-radiolabeled complexes which has allowed for an in

Zr-DFO. This methodology demonstrates potential for future application

toward the identification of metabolites in the context of preclinical and clinical development of
89

Zr-labeled mAbs as well as in the development and evaluation of novel 89Zr chelators.
Ultimately, the

89

Zr-colloid species was not carried over and used for the evaluation of

the novel ligands due to concerns over the inability to fully characterize the species. The colloid
system could not be mimicked on the macroscale and its precise composition could not be
determined. Furthermore, the practice of drying down the 89Zr-oxalate samples in an open vessel
was deemed an unnecessary contamination hazard. Although 89Zr-colloid was an interesting and
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effective alternative to the traditional

89

Zr-oxalate labeling, its disadvantages proved more

persuasive than its benefits.
While the
89

89

Zr-colloid method was able to eliminate the risk of lingering oxalate from

Zr-DFO solutions, it would be limited to small molecules and could not be carried over to

ligand-antibody work due to its low pH requirements. Additionally, the

89

Zr-colloid

radiolabeling reaction was incompatible with convenient radio-ITLC analysis for reaction
monitoring. The use of one radiolabeling method to test preliminary ligands when a different
radiolabeling method would ultimately have to be used for their intended application would open
up a world of potential issues as the difference in techniques may affect the performance and
selection of the ligands under evaluation. Therefore, the

89

Zr-oxalate method of radiolabeling

prevailed and was used in the remainder of this work.
2.4:

Experimental section

2.4.1:

Materials and methods

All chemicals, unless otherwise noted, were acquired from Sigma-Aldrich (St. Louis,
MO) and used as received without further purification. Human serum was purchased frozen from
Sigma Aldrich. All water used was ultra-pure (>18.2 MΩ cm– 1). All instruments were calibrated
and maintained in accordance with standard quality-control procedures. High resolution mass
spectrometry (HRMS) measurements were performed on a Waters SYNAPT High Definition
MS System (ESI-QTOF) and low resolution mass spectra (LRMS) were recorded with a Waters
Acquity UPLC with electrospray ionization (ESI) SQ detector. 1H NMR spectra were recorded at
ambient temperature on a Bruker 500 MHz NMR with Topsin 2.1 software. The NMR spectra
are expressed on the δ scale and were referenced to residual solvent peaks and/or internal
tetramethylsilane. The HPLC system used for analysis and purification compounds consisted of a
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Shimadzu prominence system equipped with a diode array and a radioactive detector (Bioscan
inc, DC). IR spectroscopy was performed on a solid sample using an attenuated total reflectance
attachment on a PerkinElmer Spectrum 2 FT-IR spectrometer with a UATR Two attachment.
UV-Vis spectroscopy was carried out using a Thermo Scientific Evolution 220 UV-Visible
spectrophotometer.
89

Zr was produced at Memorial Sloan Kettering Cancer Center on a TR19/9 cyclotron

(Ebco Industries Inc.) via the

89

Y(p,n)89Zr reaction and purified to yield

89

Zr with a specific

activity of 196–496 MBq/mg. Activity measurements were made using a CRC-15R Dose
Calibrator (Capintec). For the quantification of activities, experimental samples were counted on
an Automatic Wizard (2) g-Counter (Perkin Elmer). The radiolabeling of ligands was monitored
using salicylic acid impregnated instant thin-layer chromatography paper (ITLC-SA) (Agilent
Technologies) and analyzed on a Bioscan AR-2000 radio-TLC plate reader using Winscan
Radio-TLC software (Bioscan Inc., Washington, DC). All in vivo experiments were performed
according to protocols approved by the Memorial Sloan Kettering Institutional Animal Care and
Use Committee (protocol 08−07−013).
2.4.2:

Zr-DFO

Non-radioactive Zr-DFO was prepared, dissolving ZrCl4 powder in deionized water with
50 mM DFO at room temperature (ratio Zr : DFO; 1:1). Both DFO ligand and Zr-DFO were
characterized using 1H NMR (Bruker 500 MHz NMR with Topsin 2.1 software - Figure A.2.2)
as well as LRMS (Low resolution mass spectra were recorded with a Waters Acquity UPLC with
electrospray ionization SQ detector – ESI – Figure A.2.1).
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2.4.3:
89

89

Zr-oxalate radiolabeling

Zr-oxalate was prepared in-house as described by Holland et al.19 An irradiated yttrium-

89 target was dissolved in strong acids and 89Zr was separated using a hydroxamate column and
eluted with oxalic acid. This results in the 89Zr received after target processing being 89Zr-oxalate
in 1.0 M oxalic acid. This solution is then neutralized with 1.0 M sodium carbonate to reach pH
6.8-7.2. DFO was labeled at various concentrations in water or saline with the neutralized

89

Zr

solution at room temperature for varying lengths of time, typically 10-60 min. Samples were
labeled with 10 μCi to 1 mCi depending on the nature of the experiment (for reference, 1 μCi of
89

Zr equals 25 femtomoles).
2.4.4:
89

89

Zr-colloid radiolabeling

Zr-oxalate was evaporated on a heat-block at 120°C for 10 min. The dried material was

digested with 40 µL of strong acid mix (1:1 – v/v; HCl - 37% and HNO3 - 70%) and 20 µL of
glacial acetic acid and evaporated until dry.9 The final residue was then suspended in saline in
order to reach a concentration of 1 µCi/µL. The resulting solution, here called
the starting material for DFO radiolabeling. The colloidal nature of

89

89

Zr-colloid, was

Zr-colloid was verified

using Dynamic Light Scattering (DLS) at various time points post-dissolution (Figure 3.1a).
89

Zr-colloid solution were checked to be at pH 2 and then thoroughly mixed at room

temperature with 50 mM saline solution of desferrioxamine mesylate (Calbiochem, Millipore).
After incubation for at least 10 min, the final preparation was then neutralized to pH 7.5 adding
1 M Na2CO3. For all experiments 89Zr-DFO specific activity was 1.5 µCi/mg.
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2.4.5:

Chromatographic methods

2.4.5.1:
89

oxalate,

Size exclusion

Zr-DFO was evaluated using size exclusion chromatography (SEC). Neutralized

89

Zr-colloid, and

89

89

Zr-

Zr-DFO were comparatively eluted and separated with using size

exclusion chromatography with Sephadex G-25 gel (PD-10 desalting column, GE Healthcare)
and deionized water. Fractions of 1 mL were collected and each fraction was gamma counted.
2.4.5.2:

ITLC

Reactions were monitored via radio-TLC using Varian ITLC-SA strips (Agilent
Technologies) and 50 mM EDTA at pH 5 as the mobile phase. 89Zr-ligand complexes remained
at the origin, while free 89Zr was taken up by EDTA in the mobile phase and migrated along the
ITLC strip. Additional conditions evaluated included ITLC-SG strips (Agilent Technologies) and
cellulose strips cut from Whatman filter paper as well as 0.5 M citric acid and Millipore water
(see appendix for method comparison, Figure A.2.3).
2.4.5.3:

HPLC

The Ultra Fast Liquid Chromatography (UFLC) Shimadzu system was equipped with a
diode array and a radioactive detector (Bioscan inc, DC), as well as a reverse-phase (RP) HPLC
column (Jupiter 5u C18 300 Å; 250 × 4.6 mm, 5 micron) provided by Phenomenex, CA. The
radiation detection was delayed approximately 30 s as compared to UV due to detectors
sequential set-up of the detectors and the flow rate utilized.

89

Zr-DFO, non-radioactive Zr-DFO

and metal-free DFO were analyzed by HPLC at a flow rate of 1 mL/min eluted with water and
acetonitrile, both spiked with 0.1 % trifluoroacetic acid, with an increasing gradient from 10 to
100% acetonitrile over a 20 min acquisition.
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2.4.6:
89

Diffusion coefficient

Zr-DFO diffusion coefficient log D was measured (n=6) using an extraction method

separating phosphate buffered saline pH 7.4 (PBS) from 1-octanol. A PBS and 1-octanol mixture
(1:1; v/v) was stirred overnight in order to saturate each layer.

89

Zr-DFO was added to the bi-

layered preparation (6 mL) and the mixture was stirred for 1 h. Then 1 mL of each layer was
extracted and gamma counted. The diffusion coefficient log D was calculated in Equation 3.1:
Log D = log (counts per min in octanol layer ÷ counts per min in water layer) (3.1)
2.4.7:
89

Serum stability

Zr-DFO was incubated with mouse serum protein (5µCi in 250 µL of mouse serum

protein from Sigma Aldrich) at room temperature for 1 h (n=3). A gel filtration standard solution
was first eluted on the column to correlate molecular weight to elution time. 89Zr-DFO in serum
protein sample mixture was then analyzed using size exclusion chromatography (SEC,
automated Biorad size exclusion system, Biologic LP) Superdex 200 prep grade gel (column
diameter 18 mm; length 180 mm) eluted with PBS at a flow rate of 1 mL/min. The
chromatogram was acquired for 45 min using UV detection at 280 nm. Each eluted 1 mL
fraction was collected and gamma counted (Figure 2.3). The radioactive fraction (30 mL eluted
fraction) was then injected in HPLC (Figure A.2.4), in order to verify the unchanged quality of
89

Zr-DFO, post-serum incubation. The same HPLC conditions were used as previously

described. In order to get a higher radioactive signal from the HPLC analysis, this experiment
was repeated with higher specific activity 89Zr to counteract the extensive dilution resulting from
the SEC.
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2.4.8:

Cell affinity

Cell experiments were conducted using SW1222 human colorectal cancer cell line
(ATCC) which were grown in Dulbecco’s modified Eagle’s medium (DMEM, Life Technolgies,
CA) and kept under 5% CO2 incubation. 1×106 cells/well were placed in a 6 wells-plate 24 h
prior to the experiment. The following day cells were incubated with 5 µCi 89Zr-DFO (n=6) or 5
µCi of 89Zr-DFO-A33 (specific activity 2.71 mCi/mg; n=6) for 1 hour at 37°C. Cells were then
washed with cold PBS twice and harvested using trypsin (0.25%) treatment. Cells and standards
were gamma counted. The radioactivity differential was calculated using

89

Zr-DFO and

89

Zr-

DFO-A33 standards, allowing the determination of the initial dose percentage (ID %) associated
with the cells (Figure A.2.5).
89

Zr-DFO-A33 was prepared by conjugation of p-Bn-SCN-DFO with A33 (a monoclonal

antibody) and radiolabeled with neutralized 89Zr-oxalate as described by Zeglis et al.16
2.4.9:

PET imaging

Animal experiments were conducted according to National Institute of Health (NIH)
guidelines and the Institutional Animal Care and Use Committee of MSKCC.
NCRNU-M (homozygote) female mice were implanted with tumors by subcutaneous
injection of 5×106 SW 1222 cells on the right shoulder. The tumors were allowed to grow for 10
days, reaching an approximate tumor diameter of 5-7 mm.
After

89

Zr-DFO quality control, continuous PET dynamic scans (Micro-PET Focus 120

scanner, Siemens, IL) were conducted over 20 min using healthy (n=4) and tumor-bearing mice
(n=4). The mice were retro-orbitally injected (150 µCi [5.55 MBq] 89Zr-DFO per animal) under
inhalation of 1% isoflurane (Baxter Health-care, Deerfield, IL, USA) / oxygen gas mixture (flow
rate: 2 L/min) for anesthesia. To minimize the dead-time between the injection and the beginning
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of the scan, the animal was injected on the PET scanner bed. PET scans were immediately
acquired over 20 min. Dynamic scans were reconstructed using ASIPRO VM Concorde
Microsystems software, iterative 2D OSEM reconstruction method, corrected for dead-time (15
s) and separated into 10 frames of 120 s each. Selected coronal and axial slices of animals are
depicted in Figure 2.4. Time activity curves (Figure 2.5) were created averaging the regions of
interest (ROI), n=4, of the specific organs (hearts of healthy and tumor-bearing mice as well as
tumors).
2.4.10:

Biodistribution

Approximately 1 min prior to sacrifice, the vascular perfusion marker Hoechst 33342 (15
mg/kg in 0.2 mL of sterile saline) was administered intravenously via the tail vein. About 20 min
post-injection, mice were sacrificed and the organs were collected, weighed, and gamma counted
with

89

Zr-DFO standards. From this, the

89

Zr activity percentage of injected dose per gram

(%ID/g) of each organ was calculated.
2.4.11:

Histology

The harvested tumors were immersed in Tissue-tek® O.C.T. cryogenic gel and frozen.
Series of contiguous fresh-frozen tumor sections of 10 μm thickness were cut. Tumor sections
were exposed for one radionuclide half-life to a phosphor-imaging plate (Fujifilm BAS-MS2325,
Fuji Photo Film, Japan) at -20° C. The plates were placed in a BAS-1800 II Bio-Imaging
Analyzer (Fujifilm Medical Systems, USA) to readout the image. All autoradiographic and
immunostaining procedures were carried out on the same section. Dual immunofluorescence
staining of the endothelial cell marker CD31 and Hoechst was accomplished as previously
described.17 Stained sections were imaged using an Olympus BX-40 fluorescence microscope
equipped with a computer-driven motorized stage, a CC-12 digital camera and Olympus 5
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acquisition software (Olympus America, Center Valley, PA). Image sets were co-registered in
Olympus 5 software.
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CHAPTER 3: COMPARISON OF LIGAND BINDING GROUPS FOR
ZIRCONIUM-89

3.1:

Introduction
From an inorganic chemistry perspective, DFO is not ideally suited to the coordination

properties of Zr4+. The Zr4+ cation is a highly charged, hard Lewis acid with a predilection for
forming complexes with high coordination numbers. For example, eight coordinate complexes
 such as zirconium oxalate, [Zr(oxalate)4]4-  are particularly common with Zr4+.1 With this in
mind, it seems incongruous that a hexadentate ligand such as DFO is used with a metal that
prefers forming octa-coordinate complexes. In fact, previous molecular modeling of the most
favorable structure of the Zr-DFO complex revealed that in the optimized structure, two water
molecules join the metal’s coordination sphere to form an eight coordinate complex.2
Preliminary work by Brechbiel et al. has focused on investigating the coordination chemistry of
Zr4+ with different hydroxamate binding groups with the goal of gaining insights toward the
design of new chelators.3 Most notably, this work, including experimental and theoretical
treatment, further confirmed that Zr4+ preferentially forms eight coordinate complexes and thus
strengthens the argument for the development of an octadentate chelator.
With this in mind, we wanted to start the search for a better chelator based on chemical
principles. A ligand designed specifically with the chemistry of Zr4+ in mind should demonstrate
improved stability upon complexation with Zr4+. Furthermore, and perhaps even more
importantly, a more stable complex should be less prone to demetallation in vivo, resulting in
reduced bone uptake and thus a safer and more efficient 89Zr-based PET tracer. While it is clear
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from the above data that an alternative chelator for Zr4+ should be octadentate, insufficient work
has been done to explore the affinity of different binding groups with Zr4+. Herein, we endeavor
to expand the chelation of Zr4+ beyond the hydroxamate group.
Our inspiration for selecting potential new binding groups for Zr4+ came from a library of
ligands developed by Raymond et al. as actinide sequestration agents.4 The library contained a
number of ligands designed for plutonium(IV) decorporation5-7, and the similarity in
coordination chemistry between Zr4+ and Pu4+ marked these as excellent candidates. The use of
Hf4+ — the third row congener of Zr4+ — as a model for Pu4+ highlights this connection.8-11
These ligands are comprised of hard oxygen donor groups, specifically hydroxamates,
catecholates and hydroxypyridinonates.4 Both binding groups offer hard, oxygen donors
appropriate for binding Zr4+, however they vary in terms of pKa’s with values of -0.8 and 5.8 for
the hydroxypridinones compared to 9.2 and 13.0 for the catechol (Figure 3.1).4 The lower pKa
of the 1,2-HOPO group may offer an advantage for radiolabeling at lower pHs, but
hydroxamates, such as those in DFO, have a pKa of 9.4 and are known to chelate 89Zr under mild
conditions, so the catechol group may still be suitable.
Beyond the binding groups themselves, one pair of ligands in particular  3,4,3-(LI-1,2HOPO) and 3,4,3-LICAM (Figure 3.2)4  stood out as promising candidates for Zr4+ chelation.
Both are octadentate chelators composed of a spermine backbone coupled with either four
hydroxypyridinone (HOPO ligand) or catechol (LICAM ligand) groups for metal binding. These
ligands were selected to be synthesized and evaluated for use with Zr in order to directly
compare the hydroxypyridinone and catechol binding groups in the quest for an improved ligand
for 89Zr4+.
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Figure 3.1. Comparison of potential binding groups with their respective pKas.
Adapted from Gorden, A.E.V. et al. Chem. Rev. 2003, 103, 4207-4282.4
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Figure 3.2. Proposed chelators for zirconium with binding oxygens highlighted in red. The
current standard chelator, desferrioxamine B, is included on the left for comparison with the
alternative chelators shown on the right.
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3.2:

Results and discussion

3.2.1:

Synthesis and characterization

The HOPO ligand was synthesized as previously reported, with minor changes (Figure
3.3).4,

12-15

Despite this being a published synthesis, however, we encountered a number of

challenges in our production of the ligand. The simultaneous coupling of four HOPO groups
onto the amine backbone and the characterization of the resulting product proved difficult. Once
we were able to confirm that we had all four groups on, the full deprotection of all four groups
became the next hurdle. Additionally, the adaptation of this ligand for radiochemical applications
required additional purification stringency in order to eliminate the possibility of preferentially
labeling trace impurities. Therefore, for the investigation at hand, the final product was purified
via reverse-phase HPLC.
The high degree of symmetry of HOPO, combined with its flexibility, resulted in a 1HNMR with many overlapping multiplets due to different amide rotamers of the ligand. As a
result, the classification of HOPO as a mixture of rotamers of one compound rather than distinct
isomers or impurities was based on the identification of the expected compound by mass
spectrometry as well as the appearance of a single peak by HPLC analysis (Figure A.3.1-2).
Similar issues were encountered with the synthesis of the LICAM ligand ( Figure
3.4); however it was undertaken after we had overcome the hurdles of the HOPO ligand so
improved strategies were in place. Once again, the LICAM compound was characterized
primarily through mass spectrometry and HPLC due to the complicated nature of its NMR
spectrum (Figures A.3.3-4).
Due to the complicated synthesis of the complete ligands, efforts were made to
investigate the different binding groups using simpler molecules containing only a single
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Figure 3.3. Synthesis of 3,4,3-(LI-1,2-HOPO) (HOPO).
Reagents and conditions: a) CH 3COOOH (1.2 equiv), AcOH, TFA, 1 h, 79%; b) BnCl (1.2
equiv), K2CO3 (2.0 equiv), CH 3OH, 16 h, 63 oC, 92%; c) (COCl) 2 (2.2 equiv), CH 2Cl2, 025 oC, 6 h; d) spermine (0.17 equiv), TEA (2.0 equiv), CH 2Cl2, 0-25 oC, 24 h, 81% over
steps c & d; e) AcOH, HCl (12 N), 18 h, 45 oC, 42%
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Figure 3.4. Synthesis of 3,4,3-LICAM (LICAM).
Reagents and conditions: a) acetone, BnBr, K 2CO3 then MeOH, LiOH, HCl; b) DCM
(COCl)2; c) spermine, DCM, NEt 3, 0-25 oC, 12 h, 64%; d) 10% Pd/C, H 2, MeOH, r.t, 6 h,
73%

65

catechol or hydroxypyridinone group (Figure 3.5). Initially, a proof of principle experiment was
carried out with dopamine since it contained a catechol group, but then two different 'monomers'
were synthesized from the building blocks of the HOPO and LICAM ligands in order to probe
the binding of radioactive and non-radioactive Zr. The HOPO methyl monomer (HMM) and
catechol methyl monomer (CMM) units were produced by coupling the acid chloride derivatives
of the binding groups with methylamine to mimic the coupling to the spermine backbone in the
full ligands.
3.2.2:

Monomer studies

The synthesis of the octadentate ligands proved more challenging than originally
expected due to the challenges of multiple coupling reactions and the stringent purification
requirements intrinsic to tracer work. Therefore, initial evaluation was attempted with simpler
molecules to compare binding groups without requiring the complex synthesis of full ligands.
These single unit 'monomers' containing only a single catechol or hydroxypyridinone group were
created to probe the binding of Zr4+ (Figure 3.5). Experiments were done to complex these
monomers with radioactive and non-radioactive Zr on both the tracer level and macroscopic
scale respectively.
Dopamine, a readily available catechol-based molecule, was first used to evaluate the
binding potential of catechols for Zr4+. Radioactive 89Zr was added to a solution of dopamine and
a crude challenge experiment was used to determine if there was any complexation. The
radiolabeled mixture was run through a reverse phase extraction cartridge and the collected
fractions were monitored for both UV absorbance and radioactive counts. A partial correlation
between the UV and radioactive signal in the eluted fractions suggested some complexation of
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Figure 3.5. Chemical structures of the single binding unit monomers investigated. Each
monomer is a bidentate ligand with two electron donating oxygens highlighted in red.
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the

89

Zr by the dopamine (Figure 3.6). This served as a proof of concept demonstrating that

catechols did indeed have some affinity for Zr4+ and should be evaluated for possible ligands.
With this encouraging pilot study, we moved to evaluate the binding groups using the
specific monomer units we had designed to mimic the layout of the ultimate HOPO and LICAM
ligands. Both monomers were combined with non-radioactive ZrCl4 and the samples were
analyzed with LCMS in an attempt to identify potential Zr-monomer complexes. Unfortunately,
while both binding groups showed a number of peaks, none could be reasonably assigned to any
conceivable Zr-monomer complexes. It is reasonable that complexation would be complicated as
different number of units could bind to one or more Zr centers and these complexes may include
dimers or trimeric units as well as other components from the starting materials filling out the Zr
coordination sphere.
Next, both HMM and CMM were radiolabeled with neutralized

89

Zr oxalate solution to

evaluate binding on the tracer level. However, radioITLC analysis of the

89

Zr-monomer

complexes was inconclusive. No appreciable amount of labeled complex was found, which could
have two possible explanations: 1) no complexation occurred or 2) transient complexation did
occur but was not adequate for this kind of chromatography. For example, the EDTA in the
mobile phase of radioITLC analysis likely made a more stable complex with the

89

Zr4+ and

outcompeted any monomers which had initially bound to the metal, so no meaningful
information could be garnered from that analysis. RadioITLC without a chelating component in
the mobile phase proved unreliable in the separation of the free and bound 89Zr.
The radiolabeled monomers were also run through reverse phase solid phase extraction
cartridges and compared to the behavior of free 89Zr under the same conditions (Figure 3.7). The
free, unchelated 89Zr was found to elute primarily in the first 5% methanol in water wash fraction
68

Figure 3.6. Elution profile of preliminary 89Zr-dopamine experiment. A mixture of 89Zr and
dopamine was run through a C18 solid phase extraction cartridges and 1 mL fractions were
collected. The fractions were measured for radioactive counts and UV absorbance. A rough
correlation can be seen between the two which suggests that the 89Zr is in some way complexing
with the dopamine. This suggests a potential affinity of catechols for binding Zr.
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Figure 3.7. Elution profile of 89Zr-monomer mixtures with free 89Zr as a control through C18
Sep-Pak cartridges. 500 μL fractions were collected. The first 5 fractions were a wash with 5%
methanol in water. The second 5 fractions were eluted with methanol. The fractions and the
cartridges were gamma counted to account for all loaded activity. The 89Zr-HMM mixture elutes
similarly to the free 89Zr, suggesting a lack of chelation, however the 89Zr-CMM shows a
different elution profile suggesting some level of complexation occurred.
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(88%). The 89Zr-HMM mixture exhibited very similar behavior (79% in the first wash fraction)
suggesting that no meaningful complexation occurred, however the
differently. Only 16% of the

89

89

Zr-CMM sample behaved

Zr-CMM activity came out in the first wash fraction and nearly

30% of was found in the first methanol elution fraction. This suggests some level of
complexation from the catechol monomer, although the extent of complexation or the actual
speciation could not be determined in this method.
In order to probe the nature of the complexation observed in the cartridge study of the
89

Zr-CMM sample, we tried to evaluate the non-radioactive Zr-CMM mixture. To this end, a

mixtures of CMM and ZrCl4 were prepared at different ratios (1:1, 4:1, and 10:1 of CMM:ZrCl4)
and were analyzed by UV/Vis spectroscopy to probe the difference in absorbance as the catechol
groups bound to the metal. Unfortunately, the spectra did not change in any meaningful way
between the samples (Figure A.3.5). Either the catechol groups did not bind the Zr or the
conditions used in this study were insufficient to measure the differences.
Ultimately, the monomers proved insufficient to obtain any useful information on the
affinity of the binding groups for Zr. It was determined that the preorganization offered by the
full octadentate ligands would be necessary to evaluate the binding potential of the two groups.
Individual bidentate chelation was not shown to be strong enough to produce any consistent
measurable results.
3.2.3:

Ligand studies

Due to the disappointing conclusiveness of the monomer studies, the full HOPO and
LICAM ligands were synthesized and evaluated to compare the hydroxypyridinone and catechol
binding groups. Non-radioactive Zr-ligand complexes were formed on the macroscopic scale to
facilitate characterization. The complex was formed by mixing the HOPO and LICAM ligands
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with a slight excess (1.5 eq.) of ZrCl4 in water at room temperature. Both mixtures as well as the
ligands alone were analyzed by HPLC. The Zr-HOPO product was eluted as a single peak with a
retention time shifted about 30 seconds compared to the ligand alone (Figure A.3.6). The ZrLICAM mixture, on the other hand, did not consistently change retention times compared to the
ligand alone (Figure A.3.7). The slight movement may be due to wear on the column and may
not indicate a new, distinct species. The 1:1 binding of Zr4+ and HOPO was confirmed by
electrospray ionization mass spectrometry (ESI MS), which shows the expected mass signals
(837.2 [M+H]+ & 859.2 [M+Na]+) (Figure A.3.8). While mass spectroscopy also showed ZrLICAM to be a 1:1 ratio, the best matches from low resolution ESI MS suggested that the
LICAM ligand was deprotonated for only 4 out of the 8 catechol oxygens Zr-LICAM (832 [MH]- & 865 [M+Cl]-) (Figure A.3.9). The evidence of Zr-ligand complexation is much stronger
for the HOPO ligand than the LICAM on the macroscopic scale.
For our initial radiolabeling studies we used relatively high concentrations of ligand and
at 1 mM the HOPO ligand would reach 100% labeling at room temperature within 10 minutes of
the addition of 89Zr. At 10 uM the HOPO ligand attained 100% radiolabeling within 45 min. In
contrast, even at 1 mM, the LICAM ligand only achieved less than 30% radiolabeling even with
an increase in incubation time, the addition of heat, and varying the pH. This is most likely due
to the higher pKa of the catechol binding groups compared to the hydroxypyridinones. At pH 7,
the catechols are not fully deprotonated, but when you raise the pH of the reaction the Zr begins
to precipitate out of solution because Zr has very poor solubility in aqueous solution at higher
pH. Due to this incompatibility between the base strength of the binding groups and the workable
pH range of Zr and antibodies, the LICAM ligand was determined to be unsuitable for Zr
chelation and not studied any further. The consequence of these data is that the HOPO ligand
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was selected for further evaluation, while the LICAM ligand, and in fact catechols in general,
were eliminated from our pool of chelation possibilities.
3.3:

Conclusions
The catechol-based ligand, 3,4,3-LICAM (LICAM), was evaluated since catechols are

known functionalities in siderophores, but was ultimately found to be unsuitable for 89Zr4+ due to
the incompatibility between the pKa of the catechol group and the solubility of the Zr4+ cation.
Despite being octadentate and oxygen-rich, the maximum radiolabeling yield reached for the
LICAM ligand was <30%, despite varying temperature, pH, and reaction time. We believe the
issue to lie in the fact that the pKa for full deprotonation of the catechol group is 13.0, which
requires a higher pH for proper labeling; however, the Zr4+ cation is only soluble at lower pH,
and antibody radiolabeling is typically performed at ~ pH 7. This leads to a precarious balance
between keeping the

89

Zr4+ in solution and trying to get the coordinating oxygen atoms of the

catechol moiety deprotonated. Unfortunately, an appropriate compromise could not be found
that achieved >30% radiolabeling, so the ligand and catechol groups in general were dropped
from further development.
In contrast, the hydroxypyridinone ligand3,4,3-(LI-1,2HOPO) (HOPO), performed very
well in initial evaluations. The HOPO ligand achieved quantitative labeling at mild conditions
with short reaction times. This demonstrates the affinity of the hydroxypyridinone binding
groups for Zr4+ as well as the efficacy of the HOPO ligand itself. Therefore, the HOPO ligand
advanced for further investigation detailed in the next chapter.
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3.4:

Experimental section

3.4.1:

Materials and methods

All chemicals, unless otherwise noted, were acquired from Sigma-Aldrich (St. Louis,
MO) and used as received without further purification. All instruments were calibrated and
maintained in accordance with standard quality-control procedures. High resolution mass
spectrometry (HRMS) measurements were performed on a Waters SYNAPT High Definition
MS System (ESI-QTOF) and low resolution mass spectra (LRMS) were recorded with a Waters
Acquity UPLC with electrospray ionization (ESI) SQ detector. 1H NMR spectra were recorded at
ambient temperature on a Bruker 500 MHz NMR with Topsin 2.1 software. The NMR spectra
are expressed on the δ scale and were referenced to residual solvent peaks and/or internal
tetramethylsilane. The HPLC system used for analysis and purification compounds consisted of a
Shimadzu prominence system equipped with a diode array and a radioactive detector (Bioscan
inc, DC). UV-Vis spectroscopy was carried out using a Thermo Scientific Evolution 220 UVVisible spectrophotometer.
89

Zr was produced at Memorial Sloan Kettering Cancer Center on a TR19/9 cyclotron

(Ebco Industries Inc.) via the

89

Y(p,n)89Zr reaction and purified to yield

89

Zr with a specific

activity of 196–496 MBq/mg. Activity measurements were made using a CRC-15R Dose
Calibrator (Capintec). For the quantification of activities, experimental samples were counted on
an Automatic Wizard (2) g-Counter (Perkin Elmer). The radiolabeling of ligands was monitored
using salicylic acid impregnated instant thin-layer chromatography paper (ITLC-SA) (Agilent
Technologies) and analyzed on a Bioscan AR-2000 radio-TLC plate reader using Winscan
Radio-TLC software (Bioscan Inc., Washington, DC). All in vivo experiments were performed
according to protocols approved by the Memorial Sloan Kettering Institutional Animal Care and
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Use Committee (protocol 08−07−013). Purity of greater than 95% was confirmed using
quantitative HPLC analysis for non-radioactive compounds (HOPO and Zr-HOPO) and radioTLC for radioactive compounds (89Zr-HOPO).
3.4.2:

Synthesis

3.4.2.1:

HOPO-methyl monomer (HMM)

Methylamine was added to 1-Benzyloxy-2(1H)-pyridinone-6-carbonyl chloride in DCM.
The reaction mixture was washed with 1 N HCl and 10% NaHCO3. The DCM layer was dried
over Na2SO4 and evaporated to dryness. The product was washed with diethyl ether and purified
on a semi-preparative C4 column (Jupiter 250 × 10 mm, 5 µM, Phenomenox) using a gradient of
0-10% MeCN in water (both containing 0.1% TFA) over 20 min at a flow rate of 5 mL/min. The
product was collected from 4.1-5.0 min and lyophilized.
3.4.2.2:

Catechol-methyl monomer (CMM)

2,3-bis(benzyloxy)benzoyl chloride was combined with methylamine in

DCM. The

reaction mixture was washed first with 1 N HCL followed by a 10% NaHCO3 wash. The DCM
layer was dried over Na2SO4 and evaporated to dryness. The product was washed with diethyl
ether and purified on a semi-preparative C4 column (Jupiter 250 × 10 mm, 5 µM, Phenomenox)
using a gradient of 5-25% MeCN in water (both containing 0.1% TFA) over 20 min at a flow
rate of 5 mL/min. The product was collected from 4.8-6.5 min and lyophilized.
3.4.2.3:

3,4,3-(LI-1,2-HOPO)

The synthetic protocol from Xu et al. was employed with slight modifications.12
6-Carboxy-1-hydroxy-2(1H)-pyridinone

[1,2-HOPO

carboxylic

acid]

(1).

6-

Hydroxypicolinic acid (10.0 g, 71.9 mmol) and peracetic acid (21.0 g, 88.4 mmol) were added to
a stirring solution of glacial acetic acid (40.0 mL) and trifluoroacetic acid (60.0 mL). This
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mixture was stirred under nitrogen for 1 h at room temperature before being heated to 80 oC for
12 h. The reaction mixture started off a red-brown color and turned orange over time. A light
color precipitate formed, was collected by filtration, and washed with cold methanol. After
drying, the product was obtained as a beige solid (yield 79%).
1-Benzyloxy-6-carboxy-2(1H)-pyridinone [1,2-HOPOBn carboxylic acid] (2). Compound
1 (3.70 g, 23.8 mmol) and potassium carbonate (6.60 g, 47.7 mmol) were added to a stirring
solution of benzyl chloride (3.60 g, 28.6 mmol) in methanol (10.0 mL). The mixture was heated
to 63 oC and left to reflux for 16 h. The reaction mixture was a dark green suspension and formed
a precipitate over time. The blue-gray solid was filtered out of the reaction mixture and the
filtrate was collected. The solvent was evaporated and its residue was redissolved in 12.0 mL
water. The solution was acidified to pH 2 by dropwise addition of 12 N HCl. An off-white
precipitate was formed and was isolated by filtration. The product was washed with cold water
and dried to yield a light beige solid (yield 92%).
1-Benzyloxy-2(1H)-pyridinone-6-carbonyl chloride [1,2-HOPOBn acid chloride] (3). A
suspension of 2 (1.03 g, 4.20 mmol) in anhydrous dichloromethane (25 mL) was cooled to 0 oC.
Excess oxalyl chloride (0.715 mL, 9.40 mmol) was added while stirring followed by catalytic
amount of DMF (0.1 mL). Gas bubbles evolved, and the suspension became clear. The mixture
was then left at room temperature for 6 h, and the solvent was removed by rotary evaporation to
leave pale brown oil. After the oil was co-evaporated twice with toluene (10 mL), the crude acid
chloride (3) was used directly for the next reaction without any purification.
3,4,3-(LI-1,2-HOPO)Bn [benzyl-protected HOPO] (4). A solution of crude 3 (0.79 g,
3.0 mmol) in dichloromethane (15 mL) was added drop wise to a stirred solution of triethylamine
(0.84 mL, 6.0 mmol), spermine (0.10 g, 0.50 mmol) and DMAP (0.0060 g, 0.050 mmol) in dry
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dichloromethane (10 mL) at 0 oC. The reaction mixture was warmed to room temperature and
stirring was continued for 24 h. The reaction mixture was washed with 10% NaHCO3 solution,
followed by water. The organic phase was dried over anhydrous Na2SO4, filtered, and
concentrated to dryness. Purification by column chromatography (SiO2, 2-6% MeOH in CH2Cl2)
afforded the benzyl-protected precursor 3,4,3-LI(1,2-HOPOBn) (4) as white foam (yield 81%).
3,4,3-(LI-1,2-HOPO) (HOPO). Compound 4 (0.20 g, 0.18 mmol) was dissolved in 1:1
mixture of acetic acid and concentrated HCl (15 mL) at room temperature and the reaction
mixture was stirred at 50 oC for 18 h. The reaction progress was monitored by TLC. The crude
product was dried, redissolved in water, and purified by HPLC on a semi-preparative C4 column
(Jupiter 250 × 10 mm, 5 µM, Phenomenox) using a gradient of 5-28% MeCN in water (both
containing 0.1% TFA) over 20 min. The product peak was collected from 7-8.92 min and the
eluted solution was lyophilized to recover the product as a white solid. The purified ligand was
collected in multiple small batches with an approximate combined yield of 42%.
3.4.2.4:

3,4,3-LICAM

The synthetic protocol was based off that of Weitl et al.16 in combination with the
preparation of 2,3-bis(benzyloxy)benzoyl chloride as described by Zhang et. al.17
N,N'-(butane-1,4-diyl)bis(2,3-bis(benzyloxy)-N-(3-(2,3-bis(benzyloxy)benzamido)
propyl)benzamide) (3). A solution of 2,3-bis(benzyloxy)benzoyl chloride in DCM (1.54g, 4.4
mmol ) in 10 mL of DCM was added dropwise to a solution of spermine (0.202g, 1 mmol) and
NEt3 (0.505g, 5 mmol) in DCM (15 mL) at 0 oC under argon over 10 min while stirring. The
stirring was continued for another 30 min at 0 oC before the reaction mixture was allowed to
warm to room temperature and the stirring was continued overnight. The reaction mixture was
transferred into a separatory funnel and the DCM layer was washed with 1N HCl, then with 10%
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NaHCO3, followed by water. DCM layer was dried over anhydrous sodium sulfate and
evaporated to dryness. The crude compound was recrystallized with diethyl ether (yield 64%).
N,N'-(butane-1,4-diyl)bis(N-(3-(2,3-dihydroxybenzamido)propyl)-2,3-dihydroxy
benzamide) (3,4,3-LICAM). To a solution of 3 (0.146g, 0.1 mmol) in MeOH (10 mL) was
added 10% Pd/C. The reaction mixture was hydrogenated at balloon H2 pressure at room
temperature for 6 h. The catalyst was filtered through a celite pad under inert atmosphere. The
filtrate was evaporated under reduced pressure to obtain the final product. (yield= 73%)
3.4.3:

Monomer studies

3.4.3.1: Cold complexation
The catechol and hydroxypyridinone monomers (CMM and HMM) were combined with
various amounts of ZrCl4 in water at room temperature in an attempt to form Zr-monomer
complexes. These mixtures were analyzed by LCMS as well as UV/Vis spectroscopy.
3.4.3.2: Radiolabeling
Neutralized

89

Zr oxalate solution was added to a solution of dopamine for a proof of

concept experiment. The radiolabeled mixture was run through an Alltech Maxi-Clean SolidPhase Extraction Cartridges (C18 900mg sorbent, 1.35mL volume). The cartridges were
prewashed with 5 mL of each methanol, water, acetonitrile, and water again. After the samples
were loaded, the cartridges were then eluted with 2 mL each of water, acetonitrile, and water
again. 1 mL fractions were collected, promptly measured for radioactivity on a gamma counter,
and then left to decay before being measured for UV absorbance on a UV/Vis
spectrophotometer.
100 μM solutions of HMM or CMM were radiolabeled with varying amounts of
neutralized 89Zr oxalate solution at room temperature. Reaction mixtures were monitored for up
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to 1 d using radioITLC with Varian ITLC-SA strips (Agilent Technologies) and various mobile
phases including 50 mM EDTA, 0.5 M citric acid, and water. Further analysis was carried out
using Waters Sep-Pak C18 Plus Light Cartridges (130mg sorbent, 55-105 µm particle size). The
cartridges were prewashed with 5 mL of methanol and 5 mL of water. 100 μL samples of free
89

Zr oxalate, 89Zr-HMM, and 89Zr-CMM were each loaded onto cartridges, washed with 2.5 mL

of 5% methanol in water, and then eluted with 2.5 mL of methanol. 500 μL fractions were
collected during the wash and elution. Each cartridge and the collected fractions were then
measured with a gamma counter.
3.4.4:

Ligand studies

3.4.4.1: Cold complexation
Zr-ligand complexes were formed by mixing either HOPO or LICAM with a slight excess (1.5
eq.) of ZrCl4 in water or methanol at room temperature. The Zr-ligand mixtures were analyzed
by HPLC and MS (Figures A.3.6-9).
3.4.4.2: Radiolabeling
89

Zr was received after target processing as 89Zr-oxalate in 1.0 M oxalic acid. This

solution is then neutralized with 1.0 M sodium carbonate to reach the desired pH (usually 7).
Solutions of both the HOPO and LICAM ligands were prepared at 1 mM concentrations in water
and reacted with the neutralized 89Zr solution at room temperature. While this was adequate for
the HOPO ligand, it proved insufficient for the LICAM ligand. Additional radiolabeling attempts
were made for varying lengths of time (up to 24 h), pHs (6-8), and temperatures (25 or 37 oC).
None of these efforts led to considerable improvements in the labeling yield with a maximum of
30% radiolabeling achieved (individual trends can be seen in Figures A.3.10-11). The HOPO
ligand was also labeled at lower concentrations, down to 10 μM. Reactions were monitored via
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radio-TLC using Varian ITLC-SA strips (Agilent Technologies) and 50 mM EDTA at pH 5 as
the mobile phase. 89Zr-ligand complexes remained at the origin, while free 89Zr was taken up by
EDTA in the mobile phase and migrated along the ITLC strip.
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CHAPTER 4: AN ALTERNATIVE CHELATOR FOR 89ZR
RADIOPHARMACEUTICALS: RADIOLABELING AND EVALUATION OF
3,4,3-(LI-1,2-HOPO)
This chapter is an adaptation of published work, and is reproduced in part, from Deri, M. A.;
Ponnala, S.; Zeglis, B. M.; Pohl, G.; Dannenberg, J. J.; Lewis, J. S.; Francesconi, L. C. An
Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI1,2-HOPO). J. Med. Chem. 2014, 57(11), 4849-4860, Copyright 2014 American Chemical
Society.

4.1:

Introduction
The past few decades have played witness to a revolution in the understanding of the

intersection between transition metals and medicine. Not only has the body’s management of
metals emerged as an important therapeutic target, but metals have become critical components
of diagnostic and therapeutic agents. Unsurprisingly, the biomedical importance of chelators —
organic molecules capable of binding metals — has increased in parallel to this advent of metals
in medicine. The clinical use of chelators is most often associated with treatment for heavy metal
poisoning, for example the administration of ethylenediaminetetraacetic acid (EDTA) to treat
lead poisoning.1,

2

However, chelators are also critical components of metal-containing

diagnostics and therapeutics, in particular nuclear imaging agents bearing metallic radioisotopes.
In these cases, the role of the chelator is to stably sequester the radiometal and prevent its release
from the agent. While a number of excellent chelators for common radiometals are known, the
recent emergence of a few non-traditional medically useful isotopes have increased demand for
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novel chelators specifically tailored to the chemistry of these new radiometals.3, 4 The case of the
positron-emitting radiometal zirconium-89 (89Zr) provides a prime example of this phenomenon.
89

Zr is readily attracting attention as a radionuclide for positron emission tomography

(PET) imaging.5-12 In the last several years, a wide variety of preclinical studies have been
published.13-19 A number of

89

Zr-based imaging agents have been translated into the clinic,

including five current clinical trials in the US alone.20-25 While

89

Zr possesses a relatively low

energy positron (βavg = 395.5 keV) which affords images with high resolution, the principal
driver of its success has been its 78.41 h half-life. A half-life of just over 3 days allows images to
be collected multiple days after injection, making it particularly well-suited for the radiolabeling
of IgG antibodies. Radioimmunoconjugates have a circulation time of several days, and longer
imaging windows allow for both the accumulation of the tracer in the target tissue as well as the
clearance of any unbound tracer from the blood pool. This in turn leads to improved image
contrast and tumor-to-background activity ratios.
Yet a radionuclide with suitable decay characteristics is not sufficient to make an
effective imaging agent. It is also necessary to have a reliable method of chelating the radiometal
and attaching the chelate complex to the targeting vector. In the case of 89Zr, the most commonly
used chelator is desferrioxamine B (DFO, Figure 4.1). DFO, a natural bacterial siderophore, is a
hexadentate ligand with three hydroxamate groups which provide six oxygen donors  three
anionic and three neutral  for metal binding.26 In addition, DFO has a pendant amine which
has been derivatized in a number of ways to create bifunctional variants of the chelator for facile
conjugation to antibodies and other biomolecular vectors; for example, one such derivative is the
commercially available benzyl isothiocyanate DFO.27 Regardless of which bifunctional DFO
derivative is used for conjugation, DFO-mAb conjugates are typically radiolabeled with

89

Zr
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Figure 4.1. Structures of the currently used chelator for 89Zr, DFO, and the newly investigated
alternative chelator, HOPO, with binding oxygens highlighted in red.
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under mild conditions (pH 6.5-8.0, RT, 1 h).12, 28, 29 These radiolabeled bioconjugates can then be
purified by either size exclusion chromatography or centrifugal filtration prior to use.
While DFO is currently the gold standard for

89

Zr chelation, there is certainly room for

improvement. The primary issue with DFO is that even purified 89Zr-DFO-mAb conjugates have
been shown to produce significant uptake of radioactivity in the bones of mice, typically on the
order of 10 %ID/g.14, 19, 30-32 This uptake is not the result of the radioimmunoconjugate as a
whole. Rather, the free

89

Zr4+ cation is known to be osteophilic, meaning the metal itself is

readily mineralized into the skeleton.28, 33 Therefore, it becomes clear that 89Zr4+ is being released
from its chelator within the body. This uptake of

89

Zr4+ is of particular concern in the clinic, for

accumulation of 89Zr4+ in the bone can dramatically increase radiation dose to the bone marrow,
an especially radiosensitive tissue. This concern over in vivo stability has led several groups to
investigate the possibility of developing a better chelator for 89Zr.
As expressed in the Chapter 3, a ligand designed specifically with the chemistry of Zr4+
in mind may demonstrate improved stability upon complexation with Zr4+. A more stable
complex should be less prone to demetallation in vivo, resulting in reduced bone uptake and thus
a safer and more efficient

89

Zr-based PET tracer. However, at the time of this work, no novel

chelators for 89Zr4+ have appeared in the literature since the advent of 89Zr-immunoPET.
Our approach to finding a chelator for Zr4+ was inspired by a library of ligands developed
by Gordon et al. as actinide sequestration agents.34 One ligand in particular  3,4,3-(LI-1,2HOPO) (Figure 4.1)  was found to be very effective for plutonium(IV) decorporation.35-37
Knowing that zirconium and plutonium are both +4 metals with similar chemistries, it follows a
ligand that binds plutonium so well might be a promising candidate for Zr4+ chelation. This
ligand, referred to herein as HOPO, is an octadentate chelator composed of a spermine backbone
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coupled with four hydroxypyridinone groups for metal binding. The hydroxypyridinone groups
offer hard, oxygen donors appropriate for binding Zr4+ and have pKa’s of -0.8 and 5.8 compared
to the much higher pKa’s of the catecholate, hydroxamate, and alkylhydroxamate (pKa 9.5, 9.3,
and 8.7, respectively).34, 38, 39 In fact, hydroxamate groups were shown to be superior to catechol
groups in preliminary studies (see details in Chapter 3). Zr4+ has been shown to successfully
compete with Pu4+ in extraction experiments using a resin bearing 1,2-hydroxypyridinone
groups,40 which supports our hypothesis that the 1,2-hydroxypyridinone moiety would form a
strong chelator for Zr4+. The linear arrangement of donor atoms should impart faster binding
kinetics compared to their arrangement in a macrocycle. Furthermore, the increased denticity of
the HOPO ligand compared to DFO will allow for full saturation of the coordination
environment of Zr4+.38 Taken together, the eight coordinate binding and the hard oxygen donor
groups of the HOPO ligand should be an ideal coordination environment for Zr4+ and offer good
in vivo stability. While the HOPO ligand is admittedly not novel, its application to

89

Zr4+ and

PET is unique.
In this study, we investigate the synthesis and characterization of the HOPO ligand and
the Zr-HOPO complex as well as the radiolabeling, characterization, stability, and in vivo
behavior of

89

Zr-HOPO in comparison to

89

Zr-DFO. The comparative stabilities are further

investigated by density functional theory (DFT) calculations. Taken together, these studies
demonstrate the great potential of 3,4,3-(LI-1,2-HOPO) and that family of ligands as chelators
for 89Zr4+.
4.2:

Results and discussion
An ideal chelator for Zr4+ must meet a few core requirements: (1) it must be octadentate

to fully saturate the coordination sphere of Zr4+; (2) it must have hard, oxygen donors to
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compliment the hard, oxophilic Zr4+ cation; and (3), it must offer an appropriate sized cavity for
the 0.84 Å effective ionic radius of Zr4+.41 Additionally, an acyclic chelator would be preferred in
order to facilitate faster, more efficient radiolabeling conditions. It was with these factors in mind
that the HOPO ligand was chosen for investigation as an alternative, more effective chelator for
Zr4+.
4.2.1:

Synthesis and characterization.

The HOPO ligand was synthesized as previously reported (also see Chapter 3).31, 34, 42-44
However, the adaptation of this ligand for radiochemical applications required additional
purification stringency in order to eliminate the possibility of preferentially labeling trace
impurities. Therefore, for the investigation at hand, the final product was purified via reversephase HPLC.
The non-radioactive Zr-HOPO complex was formed on the macroscopic scale to
facilitate characterization. The complex was formed by mixing the HOPO ligand with a slight
excess (1.5 eq.) of ZrCl4 in water at room temperature. The 1:1 binding of Zr4+ and HOPO was
confirmed by high resolution mass spectrometry (HRMS), which shows the expected mass
signals (859.12; [M+Na]+) (Figure A.4.1). While the 1H-NMR of the Zr-HOPO complex
contained the same type of complicated overlapping multiplets as the ligand itself, there were
significant changes in the signals most closely associated with binding of Zr4+ (Figure A.4.2).
The participation of the hydroxypyridinone rings in the complexation of zirconium was
confirmed through infrared (IR) spectroscopy which shows a red-shift in the signals
corresponding to the hydroxypyridinone’s carbonyl groups (from 1630 to 1610, 1564 to 1537,
and 1375 to 1360 cm-1) groups as a result of the oxygens binding Zr4+ (Figure A.4.3).45, 46 The

86

calculated IR spectra resulting from the DFT work assign these signals to highly coupled
asymmetric carbonyl stretches (Figure A.4.4).
Next, the radioactive
ligand with a neutralized
89

89

89

Zr-HOPO complex was synthesized by radiolabeling the HOPO

Zr solution at a pH of ~7.0.

The identity of the radioactive

Zr-HOPO species was confirmed through a co-elution study wherein both the radioactive and

non-radioactive Zr-HOPO complexes were injected into the HPLC system together (Figure 4.2).
Their co-elution demonstrates that the

89

Zr-HOPO species possesses the same structure and

chemistry as the non-radioactive, characterized Zr-HOPO species. HPLC also confirmed the
purity of both the HOPO ligand and the Zr-HOPO complex to be higher than 95%. Further
characterization of the Zr-HOPO complex was attempted using ultraviolet–visible (UV-Vis)
spectroscopy, however the results were inconclusive as the spectral changes associated with the
ligand-metal complexation were minimal (Figures A.4.5-6).
4.2.2:

DFT Calculations.

The difficulties intrinsic to studying the aqueous chemistry of Zr, and these Zr-ligand
complexes in particular, preclude the use of potentiometric titrations or extensive NMR studies
due to solubility issues. Therefore, in order to further investigate the coordination chemistry of
the Zr-ligand complexes, we performed density functional theory (DFT) calculations on both ZrHOPO and Zr-DFO. Additionally, the results of the Zr-HOPO calculations led us to investigate a
slightly modified HOPO ligand adapted to overcome an observed weakness in the Zr-HOPO
structure. DFT calculations were performed using the GAUSSIAN 0947 suite of computer
programs. All calculations used the CEP-121G basis set and the B3LYP functional. We tested
four basis sets contained in GAUSSIAN 09 that can treat Zr (CEP-121G, CEP-31G, LanL2DZ
and QZVP), for their accuracy treating the gas phase acidity of two simple alcohols (ethanol and
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Figure 4.2. HPLC chromatogram of the co-injection of radioactive 89Zr-HOPO and nonradioactive Zr-HOPO. The ~30 s separation between the two peaks is due to the sequential setup
of the UV and radioactive detectors.
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methanol) as a test of their abilities to accurately treat the organic ligands (which are
polyalcohols). CEP-121G and QZVP performed the best (and about equally well). We chose
CEP-121G as it used less computational resources. The detailed data can be found in the
appendix, Table A.4.1. The geometries of all the species were completely optimized in all
internal degrees of freedom, while considering several different conformations of the ligands and
complexes. We base our reports on the lowest energy conformations. The vibrational frequencies
on the CP-corrected potential energy surface confirmed all structures to be stationary points (as
all frequencies are real) and enabled the calculation of enthalpies at 298 K, using the normal
harmonic approximations employed in the GAUSSIAN 09 program.47 The counterpoise
correction for basis set superposition error48-51 was incorporated using via optimization on the
CP-corrected potential energy surfaces (CP-OPT)2 in which two fragments were considered (the
Zr and all ligands as a single fragment) for the gas phase calculations. We used these frequencies
to calculate the IR spectrum of Zr-HOPO (Figure A.4.4) using a scaling factor of 0.992 which
we obtained for the B3LYP/CEP-121G by comparing the C=O stretch of N=methylacetamide
with the experimental value52, as we have done previously for B3LYP/D95**53. We used the
GaussView54 program to visualize the spectrum, choosing a resolution of 15 cm-1 for the best
match to the experimental spectrum.
We used the CPCM polarizable conductor-like solvent continuum model48, 50 with the
Bondi49 (rather than the default UFF55) option for the atomic radii used for the cavity as the
model for the aqueous bulk. We have recently reported that the radii used to define the cavities in
CPCM have a significant effect upon the ΔGsolv’s of both N-methylacetamide, NMA, and
water.56 The Bondi radii49 generally gave the best results when the electrostatic part was used
alone, as in this work. We note that CPCM gives ΔGsolv’s, rather than ΔH’s. For simplicity, we
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have labeled as ΔH’s the quantities obtained from a normal vibrational correction for enthalpy
calculated using the CPCM Hamiltonian. We used single point a posteriori CP corrections for
these calculations as GAUSSIAN 09 does not allow CP-OPT to be used with solvation models.
We calculated the geometry optimized structures of four complexes: (I) the Zr-HOPO complex
[Zr4+ + 3,4,3-(LI-1,2-HOPO)4-]; (II) a complex of an alternate HOPO-based ligand, where the
central aliphatic chain on the backbone possesses 3 carbons instead of 4 [Zr4+ + 3,3,3-(LI-1,2HOPO)4-]; (III) a previously studied Zr-DFO complex [Zr4+ + DFO2- + 2 H2O]2+, as well as
another conformation of the same complex that we found to be more stable (IIIa); and (IV) a
neutral, uncharged Zr-DFO complex [Zr4+ +DFO2- + 2OH-] (Figure 4.3). We considered III and
IIIa for comparison with a previous study on Zr-DFO2+, but also included IV for a better
comparison with I and II, which are both neutral complexes. All structures were evaluated in the
gas phase as well as with the CPCM to mimic an aqueous environment.
The previously reported DFT study14 of III used two different basis sets: LANL2DZ for
the Zr and 6-31+G(d) for the DFO and water molecules. Additionally, no correction was made
for basis set superposition error (BSSE). We thought it prudent to repeat this calculation using
the CEP-121G basis set to provide direct comparison to our calculations. We also further
explored the potential energy surface (PES) of III, finding a more stable structure, IIIa, that
contains H-bonds from each of the H’s on the protonated terminal amine to the oxygens of the
DFO (Figure 4.3). One of the H-bonds is bifurcated (the H interacts with two different oxygens),
a common behavior for ammonium salts.57 We found the ΔH of IIIa to be 10.6 kcal/mol lower
(gas phase) and 0.9 kcal/mol higher (aqueous solution using CPCM) than III. The lower ΔH of
III in solution is due to the extended terminal ammonium that can be more easily solvated than
the internally H-bonded structure of IIIa. Table 4.1 presents the calculated Zr-O bond distances
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Figure 4.3. General chemical structures and optimized DFT structures for (I) the Zr-HOPO
complex; (II) a complex of an alternate HOPO-based ligand [3,3,3-(LI-1,2-HOPO)] with Zr;
(III) a previously studied positively charged Zr-DFO complex; (IIIa) a new, more stable
conformation of the same charged Zr-DFO complex; and (IV) a neutral, uncharged Zr-DFO
complex
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I
II
III (ref13)
III
IIIa
IV
Zr(1,2-HOPO)4
Zr(hydroxamate)4
crystal (ref38)

CO-Zr
NO-Zr
CO-Zr
NO-Zr
CO-Zr
NO-Zr
CO-Zr
NO-Zr
CO-Zr
NO-Zr
CO-Zr
NO-Zr
CO-Zr
NO-Zr
CO-Zr
NO-Zr

Terminal Ligands
2.215
2.158
2.269
2.326
2.220
2.167
2.266
2.298
2.261
2.254
2.121
2.220
2.277
2.284
2.142
2.249
2.262
2.281
2.197
2.142
2.347
2.362
2.367
2.229
2.222
2.222
2.252
2.252
2.172
2.196
2.215
2.233

Central Ligands
2.205
2.283
2.270
2.223
2.205
2.291
2.263
2.218
2.199
n/a
2.111
n/a
2.211
n/a
2.144
n/a
2.237
n/a
2.188
n/a
2.442
n/a
2.417
n/a
2.212
2.212
2.242
2.242
2.163
2.199
2.189
2.178

Table 4.1. DFT Calculated Zr-O Bond Lengths
All bond lengths reported in Ǻ. DFT calculations were performed using the GAUSSIAN 09
program with CEP-121G as the basis set.
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in the five structures detailed above as well as for Zr chelated by four free 1,2-hydoxypyridinone
(1,2-HOPO) groups (Figure A.4.7). The bond lengths of an X-ray crystallographic study on a
related compound — Zr(hydroxamate)4 — are also included for reference.38 The Zr-O distances
for the DFO oxygens are all longer than those previously reported, but those between Zr and the
water oxygens are somewhat shorter (~0.01-0.03 Å, Table 4.1). However, the orientations of the
waters in the two structures are slightly different. The difference might be due to the BSSE
correction and/or the loss of basis set balance, especially across the Zr-O bonds. One generally
expects bond elongation when optimization is performed on a BSSE-corrected surface, as noted
for the Zr-O bonds in Zr-DFO. We have also noted that optimization of certain systems (e.g.,
water dimer58) converge to incorrect structures when small basis sets are used on a surface not
corrected for BSSE. Due to the steric problems within the ligand that modification of the ZrDFO bonds would provoke, changing the orientations of these oxygens would be more difficult
than those of the waters.
While Zr-HOPO (I) has two more Zr-O interactions than Zr-DFO (IV), we could not
assume it to be more stable, as IV has two Zr-OH interactions to compensate for the missing
interactions with the ligand. We used Reaction 4.1 to determine the relative stability of the two
complexes. We note that the structure of DFOH2 has a protonated amine that hydrogen bonds to
three oxygens, one of which is not protonated, which results in a neutral structure (Figure
A.4.8).
I + DFOH2 + 2H2O  IV + HOPOH4 (4.1)
The calculated enthalpies of this reaction are 47.9 kcal/mol (gas) and 31.8 kcal/mol (CPCM).
These data strongly suggest that Zr-HOPO is more stable than Zr-DFO. The difference between
the gas phase and CPCM enthalpies reflects the large solvation free energy of the small OH 93

anion. However, the difference seems quite large for two species that each have eight Zr-O
interactions. One reason for this large difference appears to be that Zr-O distances found in IV
are about 0.01 Å larger on average, suggesting these bonds in IV to be weaker than in I or II.
These calculations suggest a remarkable improvement in energetic favorability for Zr-HOPO
over Zr-DFO.
When we optimized the geometry of I, we found several local minima. Structure I has the
lowest energy, but we thought that we might find a more stable conformation if we eliminated
the unfavorable gauche orientation of the -(CH2)4- linker between the middle two chelating
groups of I. As we could not find a more stable structure for I, we decided to eliminate one of the
CH2 groups from I to form II: Zr complexed with a new HOPO-based ligand  3,3,3-(LI-1,2HOPO)  with a shortened center spacer in the backbone (Figure 4.3). We expect that the
modified ligand of II would bind more tightly to the Zr since it eliminates the unfavorable
gauche interaction. To test this hypothesis, we calculated the enthalpy of the reaction that
exchanges the ligands of I and II (Reaction 4.2), which we found to be -2.8 kcal/mol (gas) and 3.2 kcal/mol (CPCM), suggesting that the equilibrium constant for Reaction 4.2 be ~200 at
298 K.
I + 3,3,3-(LI-1,2-HOPO)  II + 3,4,3-(LI-1,2-HOPO) (4.2)
Thus, we expect that II would provide even further advantages over I as a ligand for Zr4+.
Accordingly, we are now exploring this possibility by synthesizing the 3,3,3-(LI-1,2-HOPO)
ligand.
4.2.3:

Radiolabeling Experiments.

Preliminary radiolabeling experiments demonstrated quantitative radiolabeling of 10 mM
HOPO with

89

Zr within 10 min at room temperature at pH 7 in water. Further experimentation
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revealed that the time necessary for complete labeling was dependent on ligand concentration,
with lower concentrations requiring more time. For example, a HOPO concentration of 10 μM
required 45 min to achieve 100% labeling. In general, radiolabeling reactions were left to
incubate for 1 h to ensure quantitative labeling, and all radiolabeling reactions were monitored
by radioactive thin layer chromatography (radio-TLC).
Radio-TLC analysis of the labeling solutions revealed an interesting concentrationdependent speciation phenomenon (Figure 4.4). At high concentrations of HOPO (e.g. 10 mM),
radio-TLC analysis 10 min after labeling revealed one sharp peak at the origin with a small bump
immediately following it. Initially, this seemed like an artifact, however when radio-TLC
analysis is repeated at later time points, this small bump grows into a second, distinct peak. Over
time, the first peak slowly converts to the second, and 24 h later, only the second peak remains.
These two peaks must represent two different complexes of

89

Zr and HOPO, one which is the

initial kinetic product and one which is the ultimate thermodynamically stable product. It is
significant to note that throughout this conversion — and at every point from 10 min onward —
no free 89Zr4+ is observed. This suggests that all of the 89Zr4+ is initially complexed by HOPO in
some fashion, but then over time converts to a different isomer or complex without the

89

Zr4+

ever being released. Most likely, this means the complex undergoes an intramolecular
rearrangement of some kind. Upon further investigation, this phenomenon was found to be
concentration-dependent. As the concentration of HOPO decreased, two things changed: the
secondary peak became increasingly prevalent at early time points, and the two peaks appeared
closer together and became less distinguishable by radio-TLC.
The observation that the first peak is less prominent at lower ligand concentrations
suggests a possible explanation for the identity of the first peak: a dimer of two ligands
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Figure 4.4. Radio-TLC profiles of the 89Zr-HOPO radiolabeling reaction over time at different
concentrations of ligand. Two peaks are observed, with the first peak (the kinetic product)
converting to the second peak (the thermodynamic product) over time. The initial area ratio and
separation of the two peaks is dependent upon the concentration of the ligand.
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simultaneously binding one

89

Zr atom. As the concentration of the ligand was decreased, the

likelihood of forming such a dimer would also decrease, and thus the first peak would be less
abundant. With this explanation, the second peak is most likely the 1:1 89Zr-HOPO complex that
was expected. This explanation also explains how the conversion of the first species to the
second could take place without releasing the metal. Converting from a dimer to a 1:1 complex
seems like a reasonable transformation, as the unused binding groups of one ligand simply
replace the binding sites of the second ligand. This hypothesis is supported by the fact that the
HPLC co-elution study (see above) was carried out 24 h after the initial radiolabeling so that the
sample only consisted of the second radio-TLC peak. HPLC analysis showed the compound
responsible for the second radio-TLC peak to elute with the characterized, 1:1 non-radioactive
Zr-HOPO complex, thus confirming its identity.
An explanation for the second observation — that the two peaks get closer together as the
ligand concentration decreases — is somewhat more elusive; however it is a consistently
observable trend. The major difficulty in elucidating the exact speciation is that these phenomena
seem only to occur at the tracer level. In these experiments, the ligand concentrations are in the
mM to μM range, while the concentration of

89

Zr is in the nM to pM range. These conditions

cannot be mimicked on the macroscale without inordinate amounts of the HOPO ligand (e.g,
~3.4 kg of HOPO for every 10 mg of Zr), so analysis is limited to tests that can be carried out on
the radioactive samples. Furthermore, as the concentration of the ligand is reduced and
approaches that of the metal, the two peaks move closer together to the point where they become
indistinguishable. This trend complicates matters because as the two peaks move ever closer
together, they begin to appear to be one peak, yet it is impossible to know for certain which of
the two original peaks this species represents.
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Finally, an alternative explanation for the two peaks is that they simply represent two
different coordination structures of the 1:1 Zr-HOPO complex. For example, the initial peak may
be HOPO bound to Zr by only six donor groups which converts to the second peak of full
octadentate chelation as the final HOPO group changes conformation to bind the metal. While
this explanation is consistent with the fact that the conversion between the two species does not
involve releasing the metal, it does not provide a justification for the concentration dependence.
Further investigations into these speciation phenomena are on-going.
Recently, a study investigating the luminescence of Eu3+ complexes with the same (3,4,3LI-1,2-HOPO) ligand has shown a similar phenomenon. Examination of measured luminescence
lifetimes of isolated Eu-HOPO compared to in situ formed Eu-HOPO suggested a kinetic
isomer wherein the HOPO ligand binds the Eu3+ in such a way that the Eu3+ may be bound to a
water molecule. The conversion of the kinetic isomer to the longer lived thermodynamic isomer
was determined by luminescence quantum yield, luminescence lifetime measurements and
magnetic circular dichroism spectroscopy. The authors propose that the Eu-HOPO kinetic isomer
may possess a bound water molecule as well as a lower degree of f-orbital overlap.59
4.2.4:

Stability Studies

While this study did not endeavor to measure stability constants due to the difficulty of
such measurements and the need for specialized equipment, Sturzbecher-Hoehne has recently
reported the solution thermodynamic stability of the Zr-HOPO complex. The log β110 was
determined to be 43.1 ± 0.6, attesting to the extraordinary stability of the Zr4+ complex further
supporting development of this ligand for 89Zr PET radiopharmaceutical applications.60
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4.2.4.1:

Serum Stability

In order to gain insight into the in vitro and in vivo kinetic inertness of the Zr-HOPO
complex, serum stability tests were performed to simulate biological conditions. Both
HOPO and

89

89

Zr-

Zr-DFO complexes were found to be stable over a 7 d period at 37 oC in human

serum (98.8% and 98.3% intact respectively). Further, no protein-bound 89Zr was observed in the
serum samples containing the

89

Zr-ligand complexes, which confirms that the complexes

remained intact.
4.2.4.2:

EDTA challenge

Both HOPO and DFO were labeled with

89

Zr and then incubated with a 100-fold excess of

EDTA at a range of pH values at 37 oC for a period of 7 d in order to examine the stability of the
Zr-ligand complexes and their susceptibility to transchelation (Table 4.2). Analysis of the
samples by radio-TLC allowed for the differentiation of the complexes since
migrates along the ITLC strip, while both

89

Zr-DFO and

89

89

Zr-EDTA

Zr-HOPO remain at the origin. DFO

was shown to be surprisingly vulnerable to transchelation, most notably at lower pHs but also at
neutral and biological pHs. In contrast, HOPO demonstrated a remarkable resistance to
transchelation, remaining >99% intact over the full 7 days for the entire range of pH values
tested. The fact that a 100-fold excess of EDTA was unable to strip the

89

Zr from HOPO is a

testament to the stability of the complex. In contrast, the release of 89Zr from DFO suggests that
the ligand is susceptible to transchelation and may experience similar release in vivo to any
number of competing substances in the body. Additionally, as tumors are known to be more
acidic than healthy tissues, the greatly improved stability of the Zr-HOPO complex over Zr-DFO
at lower pH may prove beneficial for cancer imaging.
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Starting
Complex
89
Zr-HOPO

89

Zr-DFO

pH
8.0
7.5
7.0
6.5
6.0
5.5
5.0
8.0
7.5
7.0
6.5
6.0
5.5
5.0

Initial
99.7±0.6
100
100
100
100
99.5±0.9
99.7±0.6
100
100
100
100
100
100
100

% Intact Starting Species by Incubation Time
1h
3h
1d
3d
5d
99.8±0.4
100
100
100
100
99.3±1.3
100
100
100
100
99.0±1.8
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
99.0±0.9
93.0±4.1
87.9±6.7
100
99.3±0.6
97.3±2.3
93.7±3.2
89.9±4.0
100
98.8±0.9
96.7±1.7
95.0±1.8
92.8±3.3
100
98.7±0.8
96.5±1.3
93.4±3.1
90.1±8.5
99.9±0.2
96.2±0.6
93.4±1.8
88.6±5.9
90.0±3.5
97.1±0.8
90.7±1.7
64.7±3.0
44.1±10.0
39.7±12.8
86.6±1.5
55.7±3.8
3.0±0.8
2.4±0.9
1.8±0.4

7d
100
100
100
100
99.6±0.7
100
99.2±1.5
76.1±11.9
75.5±14.1
90.4±4.5
87.0±6.8
80.1±11.6
36.3±17.0
1.5±0.2

Table 4.2. EDTA Ligand Challenge
Radiolabeled ligand complexes were incubated with 100-fold excess EDTA at set pH values at
37 oC for 7 d. The experiment was done in triplicate. Green shading indicates >99% intact,
yellow indicates 99-90% intact, orange indicates 90-80% intact, and red indicates <80% intact.
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4.2.4.3:

Metal Cation Competition

As a counterbalance to the EDTA challenge that evaluated the potential for another
ligand to outcompete HOPO for the metal cation, a metal competition study was performed to
see if other metal cations could outcompete 89Zr for the HOPO binding pocket. Both HOPO and
DFO were labeled with

89

Zr and then incubated with a 10-fold excess of various metal salts at

pH 7.4 at 37 oC (Table 4.3). The samples were monitored for 7 d by radio-TLC to determine the
percentage of intact

89

Zr-ligand complex. Both

89

Zr-DFO and

89

Zr-HOPO proved relatively

stable (>95% intact) when challenged with the majority of competing metals with the notable
exception of Fe3+. In this case, after 7 d of incubation with FeCl3, HOPO released ~17% of the
89

Zr4+ compared with DFO which released >50% of the

89

Zr4+. Since DFO is originally a

siderophore, its affinity for iron over zirconium is unsurprising. DFO also exhibited a slight
release of

89

Zr4+ in the presence of Ga3+ (~9%). This competition further demonstrates the

stability of the Zr-HOPO complex and shows an advantage over Zr-DFO.
4.2.5:

In Vivo Studies.

An advantage of working with a ligand that has already been evaluated for a different
biological application is that studies into the toxicity of the compound have already been carried
out.31 The toxicity of HOPO was studied in both mice42 and baboons44 and neither showed any
evidence of harm with frequent, repeated injections of the HOPO ligand at concentrations of 10
μmol/kg and 30 μmol/kg respectively. These data — combined with the fact that the extremely
small amounts of compound needed for radiopharmaceutical studies are far below the threshold
for pharmacological effects — allowed for the immediate evaluation of

89

Zr-HOPO in mice

without concerns about adverse reactions.
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Competing
Metal
Cation
Co2+

1h
89
Zr-HOPO 89Zr-DFO
98.5 ± 2.2 92.5 ± 0.4

% Intact Starting Species by Incubation Time
1d
5d
89
89
89
Zr-HOPO
Zr-DFO
Zr-HOPO 89Zr-DFO
98.2 ± 2.6
98.6 ± 2.0 96.2 ± 0.5
93.4 ± 3.1

7d
Zr-HOPO 89Zr-DFO
98.9 ± 1.6
95.8 ± 1.1

89

Cu2+

98.2 ± 2.5

95.8 ± 4.0

98.1 ± 2.7

98.2 ± 2.6

98.3 ± 2.4

96.8 ± 1.5

98.4 ± 2.3

95.3 ± 0.2

3+

97.0 ± 4.2

90.6 ± 4.5

89.8 ± 5.4

48.2 ± 27.0

90.5 ± 3.8

51.9 ± 11.2

83.0 ± 4.2

39.1 ± 9.9

3+

98.4 ± 2.3

94.2 ± 5.6

97.9 ± 3.0

94.9 ± 4.3

97.3 ± 1.9

93.0 ± 4.4

96.4 ± 0.6

91.1 ± 2.2

3+

98.2 ± 2.6

94.3 ± 1.4

97.8 ± 3.1

95.0 ± 2.7

96.5 ± 2.9

98.4 ± 2.2

94.5 ± 4.1

97.0 ± 0.7

+

99.0 ± 1.5

97.2 ± 4.0

98.7 ± 1.9

94.8 ± 3.5

98.5 ± 2.2

97.6 ± 0.7

98.1 ± 0.7

97.0 ± 1.6

2+

98.3 ± 2.5

94.4 ± 0.02

98.3 ± 2.5

95.6 ± 2.5

98.6 ± 2.0

98.1 ± 0.8

98.7 ± 1.8

96.5 ± 0.1

2+

98.4 ± 2.3

97.2 ± 4.0

98.4 ± 2.2

94.9 ± 3.2

98.7 ± 1.9

97.0 ± 1.2

97.4 ± 0.1

97.8 ± 1.1

2+

98.6 ± 2.0

92.9 ± 2.2

98.7 ± 1.9

97.9 ± 3.0

97.7 ± 3.3

97.6 ± 3.4

98.3 ± 2.4

96.4 ± 1.3

Fe

Ga

Gd
K

Mg
Ni

Zn

Table 4.3. Metal Competition
Radiolabeled ligand complexes were incubated with a 10-fold excess of various biologically
relevant metal salts in PBS at a pH of 7.4 at 37 oC for 7 d. The experiment was repeated twice.
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4.2.5.1:

Imaging

PET imaging studies were performed in order to investigate the in vivo pharmacokinetics of the
89

Zr-HOPO complex. To this end, the 89Zr-HOPO complex (260 μCi, 9.6 MBq, in 200 μL 0.9%

sterile saline) was injected into healthy mice and imaged at four time points using PET (Figure
4.5). At 10 min, the vast majority of the radioactivity is observed in the bladder, which indicates
rapid renal clearance. At the remaining time points (4, 12, and 24 h), much of the radioactivity is
seen in the gut, signifying hepatobiliary as well as renal excretion. Interestingly, there was
significant activity localized in the gall bladder: this is most likely a consequence of the
hepatobiliary excretion of the complex through the gut of the mice but is not fully understood at
present. This explanation is supported by the fact that the activity in the gall bladder decreases
over time. Importantly, no significant bone uptake was observed in the imaging at any time
point, indicating that there was no release of the

89

Zr4+ cation from the ligand in vivo. For

comparison, previous studies with the 89Zr-DFO complex show only rapid renal clearance of the
radiotracer.14, 33, 61
4.2.5.2:

Biodistribution

An ex vivo biodistribution study was also performed in healthy mice to further probe the
biological behavior of the

89

Zr-HOPO complex. The results of this study match the trends

observed in the PET images, including the involvement of both the renal and hepatobiliary
clearance pathways. (Table 4.4). At 10 min post injection, the activity was found largely in the
kidneys (9.46 ± 2.71 %ID/g), suggesting rapid renal excretion, as well as the small intestine
(5.99 ± 1.18 %ID/g) and the gall bladder (6.61 ± 2.87 %ID/g), consistent with hepatobiliary
excretion. By the 1 h time point, most of the activity had already cleared through the kidneys
(1.05 ± 0.51 %ID/g) but was still seen in the gall bladder (6.94 ± 3.38 %ID/g). The large
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Figure 4.5. Coronal PET images of 89Zr-HOPO. Healthy mice were administered 89Zr-HOPO
(260 µCi [9.6 MBq] in 0.9 % sterile saline) via tail vein injection and imaged between 10 min
and 24 h after injection. The gall bladder (a), gut (b), and bladder (c) can be visualized. The 89ZrHOPO complex undergoes rapid renal clearance followed by slower hepatobiliary clearance. No
uptake of 89Zr in the bone is observed.
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intestine contains the majority of the radioactivity at 4 h (7.17 ± 2.15 %ID/g) while the 12 and
24 h time points demonstrate the further clearance of the remaining activity from all of the
organs examined. Notably, the low amount of activity in the bone, which decreases over time
(from 1.04 ± 0.44 to 0.17 ± 0.03 %ID/g), is consistent with the clearance of the intact complex
rather than accumulation due to mineralization of the free radiometal.
The

89

Zr-HOPO clearance pathways are similar to the clearance of the

238

Pu-HOPO

complex that was injected intraveneously or intraperitoneally.62 Also, dose dependent removal of
238

Pu from mice by orally administred HOPO resulted in similar hepatobiliary clearance at

24 h.63
In order to make direct comparisons, the in vivo biodistribution of

89

Zr-DFO was

investigated in the same study (Figure 4.6). As expected, 89Zr-DFO cleared exclusively through
the kidneys and thus was eliminated more quickly than 89Zr-HOPO. The fact that 89Zr-DFO does
not show any gall bladder uptake further suggests that the uptake of

89

Zr-HOPO in the gall

bladder is a result of hepatobiliary excretion. Other than the difference in excretory pathways, the
clearance of the two complexes through the blood and other organs appears similar, with neither
complex accumulating appreciably anywhere in the body.
There is a statistically significant difference in the amount of activity in the bone between
89

Zr-DFO and 89Zr-HOPO, with higher levels observed for 89Zr-HOPO. This could be the result

of the release of the

89

Zr4+ cation from the HOPO ligand due to instability or metabolism;

however, if this were the case, we would expect to see a more substantial amount of radioactivity
in the bone and for the amount of activity to stay constant or grow over time. Instead, with such a
small amount of activity and no evidence of long-term accumulation of the radiometal in the
bone, this is most likely a question of the perfusion and clearance kinetics of

89

Zr-HOPO rather
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10 min
Zr-HOPO

Zr-DFO

1h
Zr-HOPO

4h
Zr-DFO

Zr-HOPO

12 h
Zr-DFO

Zr-HOPO

24 h
Zr-DFO

Zr-HOPO

Zr-DFO

Blood

3.24 ± 0.66 5.11 ± 0.90 0.17 ± 0.10 0.10 ± 0.04 0.05 ± 0.04 0.03 ± 0.01 0.02 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.02 ± 0.02

Heart

1.57 ± 0.22 2.17 ± 0.62 0.12 ± 0.06 0.06 ± 0.02 0.06 ± 0.01 0.03 ± 0.01 0.06 ± 0.01 0.02 ± 0.00 0.07 ± 0.01 0.02 ± 0.01

Gall
Bladder

6.61 ± 2.87 1.57 ± 0.25 6.94 ± 3.38 0.47 ± 0.14 1.00 ± 0.41 0.26 ± 0.15 2.45 ± 1.02 0.16 ± 0.14 1.15 ± 0.59 0.23 ± 0.21

Liver

3.29 ± 0.75 0.88 ± 0.49 0.22 ± 0.09 0.24 ± 0.07 0.13 ± 0.01 0.12 ± 0.03 0.09 ± 0.02 0.06 ± 0.02 0.06 ± 0.03 0.11 ± 0.02

Stomach 1.22 ± 0.39 0.62 ± 0.28 0.30 ± 0.15 1.10 ± 0.51 0.50 ± 0.74 0.06 ± 0.02 0.01 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.01 ± 0.01
Large
0.26 ± 0.15 0.43 ± 0.13 0.09 ± 0.06 0.02 ± 0.01 7.17 ± 2.15 0.62 ± 0.55 0.10 ± 0.03 0.07 ± 0.05 0.03 ± 0.02 0.02 ± 0.01
Intestine
Small
5.99 ± 1.18 0.94 ± 0.16 1.11 ± 0.35 0.35 ± 0.17 0.12 ± 0.13 0.04 ± 0.02 0.02 ± 0.01 0.01 ± 0.01 0.02 ± 0.00 0.02 ± 0.01
Intestine
Kidney

9.46 ± 2.71 14.44 ± 5.88 1.05 ± 0.51 1.39 ± 0.55 0.40 ± 0.14 1.10 ± 0.44 0.53 ± 0.23 0.36 ± 0.13 0.51 ± 0.29 1.12 ± 0.33

Bladder

2.04 ± 1.06 2.50 ± 0.48 0.73 ± 0.36 2.47 ± 1.30 0.58 ± 0.27 1.22 ± 0.77 0.54 ± 0.26 0.69 ± 0.31 0.28 ± 0.14 0.56 ± 0.41

Muscle

0.36 ± 0.06 0.73 ± 0.56 0.10 ± 0.03 0.02 ± 0.01 0.09 ± 0.06 0.01 ± 0.01 0.06 ± 0.01 0.01 ± 0.00 0.06 ± 0.01 0.01 ± 0.00

Bone

1.04 ± 0.44 0.43 ± 0.10 0.29 ± 0.09 0.07 ± 0.04 0.23 ± 0.12 0.04 ± 0.02 0.25 ± 0.07 0.03 ± 0.01 0.17 ± 0.03 0.06 ± 0.01

Table 4.4. Biodistribution Results
All values reported as %ID/g. Healthy, athymic nude mice were injected with either 89Zr-HOPO
or 89Zr-DFO (24-35 µCi [0.89-1.29 MBq] in 0.9 % sterile saline) via the tail vein, sacrificed at
specified time points, and necropsied. Organs were collected, weighed, and measured for
radioactivity using a gamma counter. N = 4 for each compound at each time point.
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Figure 4.6. Biodistribution of 89Zr-HOPO and 89Zr-DFO in select organs. Healthy, athymic nude
mice were injected with either 89Zr-HOPO or 89Zr-DFO (24-35 µCi [0.89-1.29 MBq] in 0.9 %
sterile saline) via the tail vein, sacrificed at specified time points, and necropsied. The
concentration of radioactivity in the chosen organs is expressed as %ID/g and presented as an
average value from four animals ± standard deviation. Bl = Blood, GB = Gall Bladder, L =
Liver, LI = Large Intestines, SI = Small Intestines, K = Kidney, Bo = Bone. *Indicates P values
of <0.05.
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than demetallation. Since

89

Zr-DFO is only cleared renally, and not through the hepatobiliary

system, it is excreted from the body faster than 89Zr-HOPO, as evidenced by the blood clearance
curve (Figure 4.7). We postulate that just as 89Zr-HOPO takes a longer time to clear the blood, it
also takes a longer time to clear the bone. The higher levels of

89

Zr measured in the bone are

likely a result of higher levels of 89Zr still present in the mouse.
The difference in clearance pathways between 89Zr-HOPO and 89Zr-DFO should not be a
concern in the long run. Upon conjugation to an antibody, the pharmacokinetics of the

89

Zr-

HOPO complex will be completely superseded by those of the biomacromolecule. However, at
this point in the development of the ligand  with only the bare

89

Zr-ligand complex available

 it is only possible to test its in vivo stability for the comparatively short circulation time
associated with the small molecule complex as opposed to the several day circulation time of a
radioimmunoconjugate. Therefore, while the in vivo stability of the

89

Zr-HOPO complex

demonstrated here is very promising, it alone is insufficient to prove its viability in 89Zr-HOPObased radioimmunoconjugates. With this in mind, the longer duration in vitro studies were
intended to supplement the in vivo experiments by allowing us to probe the longer stability
requirements of the antibody labeling applications. In sum, the combination of the in vitro and in
vivo experiments gives a more complete picture of the stability of the

89

Zr-HOPO complex and

illustrates the great potential of the HOPO ligand.
4.3:

Conclusions
In terms of Zr4+ chelation and stability, 3,4,3-(LI-1,2-HOPO) has proven to be a superior

ligand compared to DFO. We have synthesized the HOPO ligand, synthesized and characterized
the Zr-HOPO complex, and evaluated the stability and behavior of the 89Zr-HOPO complex both
in vitro and in vivo. HOPO has proven comparable — and often superior — to DFO in every test
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Figure 4.7. Blood clearance of 89Zr-HOPO and 89Zr-DFO in healthy, athymic nude mice (n = 4)
over time. Inset shows a zoomed graph for further detail.
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we have conducted, both experimentally and computationally. Our DFT calculations have shown
Zr4+ complexed with HOPO to be significantly more stable than with DFO and have suggested
that the complex with 3,3,3-(LI-1,2-HOPO) — a modified hydroxypyridinone-based ligand —
might be even more stable still. The improved stability of the

89

Zr-HOPO complex is most

dramatically shown in the EDTA challenge experiments in which the
able to resist transchelation far better than

89

89

Zr-HOPO complex is

Zr-DFO. This increase in stability is especially

significant because it is observed not only at lower pHs like 5.0-6.5 at which the lower pKa of
the hydroxypyridinone was an expected advantage, but also at biologically relevant pHs like 7.07.5 at which DFO was still susceptible to partial transchelation. In addition, we have shown the
89

Zr-HOPO complex to have good biological behavior — clearing the body cleanly without any

signs of demetallation.
The ultimate test of the efficacy of the HOPO ligand will come when the ligand can be
conjugated to an antibody, radiolabeled, and tested in vivo in the context of its desired
application. To this end, bifunctionalization of the HOPO ligand is currently underway, and
evaluation of the ligand when conjugated to an antibody was undertaken, and evaluation of the
ligand when conjugated to an antibody will be discussed in Chapter 5. Additionally, the 3,3,3(LI-1,2-HOPO) ligand may be synthesized in the future to follow up on the intriguing results of
the DFT calculations which suggest that a shortened backbone will impart even greater stability
upon binding of Zr4+. For now, the HOPO ligand shows tremendous promise as a chelator for
89

Zr and may eventually supplant DFO for immunoPET applications.
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4.4:

Experimental section

4.4.1:

Materials and methods

All chemicals, unless otherwise noted, were acquired from Sigma-Aldrich (St. Louis,
MO) and used as received without further purification. Human serum was purchased frozen from
Sigma Aldrich. All water used was ultra-pure (>18.2 MΩ cm– 1). All instruments were calibrated
and maintained in accordance with standard quality-control procedures. High resolution mass
spectrometry (HRMS) measurements were performed on a Waters SYNAPT High Definition
MS System (ESI-QTOF) and low resolution mass spectra (LRMS) were recorded with a Waters
Acquity UPLC with electrospray ionization (ESI) SQ detector. 1H NMR spectra were recorded at
ambient temperature on a Bruker 500 MHz NMR with Topsin 2.1 software. The NMR spectra
are expressed on the δ scale and were referenced to residual solvent peaks and/or internal
tetramethylsilane. The HPLC system used for analysis and purification compounds consisted of a
Shimadzu prominence system equipped with a diode array and a radioactive detector (Bioscan
inc, DC). IR spectroscopy was performed on a solid sample using an attenuated total reflectance
attachment on a PerkinElmer Spectrum 2 FT-IR spectrometer with a UATR Two attachment.
UV-Vis spectroscopy was carried out using a Thermo Scientific Evolution 220 UV-Visible
spectrophotometer.
89

Zr was produced at Memorial Sloan Kettering Cancer Center on a TR19/9 cyclotron

(Ebco Industries Inc.) via the

89

Y(p,n)89Zr reaction and purified to yield

89

Zr with a specific

activity of 196–496 MBq/mg. Activity measurements were made using a CRC-15R Dose
Calibrator (Capintec). For the quantification of activities, experimental samples were counted on
an Automatic Wizard (2) g-Counter (Perkin Elmer). The radiolabeling of ligands was monitored
using salicylic acid impregnated instant thin-layer chromatography paper (ITLC-SA) (Agilent
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Technologies) and analyzed on a Bioscan AR-2000 radio-TLC plate reader using Winscan
Radio-TLC software (Bioscan Inc., Washington, DC). All in vivo experiments were performed
according to protocols approved by the Memorial Sloan Kettering Institutional Animal Care and
Use Committee (protocol 08−07−013). Purity of greater than 95% was confirmed using
quantitative HPLC analysis for non-radioactive compounds (HOPO and Zr-HOPO) and radioTLC for radioactive compounds (89Zr-HOPO).
4.4.2:

3,4,3-(LI-1,2-HOPO) (HOPO)

The ligand was synthesized as previously described with slight modification. The details
are presented in the supporting information.
4.4.3:

Zr-HOPO

A solution of zirconium chloride (1.5 mg, 6.0 µmol) in water (0.5 mL) was added to a
solution of HOPO (3.0 mg, 4.0 µmol) in water (0.5 mL). The mixture was vortexed and left for
15 min. The resulting solution was cloudy with some white precipitate. The complex was not
very soluble in water; however enough compound remained in soluble to allow for analysis of
the complex via HRMS and HPLC. NMR analysis remained difficult due to low solubility as
well as the indistinct, overlapping multiplets of the HOPO ligand itself (Figure A.4.2). A
solution of non-radioactive Zr-HOPO was lyophilized and the resulting off-white powder was
analyzed by IR spectroscopy. Characterization of the Zr-HOPO complex by UV-Vis
spectroscopy was attempted, but not conclusive. The details are presented in the supporting
information.
4.4.4:
89

Radiolabeling studies

Zr was received after target processing as

89

Zr-oxalate in 1.0 M oxalic acid. This

solution is then neutralized with 1.0 M sodium carbonate to reach pH 6.8-7.2. Both the DFO and
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HOPO ligands were labeled at various concentrations in water or saline with the neutralized 89Zr
solution at room temperature for varying lengths of time, typically 10-60 min. Samples were
labeled with 10 μCi to 1 mCi depending on the nature of the experiment (for reference, 1 μCi of
89

Zr equals 25 femtomoles). Reactions were monitored via radio-TLC using Varian ITLC-SA

strips (Agilent Technologies) and 50 mM EDTA at pH 5 as the mobile phase.
complexes remained at the origin, while free

89

89

Zr-ligand

Zr was taken up by EDTA in the mobile phase

and migrated along the ITLC strip.
4.4.5:
89

Serum stability study

Zr-HOPO and

89

Zr-DFO were prepared according to the radiolabeling protocol as

described above. For each

89

Zr complex, as well as for free, unchelated

89

Zr, solutions were

made consisting of 1 mL human serum and 100 μL of the 89Zr species and were placed in a heat
block at 37 oC with agitation. Samples were monitored using radio-TLC immediately after
mixing and then daily for 1 week. Intact

89

Zr-ligand complexes remained at the origin of the

ITLC strip, while free 89Zr was either bound by serum proteins or was picked up by EDTA in the
mobile phase and migrated along the ITLC strip. The stability of the complexes was measured as
the percentage of 89Zr that was retained at the origin of the ITLC strip and therefore still bound to
the chelator. Free

89

Zr incubated in serum appeared on radio-TLC as a series of messy, broad

peaks ranging from the origin to the solvent front. This was likely a result of 89Zr being bound to
a variety of serum components with different retention factors. In order to confirm that the sharp
peaks at the origin seen in the 89Zr-ligand samples were in fact the 89Zr-ligand complexes and not
protein-bound 89Zr, size exclusion chromatography (SEC) was performed on the serum samples
after 7 days (Figure 4.8). SEC was carried out with a hand-packed column (18 x 180 mm) of
Superdex 200 prep grade gel filtration media (GE Healthcare) on a BioLogic LP automated
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Figure 4.8. SEC chromatograms of 89Zr-HOPO, 89Zr-DFO, and free 89Zr in serum after 7 days.
Solid lines are the UV absorbance due to the serum components and to the HOPO ligand itself.
Dotted lines are the radiotrace associated with the 89Zr.
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liquid chromatography system (BioRad) with a flow rate of 1 ml/min for 45 min using PBS as
the eluant. Serum protein components were observed in the UV chromatogram (280 nm) while
89

Zr species were tracked by gamma counting collected 1 mL fractions. Both

89

Zr-ligand serum

samples eluted at ~28 min, which corresponds to the retention time of the pure
controls. The control sample of free

89

89

Zr-ligand

Zr in serum, however, eluted at ~20 min, which

corresponds to the molecular weight of a major serum protein component as seen in the UV
chromatogram.
4.4.6:

EDTA challenge study

100 μL samples were prepared of 100 μM ligand to be tested (HOPO or DFO). 100 μL of
89

Zr solution (~100 μCi) at pH 7 were added to each sample. Each sample was then spotted onto

an ITLC strip, developed, and analyzed to obtain an initial measure of the percent labeling. The
samples were left to incubate at room temperature for 1 h. Following incubation, 200 μL of
5 mM EDTA at different pHs (5.0, 5.5, 6.0, 6.5, 7.0, 7.5, and 8.0) were added to the samples.
Lastly, 100 μL of 500 mM acetate buffer were added to each sample to maintain the
experimental pHs of the solutions. The final composition of the samples was 500 μL total
volume, ~100 μCi 89Zr, 100 mM acetate buffer, and a 1:100 ratio of ligand:EDTA. The samples
were then transferred to a heat block at 37 oC to incubate for 7 d with agitation. Samples were
monitored by radio-TLC at 1 h, 3 h, 1 d, 3 d, 5 d, and 7 d post-incubation. Three samples were
prepared at each pH to obtain triplicate data for statistics.
4.4.7:

Metal cation competition study

1 mL solutions of 200 μM HOPO and DFO were prepared and radiolabeled with 1 mL
(30-50 μCi) of neutralized 89Zr each. Samples were left to incubate at room temperature for 1 h
before being monitored by radio-TLC to confirm complete labeling. The

89

Zr-ligand samples
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were then split into 200 μL aliquots and added to 200 μL solutions of prepared 1 mM metal salts
[cobalt(II) chloride, copper(II) chloride, iron(III) chloride, gallium(III) nitrate, gadolinium(III)
chloride, potassium carbonate, magnesium chloride, nickel(II) acetate, and zinc acetate].
Samples of

89

Zr-ligands complexes in competing metal solutions were put in a heat block at

37 oC to incubate with agitation. Sample mixtures were checked by radio-TLC after 1 h, 1 d, 5 d,
and 7 d. Experimental data represent the averages and standard deviations of two sets of
experiments.
4.4.8:

PET imaging

PET imaging experiments were conducted on a microPET Focus 120. Healthy female,
athymic nude mice were administered

89

Zr-HOPO (9.6 MBq [260 μCi] in 200 μL 0.9% sterile

saline) via intravenous tail vein injection (t = 0). Approximately 5 min prior to the acquisition of
PET images, mice were anesthetized by inhalation of 2% isoflurane (Baxter Healthcare,
Deerfield, IL)/oxygen gas mixture and placed on the scanner bed; anesthesia was maintained
using 1% isoflurane/gas mixture. PET data for each mouse were recorded via static scans at
various time points between 10 min and 24 h. An energy window of 350-700 keV and a
coincidence timing window of 6 ns were used. Data were sorted into 2D histograms by Fourier
rebinning, and transverse images were reconstructed by filtered back-projection (FBP) into a 128
× 128 × 63 (0.72 × 0.72 × 1.3 mm3) matrix. The image data were normalized to correct for nonuniformity of response of the PET, dead-time count losses, positron branching ratio, and physical
decay to the time of injection, but no attenuation, scatter, or partial-volume averaging correction
was applied. The counting rates in the reconstructed images were converted to activity
concentrations (percentage injected dose per gram of tissue, %ID/g) by use of a system
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calibration factor derived from the imaging of a mouse-sized water-equivalent phantom
containing 89Zr. Images were analyzed using ASIPro VM software (Concorde Microsystems).
4.4.9:

Biodistribution

Acute in vivo biodistribution studies were performed in order to evaluate the uptake of
the 89Zr-HOPO and 89Zr-DFO in healthy female, athymic nude mice. Mice were warmed gently
with a heat lamp for 5 min before administration of
200 μL 0.9% sterile saline) or

89

89

Zr-HOPO (0.89-1.11 MBq [24-30 μCi] in

Zr-DFO (1.11-1.29 MBq [30-35 μCi] in 200 μL 0.9% sterile

saline) via intravenous tail vein injection (t = 0). Animals (n = 4 per group) were euthanized by
CO2(g) asphyxiation at 10 min, 1 h, 4 h, 12 h, and 24 h. After asphyxiation, 14 organs were
removed, rinsed in water, dried in air for 5 min, weighed, and counted in a gamma counter
calibrated for 89Zr. Counts were converted into activity using a calibration curve generated from
known standards. Count data were background- and decay-corrected to the time of injection, and
the percent injected dose per gram (%ID/g) for each tissue sample was calculated by
normalization to the total activity injected. The full data set of organs is included in the appendix
(Table A.4.2) along with values represented in %ID without normalization (Table A.4.3).
Biodistribution data were assessed by unpaired t tests using GraphPad Prism (version 6.02 for
Windows GraphPad Software, San Diego, CA, U.S.) in order to determine any significant
differences (p <0.05) (Table A.4.4).
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CHAPTER 5: P-SCN-BN-HOPO: A NOVEL BIFUNCTIONAL
CHELATOR FOR 89ZR IMMUNOPET

5.1:

Introduction

5.1.1: Literature review
Recently there has been a surge of interest in the development of an alternative chelator
for 89Zr4+ to replace DFO, with several novel ligand systems being reported within the past year
or so (Figure 5.1).1-7 While multiple studies demonstrate the issue of bone uptake seen with 89ZrDFO complexes and stressed the need for improved chelators8-11, the first investigation towards
designing a better chelator of Zr4+ came from Guérard et. al.12 While not testing a preorganized
ligand system, this paper examined the coordination chemistry of the Zr4+cation using multiple,
individual bidentate hydroxamate ligands. Through a combination of density functional theory
(DFT) calculations, potentiometry experiments, and X-ray crystal structure analysis, the
advantage of an octa-coordinate zirconium complex was confirmed.

Zr4+ was shown to

preferentially form complexes with eight oxygen donors contained within four hydroxamate
groups.

Additionally, N-methyl acetohydroxamic acid was found to be superior to

acetohydroxamic acid. This study opened the door for the investigation of octadentate ligands to
replace the hexadentate DFO chelator with the goal of improving in vivo stability.
Not long after that report, Price et. al1 published work on H6phospa (Figure 5.1), an
octadentate, picolinate-based chelator that they evaluated not only with
177

89

Zr, but with

111

In and

Lu as well. This N4O4 ligand combined 2 carboxylic acids, 4 nitrogen atoms in an acyclic

backbone, and 2 methylene phosphonate groups to form a proposed eight coordinate
118

Figure 5.1. Chemical structures of newly developed ligands evaluated with 89Zr4+. The binding
donor groups are highlighted in red and the conjugation points of the bifunctional ligands are
shown in blue. The molecules are divided by their progress in development as: monofunctional
ligand which cannot be attached to a targeting vector, bifunctional ligands that have yet to be
attached to anything, and bifunctional chelators which have been shown to bind a metal and be
conjugated to a targeting molecule. The ligands are further divided between those that were
found to effectively bind Zr and those that were found to be unsuitable.
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environment for Zr4+. However, when the bifunctional derivative of H6phospa — p-SCN-BnH6phospa — was conjugated to an antibody and tested with

89

Zr, it only achieved a maximum

radiolabeling yield of 12% under optimized conditions. This paper also reports previously
unpublished results of a related ligand, H4octapa (Figure 5.1), containing more carboxylic acid
groups instead of the methylene phosphonate groups in H6phospa, which was evaluated with 89Zr
and achieved no appreciable radiolabeling. So while the picolinate-based ligands were overall
found to be inadequate for chelating

89

Zr4+, it was shown that methylene phosphonate groups

were superior binding groups than carboxylic acids. Stability studies were not performed on the
89

Zr-H6phospa-trastuzumab due to its low radiolabeling yield.

If the previous paper

demonstrated that an octadentate ligand was needed to securely bind Zr4+, then this paper
demonstrates the inadequacy of nitrogen-containing ligand systems for the oxophilic Zr4+ cation.
Another bifunctional chelator that was developed for a different radiometal, in this case 68Ga, but
tested with 89Zr is YM103 from Ma et. al.2 YM103 is a bifunctional isothiocyanate derivative of
the hexadentate ligand CP256 which is made up of three 3-hydroxy-4-pyridinone (HPO) groups.
YM103 was shown to bind 89Zr4+ and performed well in in vitro studies showing >95% stability
in serum; however, the

89

Zr-YM103-trastuzumab complex was demonstrated to be unstable in

vivo with nearly 30 %ID/g of the

89

Zr localized in the bone. The release of the

89

Zr4+ cation

suggested by the high bone uptake is likely due to the lability of a six coordinate Zr complex. As
confirmed by Guérard et. al.,3 Zr4+ ideally forms an eight coordinate complex and would thus
benefit from an octadentate ligand.
Following through on their exploratory hydroxamate work, Guérard et. al.3 developed a
series of cyclic (C5-C7) and acyclic (L5-7) tetrahydroxamate ligands (Figure 5.1) for evaluation
with Zr4+. Of the synthesized ligands, the pair with the largest spacer, a 7 carbon alkyl chain
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between hydroxamates, was found to be the best chelator both experimentally and
computationally. The 89Zr complexes of both the cyclic and acyclic versions of this ligand were
stable after 7 d in sodium phosphate buffer at pH 7.4 at 20 °C as well as in human serum at 37
°C, which is also true for 89Zr-DFO. When the 89Zr-ligand complexes were incubated in a 1750
fold excess of EDTA at 37 °C and pH 7 for 7 d, both tetrahydroxamate ligands showed greater
stability than DFO, with the new cyclic ligand showing the greatest stability of 87% intact
complex after 7 d.

Both ligands achieved over 99% radiolabeling yield at 7.5 nmol

concentrations within 2 h at 20 °C at pH 7, and within 30 min if heated to 50 °C. These
octadentate, hydroxamate-based chelators look quite promising, and synthesis of the bifunctional
versions of the two leading candidates are underway to enable further studies in vivo.
Within our own group, we investigated the potential of a non-hydroxamate-based ligand
— 3,4,3-(LI-1,2-HOPO) or HOPO (Figure 5.1)

4

— which has four hydroxypyridinone groups

for metal binding and comes from the actinide sequestration literature.13 We posit that the lower
pKa of the 1,2-hydroxypyridinone as compared to that of the hydroxamic acid (5.8 vs. 9.4) will
lead to easier deprotonation at physiological pH and thus greater stability of the Zr-ligand
complex. DFT calculations suggest a significantly lower energy for the Zr-HOPO complex as
compared to Zr-DFO. HOPO achieved 100% radiolabeling at 10 µM within 45 min at room
temperature at pH 7. The 89Zr-HOPO complex showed equal stability to 89Zr-DFO in serum at 37
°C over 7 d and slightly better stability in a metal competition experiment where Fe3+ was able to
out compete 89Zr4+ for DFO about twice as much as HOPO. Most significantly, when incubated
in a 100-fold excess of EDTA at 37 °C at various pH values from 5-8 for 7 days,
was >99% stable over the full range of pH while
every pH tested.

89

89

89

Zr-HOPO

Zr-DFO was susceptible to transchelation at

Zr-HOPO was 10-98% more stable than

89

Zr-DFO in the EDTA challenge,
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with the most extreme difference in stability being at the lower pH values. Preliminary in vivo
experiments were conducted on the
The

89

89

Zr-HOPO to probe its biological behavior and stability.

Zr-HOPO complex was found to clear both renally and intestinally with no observable

accumulation in the bone, which suggests the complex was stable over the 24 h experiment.
Work towards the bifunctionalization of the HOPO ligand is currently being carried out in order
to allow conjugation to an antibody for longer in vivo evaluation.
Subsequently, Patra et. al5 published what is perhaps the most straightforward new ligand
for Zr4+: an octadentate derivative of DFO called DFO* (Figure 5.1). Using desferrioxamine
mesylate as a starting material, a simple extension containing an additional hydroxamate group
was added to the amine tail of DFO. This extended ligand continues the same spacer lengths as
DFO, but with two additional oxygen donors available for binding. The complex of Zr4+ with
this octadentate DFO* was predicted to be more stable than that with hexadentate DFO by DFT
calculations. Since DFO* contains an amine tail just like the standard DFO ligand, it was able to
be modified with succinic anhydride to create a bifunctional chelator with a carboxylic acid end,
which can be attached to the amine of a biomolecule. This DFO*-CO2H (Figure 5.1) was then
conjugated to the peptide bombesin (BBS) and radiolabeled with

89

Zr at room temperature and

neutral pH for 1.5-2 h. The 89Zr-DFO*-BBS complex was evaluated in comparison with a 89ZrBBS complex made using p-SCN-Bn-DFO as a standard. The stability of the two complexes
was evaluated in a 300- and 3000-fold excess of DFO over 24 h as a transchelation challenge.
The octadentate DFO* complex was shown to be significantly more stable than the hexadentate
DFO complex in this challenge. No additional stability experiments were reported for longer
time points or conditions. While the development of a bifunctional derivative of this ligand puts
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it a step ahead synthetically of two of the previous ligands discussed, its stability has not yet been
tested in vivo nor in serum, or in any experiments for longer than 24 h.
Another set of non-hydroxamate-based ligands were investigated by Pandya et. al6 that
contain four terephthalamide (TAM) binding groups for octadentate chelation. These two ligands
abbreviated only as BFC 1 and 2 (Figure 5.1) are large di-macrocyclic structures with a built in
amine pendant arm as well as two short PEG units. While the presence of the pendant amine
makes these ligands by definition bifunctional, additional chemistry would be necessary to attach
it to most biological molecules and in the current report, no conjugation was explored. Both
ligands were shown to bind Zr in a 1:1 metal:ligand ratio both experimentally and theoretically.
The

89

Zr-ligand complexes performed well in in vitro stability studies, even showing improved

stability over 89Zr-DFO in a DTPA competition experiment. In vivo biodistribution studies were
also carried out on the

89

Zr-ligand complexes and no prominent bone uptake was noted within

the fast circulation time of the complex. BFC 1 was chosen as the preferred ligand based on the
fact that the 89Zr complex cleared more quickly and showed less activity in the liver than BFC 2.
Most recently, Zhai et. al7 have reported a competitive hexadentate ligand based on a derivatized
fusarinine C (FSC) molecule (Figure 5.1). This is a cyclic ligand with a hydroxamate structure
very similar to DFO. The prepared
over

89

89

Zr-FSC-RGD complexes demonstrated improved stability

Zr-DFO-RGD in in vitro transchelation studies (93.9% stability vs 42.2% respectively).

The cyclic nature of the ligand likely provides greater kinetic stability as it is more difficult for
competing materials to access the metal. However, providing only six donor groups for the
binding of Zr4+ allows for the possibility of additional molecules being needed to satisfy the
coordination sphere. Currently, the

89

Zr-FSC-RGD complex has only been evaluated with short

term in vivo experiments (4 h biodistribution, 24 h PET image) which do not give a full picture
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of its long term in vivo stability. Further experiments with longer circulating targeting molecules
such as antibodies are necessary to reveal the practicality of this chelator.
Additionally, our lab has investigated a catechol-based version of the HOPO ligand:
3,4,3-LICAM (LICAM) (Figure 5.1, see Chapter 3 for additional information), which was also
taken from the actinide literature.13 This variant was evaluated since catechols are known
functionalities in siderophores, but was ultimately found to be unsuitable for

89

Zr4+ due to the

incompatibility between the pKa of the catechol group and the solubility of the Zr4+ cation.
Despite being octadentate and oxygen-rich, the maximum radiolabeling yield reached for the
LICAM ligand was <30%, despite varying temperature, pH, and reaction time. We believe the
issue to lie in the fact that the pKa for full deprotonation of the catechol group is 13.0, which
requires a higher pH for proper labeling; however, the Zr4+ cation is only soluble at lower pH,
and antibody radiolabeling is typically performed at ~ pH 7. This leads to a precarious balance
between keeping the

89

Zr4+ in solution and trying to get the coordinating oxygen atoms of the

catechol moiety deprotonated. Unfortunately, an appropriate compromise could not be found
that achieved >30% radiolabeling, so the ligand and catechol groups in general were dropped
from further development.
Thus far, there has been no reporting of a new ligand for

89

Zr4+ that has been

demonstrated to be viable in vivo for a sufficient length of time for antibody imaging. Several
potential ligands require additional development while others simply require further evaluation.
Herein, we present the first successful demonstration of an alternative chelator for

89

Zr that

includes PET imaging and biodistribution data that shows improved stability over DFO across a
period of several days in vivo.
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Figure 5.2. Chemical structures of the current standard bifunctional chelator, p-SCN-Bn-DFO,
and our proposed alternative chelator, p-SCN-Bn-HOPO, based on the previously described
3,4,3-(LI-1,2-HOPO) ligand. The binding oxygen donor groups are highlighted in red.
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5.1.2: p-SCN-Bn-HOPO
The 3,4,3-(LI-1,2-HOPO) ligand showed tremendous promise in our preliminary
evaluation, therefore we endeavored to develop a bifunctional variant of the HOPO ligand for
further evaluation and application in antibody-based PET imaging. The result of this venture is
the bifunctional chelator: p-SCN-Bn-HOPO (Figure 5.2). This molecule is the HOPO ligand
with a para-benzyl-isothiocyanate pendant arm added to one of the secondary amines in order to
be directly comparable with the current most used bifunctional chelator: p-SCN-Bn-DFO
(Figure 5.2).
5.2:

Results and discussion

5.2.1:

Synthesis and characterization

Initial attempts were made to attach a linker arm directly to one on the secondary amines
of the original 3,4,3-(LI-1,2-HOPO) ligand in order to make it bifunctional, however our efforts
were unsuccessful. Coupling to a single secondary amine that already had an amide bond proved
to be impractical and so we developed a novel synthesis to rebuild the ligand from scratch
(Figure 5.3). The new method built the pendant arm into the backbone itself before coupling the
hydroxypyridinone groups onto it. The synthesis of the bifunctional chelator proved to be
challenging, with a particular difficulty in the deprotection and purification steps, but it was
ultimately achieved. The final product, p-SCN-BN-HOPO, was purified by HPLC and
characterized by NMR, IR, and HRMS.
5.2.2:

Ligand-antibody conjugation

p-SCN-BN-DFO was conjugated to antibodies through the formation of a thiourea bond
with the amine sidechain of a lysine residue. The p-SCN-BN-HOPO ligand was designed to be
attached in the very same way. Both ligands were conjugated to trastuzumab at a ratio of 5:1
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Figure 5.3. Synthetic scheme for p-SCN-BN-HOPO. i) Ethyl trifluoroacetate, MeOH, -78 oC,
1 h; ii) (BOC)2O, MeOH, r.t, 18 h; iii) con. NH4OH, r.t, 15 h (28% over 3 steps); iv) 4-Nitro
phenylethyl bromide, K2CO3, DMF, 60 oC, 12 h, 38%; v) 4 M HCl in Dioxane, r.t, 2 h; vi) 1(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylic acid chloride, NEt3, DCM, 0-25 oC, 12 h,
56% (over 2 steps); vii) Raney Ni, H2, MeOH, 3 h; viii) 1:1 (AcOH: HCl), 50 oC; ix) Di-2pyridyl thiocarbonate, NEt3, CH3CN, H2O, r.t, 1 h
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ligand:antibody in the reaction mixture. The number of chelates per antibody was initially
investigated by MALDI-TOF mass spectrometry, however the error was found to be too large to
provide conclusive values. Subsequently, the average number of chelates per antibody was
determined to be 2.0 ± 0.5 for p-SCN-BN-DFO and 2.8 ± 0.2 for p-SCN-BN-HOPO through a
simplified isotopic dilution assay.
5.2.3:

Radiolabeling

All compounds were radiolabeled under mild conditions using a

89

Zr-oxalate solution

at pH 7 and room temperature. Reaction progress was monitored using radioITLC. First, the
bifunctional chelators p-SCN-Bn-HOPO and p-SCN-BN-DFO were radiolabeled on their
own without being attached to any targeting vectors to compare their Zr binding ability. Both
ligands labeled quantitatively within 1 h without issues. This confirmed that the benzyl
isothiocyanate linker arm did not interfere with the metal binding. Next, the chelator modified trastuzumab complexes were radiolabeled under the same conditions. Both
complexes labeled within 1-3 h at room temperature and achieved specific activities of
approximately 2 mCi/mg. Radiolabeled antibody conjugates were purified via size exclusion
chromatography and spin filtration.
5.2.4:

Serum stability
Zr-ligand complexes alone as well as the

89

evaluated for stability in human serum at 37 oC. Both

89

The

89

Zr-ligand-antibody complexes were
Zr-ligand complexes showed great

stability with 97.7 ± 0.2% of the p-SCN-Bn-DFO complex and 97.5 ± 0.5% of the p-SCN-BnHOPO complex intact after 7 d. When the ligands were conjugated to trastuzumab and then
labeled, both complexes demonstrated slight decreases in stability, with the
tratuzumab complex showing 94.7 ± 0.7% stability and the

89

89

Zr-DFO-

Zr-HOPO-tratuzumab complex
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showing 89.2 ± 0.9% stability. While 89.2% for the HOPO complex is still reasonably stable, it
is notably less than the 94.7% stability of the DFO conjugate. The reason for the change in
stability between the 89Zr-ligand complexes and the 89Zr-ligand-antibody complexes is currently
unknown, but may be due to the influence of the antibody sidechains altering the chelation
environment of the metal either during radiolabeling or during the serum incubation.
5.2.5:

Immunoreactivity

The viability of the 89Zr-labeled trastuzumab complexes was assayed against BT474 cells
to ensure that the conjugation of the chelators did not disrupt the biologically activity of the
antibody. The

89

Zr-DFO-trastuzumab and

89

Zr-HOPO-trastuzumab conjugates were found to

have immunoreactive fractions of 88.6 ± 2.1 % and 92.4 ± 6.8 % respectively.
5.2.6:

In vivo studies

5.2.5.1: Imaging
PET imaging was carried out in order to directly compare the in vivo behavior and
pharmacokinetics of the DFO- and HOPO-based

89

Zr-trastuzumab radioimmunoconjugates.

Female, athymic nude mice with subcutaneous BT474 xenografts in their right shoulders were
injected with either 89Zr-DFO-trastuzumab or 89Zr-HOPO-trastuzumab (n=4 for each compound)
and imaged over 9 d. The resulting images showed good tumor uptake for both compounds,
but with a marked decrease in the appearance of bone uptake for the
images (Figure 5.4). The reduced bone uptake seen with
superior stability of the

89

89

89

Zr-HOPO-trastuzumab

Zr-HOPO-trastuzumab suggests

Zr-HOPO complex. The difference in in vivo performance in contrast

to the in vitro stability study highlights the inadequacy of the serum stability assay alone.
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Figure 5.4. PET images of 89Zr-HOPO-trastuzumab (top) and 89Zr-DFO-trastuzumab (bottom) in
female, athymic nude mice with BT474 xenografts on their right shoulders (9.25-9.99 MBq
[250-270 μCi] in 200 μL 0.9% sterile saline). Representative images are shown for each
compound following a single mouse over 9 d with coronal slice images above corresponding
maximum intensity projection images. Both compounds show good tumor to background
contrast, but the 89Zr-DFO-trastuzumab shows evidence of bone uptake suggesting in vivo
release of 89Zr4+.
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This demonstrates the successful use of

89

Zr-HOPO-trastuzumab to image BT474 breast cancer

with low background, good tumor to organ contrast, and, importantly, very low bone uptake.
5.2.5.2: Biodistribution
Acute biodistribution experiments were performed to further probe the localization and
uptake of

89

Zr-DFO-trastuzumab and

89

Zr-HOPO-trastuzumab. These results corroborate the

observations from the PET images with the activity associated with all collected tissues, except
the tumors and the bone, decreasing over time (Figure 5.5). Both compounds showed good
uptake in the tumor with the DFO complex achieving even higher uptake than the HOPO
compound (138.2 ± 35.3 vs. 61.9 ± 26.4 %ID/g, Table 5.1). Biodistribution data confirmed the
lower bone activity of the HOPO conjugate, measuring 17.0 ± 4.1 %ID/g in the bone for the
89

Zr-DFO-trastuzumab while the 89Zr-HOPO-trastuzumab only had 2.4 ± 0.3 %ID/g.

The amount of activity seen in the bone with

89

Zr-HOPO-trastuzumab is consistently less than

the residual bone activity which means it is possible that there is no specific bone accumulation
since the %ID/g values do not increase over time (Figure 5.6). This is particularly striking when
compared with the constantly increasing bone uptake seen with

89

Zr-DFO-trastuzumab which is

indicative of accumulation of 89Zr4+ in the skeleton.
While

89

Zr-DFO-trastuzumab has a better tumor:blood ratio than

89

Zr-HOPO-

trastuzumab (31.4 vs. 14.4, respectively), the 89Zr-HOPO-trastuzumab complex has a drastically
improved tumor:bone ratio of 25.8 compared to that of

89

Zr-DFO-trastuzumab (8.1). Both

compounds show a high contrast between the tumor and the general background as represented
by the blood activity, but

89

Zr-HOPO-trastuzumab provides a much better contrast between the

tumor and the bone specifically. This benefit of the improved stability of the p-SCN-Bn-HOPO
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Figure 5.5. Select biodistribution data of 89Zr-HOPO-trastuzumab (red) and 89Zr-DFOtrastuzumab (blue) in female, athymic nude mice with BT474 xenografts (0.59-0.74 MBq [1620 μCi] in 200 μL 0.9% sterile saline). Both compounds successfully target and accumulate in
the BT474 tumors with good tumor to background contrast, but 89Zr-DFO-trastuzumab has ~2.5
times the absolute uptake in the tumor. The distribution pattern is very similar for all non-target
organs except for the bone. The 89Zr-DFO-trastuzumab mice show an increasing level of activity
in the bone suggesting in vivo release of 89Zr4+ and accumulation in the bone, whereas the 89ZrHOPO-trastuzumab mice show only a low level of activity in the bone which is below the level
of the blood and does not increase over time.
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Table 5.1. Biodistribution data with values expressed as %ID/g. Studies were performed in BT474 tumor-bearing female,
athymic nude mice administered 89Zr-HOPO-trastuzumab (0.59-0.67 MBq [16-18 μCi] in 200 μL 0.9% sterile saline) or
89
Zr-DFO-trastuzumab (0.67-0.74 MBq [18-20 μCi] in 200 μL 0.9% sterile saline) via intravenous tail vein injection
(n = 4 per group).

Figure 5.6. Comparison of the levels of radioactivity in the blood and bone of BT474 tumorbearing female, athymic nude mice after injection of either 89Zr-HOPO-trastuzumab (red) or
89
Zr-DFO-trastuzumab (blue) (0.59-0.74 MBq [16-20 μCi] in 200 μL 0.9% sterile saline). While
the activity in the blood starts high and decreases over time, the activity in the bone is very
different for the two compounds. The 89Zr-HOPO-trastuzumab mice show a near constant level
(≤2.0 %ID/g) of activity in the bone which never exceeds the level of activity remaining in the
blood. The 89Zr-DFO-trastuzumab mice show an increasing amount of radioactivity in the bone
over time which far surpasses the level in the blood and suggests release of the 89Zr4+ cation in
vivo which is known to preferentially accumulate in the bone.
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ligand could make a meaningful difference in clinical imaging by enabling easier distinction of
bone metathesis as well as reducing the radiation dose to healthy bone and bone marrow.
5.3:

Conclusions
The 3,4,3-(LI-1,2-HOPO) ligand was found to exhibit excellent stability for

89

Zr

complexes in a previous study.4 The development of a bifunctional derivative of the HOPO
ligand was the next logical step and led to the design and synthesis of p-SCN-Bn-HOPO. This
bifunctional ligand was shown to bind 89Zr as expected and was evaluated for conjugation to an
antibody,

radiolabeling

of

the

ligand-antibody

complex,

and

application

of

the

radioimmunoconjugate in vivo. The p-SCN-Bn-HOPO prepared comparably to the standard of pSCN-Bn-DFO chelator, achieving specific activities ~2 mCi/mg and remaining ~90% stable
through a 7 d incubation in human serum. The greatest distinction between the two compounds
was the amount of bone uptake seen in the imaging and biodistribution experiments; the activity
measured in the bone for

89

Zr-HOPO-trastuzumab was more than 7 times lower than for

89

Zr-

DFO-trastuzumab. While the absolute uptake in BT474 breast cancer tumors was just over 2
times higher for
89

89

Zr-DFO-trastuzumab, the tumor:bone ratio was more than 3 times higher for

Zr-HOPO-trastuzumab. This improved contrast between tumor and bone could be

advantageous for the detection of bone metathesis and for the general clarity of the images.
Furthermore, the lower bone uptake is the ultimate proof that the p-SCN-Bn-HOPO ligand forms
a more stable complex with 89Zr4+ than p-SCN-Bn-DFO and reduces the release of free 89Zr4+ in
vivo.
The bifunctional chelator p-SCN-Bn-HOPO was shown to be an effective alternative for
the chelation of

89

Zr4+ for immunoPET applications. It successfully reduces the levels of

radioactivity in the bones of mice compared with the use of p-SCN-Bn-DFO. This study not only
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led to a superior ligand for

89

Zr, but also demonstrates the power of inorganic chemical

principles to suggest the best chelation system for a metal which can actually be seen to make a
difference in biological applications.
5.4:

Experimental section

5.4.1:

Materials and methods

All chemicals, unless otherwise noted, were acquired from Sigma-Aldrich (St. Louis,
MO) and used as received without further purification. All instruments were calibrated and
maintained in accordance with standard quality-control procedures. High-resolution mass
spectrometry was carried out through electrospray ionization using an Agilent 6520 QTOF
instrument. 1H and 13C NMR spectra were recorded at varying temperatures on a Bruker Avance
III spectrometer equipped with a triple resonance inverse cryoprobe, with 1H and 13C resonance
frequencies of 600.13 MHz and 150 mHz or a Bruker DRX spectrometer equipped with a 1H, 13C
cryoprobe, with respective resonance frequencies of 500.13 MHz and 125.76 MHz with Topsin
software. The NMR spectra are expressed on the δ scale and were referenced to residual solvent
peaks and/or internal tetramethylsilane. The HPLC system used for analysis and purification
compounds consisted of a Rainin HPXL system with a Varian ProStar 325 UV-Vis Detector
monitored at 254 nm. Analytical chromatography was carried out using a Waters Symmetry C18
Column, 100Å, 5 µm, 4.6 mm X 100 mm at a flow rate of 1.0 mL/min and purification was done
with a preparatory Waters Symmetry C18 Prep Column, 100Å, 5 µm, 19 mm X 100 mm at a
flow rate of 17.059 mL/min. IR spectroscopy was performed on a solid sample using an
attenuated total reflectance attachment on a PerkinElmer Spectrum 2 FT-IR spectrometer with a
UATR Two attachment.
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89

Zr was produced at Memorial Sloan Kettering Cancer Center on a TR19/9 cyclotron

(Ebco Industries Inc.) via the

89

Y(p,n)89Zr reaction and purified to yield

89

Zr with a specific

activity of 196–496 MBq/mg. Activity measurements were made using a CRC-15R Dose
Calibrator (Capintec). For the quantification of activities, experimental samples were counted on
an Automatic Wizard (2) g-Counter (Perkin Elmer). The radiolabeling of ligands was monitored
using salicylic acid impregnated instant thin-layer chromatography paper (ITLC-SA) (Agilent
Technologies) and analyzed on a Bioscan AR-2000 radio-TLC plate reader using Winscan
Radio-TLC software (Bioscan Inc., Washington, DC). All in vivo experiments were performed
according to protocols approved by the Memorial Sloan Kettering Institutional Animal Care and
Use Committee (protocol 08−07−013). Purity of greater than 95% was confirmed using
quantitative HPLC analysis for non-radioactive compounds (HOPO and Zr-HOPO) and radioTLC for radioactive compounds (89Zr-HOPO).
5.4.2:

Synthesis

Detailed analytical and spectral data are included in the Appendix.
5.4.2.1:

(N1,

N4,

N9

–

Tri-tert-butoxycarbonyl)-1,12-di-amino-4,9-

diazadodecane (4):
The tri-BOC-protected spermine was prepared according to Geall et al.14 To a flask
containing spermine (1) (2.02 g, 10 mmol) in 150 ml methanol at -78 oC under argon was added
dropwise ethyl trifluoroacetate (1.42 g, 10 mmol ) in 100 mL of methanol over 30 min while
stirring. Stirring was continued for another 30 min and the reaction mixture was allowed to come
to 0 oC. An excess of di-tert-butyl dicarbonate (60 mmol) in 100 mL methanol was added over a
period of 1 h. The reaction mixture was stirred at room temperature for 18 h. Concentrated
ammonium hydroxide solution was added to the reaction mixture until the pH reached 11 and the
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reaction was stirred for another 15 h at room temperature. The methanol was evaporated under
reduced pressure and the resulting liquid was dissolved in methylene chloride, washed with
water, dried over anhydrous sodium sulfate, and evaporated to dryness. The crude compound
was purified by column chromatography silica using CH2Cl2: MeOH: conc NH3 70:10:1 to
50:10:1 (v/v/v) yielding the desired product 4 (yield 28%). Products 2 and 3 were used directly
and not isolated.
1

H-NMR (CDCl3, 400 MHz): δ 3.07-3.21 (m, 10H), 2.68 (t, 2H), 2.08 (bs, 2H), 1.59-1.70

(m, 4H), 1.41-1.46 (m, 31H).

13

C-NMR (CDCl3, 100 MHz): δ 156.04, 155.55, 79.48, 78.88,

46.80, 43.79, 38.76, 37.35, 32.46, 30.9, 28.42. HRMS calculated for C25H50N4O6 ([M+H]+),
503.38, found 503.3817.
5.4.2.2:

tert-butyl(4-((tert-butoxycarbonyl)(3-((4-nitrophenethyl)amino)

propyl)amino)butyl)(3-((tert-butoxycarbonyl)amino)propyl)carbamate (5):
A solution of 4-nitrophenylethyl bromide (0.126 g, 0.55 mmol) in DMF (2 mL) was
added to a suspension of 4 (0.201 g, 0.5 mmol) and K2CO3 (0.138 g, 1 mmol) in DMF (5 mL)
under N2. The resulting reaction mixture was stirred at 60 oC for 12 h. Solvent was removed
under vacuum and the resulting residue was dissolved in methylene chloride, washed with water,
dried over anhydrous sodium sulfate, and evaporated to dryness. The crude compound was
purified by column chromatography silica using 1% methanol in methylene chloride to give
compound 5 as a gummy solid. (Yield = 30%).
1

H NMR (500 MHz, CDCl3): (mixture of rotamers)  8.10-8.09 (d, 2H), 7.36 (d, 2H),

3.28-2.58 (m, 20H), 1.80 (bs, 2H), 1.58 (bs, 2H), 1.38-1.36 (m, 27H).

13

C NMR (500 MHz,

CDCl3): (mixture of rotamers)  156.1, 155.9, 129.8, 123.9, 79.3, 78.7, 78.3, 49.85, 49.83,
49.80, 49.76, 49.72, 47.1, 47.0, 46.94, 46.91, 46.89, 46.86, 46.77, 46.72, 46.67, 46.60, 46.52,
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46.46, 46.41, 46.38, 46.33, 46.27, 46.26, 46.23, 46.20, 45.69, 45.66, 44.28, 44.20, 43.88, 43.83,
43.78, 43.52, 43.47, 43.40, 43.38, 43.32, 37.76, 37.68, 37.64, 37.60, 37.56, 37.51, 37.48, 37.38,
34.45, 34.40, 34.15, 28.45; HRMS calculated for C33H57N5O8 ([M+H]+), 651.4207, found
652.4387.
5.4.2.3:

N1-(3-aminopropyl)-N4-(3-((4-nitrophenethyl)amino)propyl)butane-

1,4-diamine (6):
A solution of 4M HCl in dioxane (5 mL) was added to a stirring solution of 5 (0.17g, .5
mmol) in CH2Cl2 (10 mL), under nitrogen, at 25 °C. After 2 h, the solution was concentrated in
vacuo and co-distilled with toluene (3×5 mL) (poly-HCl salt). This compound was not isolated,
but rather used directly in the next step.
5.4.2.4:

1-(benzyloxy)-N-(3-(1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-

carboxamido)propyl)-N-(4-(1-(benzyloxy)-N-(3-(1-(benzyloxy)-N-(4-nitrophenethyl)-2-oxo1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2-dihydropyridine-3carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (7):
A solution of 1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carbonyl chloride (0.789g, 3
mmol) in methylene chloride (15 mL) was added drop wise to a stirred solution of triethylamine
(0.835 mL, 6 mmol), 6 (0.351g, 1 mmol) and DMAP (0.006g, 0.05 mmol) in dry methylene
chloride (10 mL) at 0oC . The reaction mixture was warmed to room temperature and stirred for
24 h. The reaction mixture was washed with 10% NaHCO3 solution, followed by water. The
organic phase was dried over anhydrous Na2SO4 and was then removed with a rotary evaporator.
The crude product was purified through column chromatography over silica gel using 2-4%
methanol in dichloromethane eluent producing in 5 as brown foam (yield 56%).
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1

H NMR (600 MHz, CDCl3): (mixture of rotamers)  8.16-7.25 (m, 20H), 7.19-4.86 (m,

16H), 3.82-2.06 (m, 25H), 1.84-0.63 (m, 8H);

13

C NMR (600 MHz, CDCl3): (mixture of

rotamers)  1420.16, 142.14, 139.12, 139.05, 139.0, 138.97, 138.87, 138.82, 138.78, 138.70,
138.66, 138.59, 138.55, 138.50, 133.16, 133.13, 133.06, 130.86, 130.80, 130.72, 130.66, 130.45,
135.41, 135.37, 130.34, 130.32, 130.29, 130.26, 130.23, 129.79, 129.76, 129.73, 129.70, 129.65,
129.62, 129.56, 123.97, 123.92, 123.83, 123.76, 123.74, 123.36, 122.79, 122.65, 122.57, 122.53,
122.52, 122.48, 104.07, 103.62, 103.54, 103.49, 103.40, 103.34, 79.66, 46.97, 46.08, 46.02,
41.99, 40.64, 36.95, 36.93, 36.89, 36.81, 34.61, 33.39, 33.23, 33.11, 26.09, 26.88, 25.52, 25.49,
25.32, 25.18, 25.11, 24.84, 24.80, 24.53, 24.17, 24.13, 23.98; HRMS calculated for C70H69N9O14
([M+H]+), 1260.5042, found 1260.5038.
5.4.2.5:

N-(4-(N-(3-(N-(4-aminophenethyl)-1-(benzyloxy)-2-oxo-1,2-

dihydropyridine-3-carboxamido)propyl)-1-(benzyloxy)-2-oxo-1,2-dihydropyridine-3carboxamido)butyl)-1-(benzyloxy)-N-(3-(1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2carboxamido)propyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (8):
To a suspension of Raney nickel in (1:1) MeOH : THF (10 mL), 7 (0.2g, 0.157 mmol)
was added and hydrogenated at balloon H2 pressure at room temperature for 3 h. The catalyst
was filtered through a celite pad under inert atmosphere. The filtrate was evaporated under
reduced pressure to obtain the crude amine. This crude product was used directly in the next step
without further workup. For characterization purposes, some of this product was HPLC purified
as a cream colored solid.
1

H NMR (600 MHz, DMSO-d6): (mixture of rotamers)  8.70-8.64 (m, 1H), 7.44-7.33

(m, 27H), 6.93-6.89 (m, 1H), 6.89-6.80 (m, 3H), 6.64-6.62 (m, 4H) , 6.31-6.10 (m, 4H), 5.385.26 (m, 5H), 5.04-4.99 (m, 3H), 3.60-3.55 (m, 18H), 3.16-3.13 (m, 14H), 1.76-1.21 (m, 10H);
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C NMR (600 MHz, DMSO-d6): (mixture of rotamers)  158.77, 158.70, 158.28, 158.25,

13

158.18, 158.14, 155.63, 155.30, 155.27, 155.09, 155.06, 155.03, 141.89, 141.63, 141.60, 140.70,
140.59, 140.51, 136.82, 136.77, 136.64, 131.65, 161.41, 131.38, 131.35, 127.49, 127.44, 127.38,
127.29, 126.97, 126.87, 126.27, 126.23, 126.20, 120.31, 120.35, 119.75, 117.81, 115.46, 113.1,
101.62, 100.26, 100.1, 76.16, 76.10, 59.81, 52.71, 45.56, 45.49, 43.71, 43.47, 43.31, 41.3, 39.83,
39.65, 34.51, 34.45, 34.18, 34.11, 31.09, 29.71, 25.62, 24.36, 23.29, 22.73, 22.54, 22.43, 21.75,
21.38, 21.29; HRMS calculated for C70H72N9O12 ([M+H]+), 1230.5300, found 1230.5299.
5.4.2.6:

4-(11,15-bis(1-hydroxy-2-oxo-1,2-dihydropyridine-3-carbonyl)-1-(1-

hydroxy-6-oxo-1,6-dihydropyridin-2-yl)-6-(1-hydroxy-6-oxo-1,6-dihydropyridine-2carbonyl)-1-oxo-2,6,11,15-tetraazaheptadecan-17-yl)benzenaminium chloride (9):
Crude 8 was dissolved in a 1:1 mixture of acetic acid and concentrated HCl (6 mL) at
room temperature and heated to 45-50 oC for 18 h. The reaction progress was monitored by LCMS. The crude product was dried and redissolved in water/acetonitrile and purified by HPLC on
a preparative C18 column (Waters Symmetry C18 Prep Column, 100Å, 5 µm, 19 mm X 100
mm) at 17.059 mL/min using a gradient of 10-23% MeCN in water (both containing 0.1% TFA)
with an initial hold at 10% MeCN for 1.33 mins and then a ramp to 23% MeCN over 20 minutes.
The product peak was collected from 6.45-8.26 min and the eluted solution was lyophilized to
recover the product as an off white solid. The purified ligand was collected in multiple small
batches with an approximate combined yield of 70%.
The purified sample was confirmed by HPLC on a analytical C18 column (Waters
Symmetry C18 Prep Column, 100Å, 5 µm, 4.6 mm X 100 mm) at 1 mL/min using a gradient of
10-30% MeCN in water (both containing 0.1% TFA) with an initial hold at 10% MeCN for 1.33

141

mins and then a ramp to 30% MeCN over 30 minutes followed by a ramp to 95% MeCN over 1
minute and an isocratic hold at 95% MeCN for 5.66 minutes.
1

H NMR (500 MHz, CDCl3): (mixture of rotamers)  7.44-7.28 (m, 5H), 7.20-7.16 (dd,

J1, J2=6 Hz, 1H), 7.08-7.01 (m, 2H), 6.54-6.53 (m, 4H), 6.33-6.32 (m, 3H) , 6.18-6.21 (m,
0.5H), 5.74-5.67 (m, 0.5H), 3.65-3.51 (m, 4H), 3.51-3.16 (m, 8H), 3.12-2.70 (m, 11H), 1.91-1.38
(m, 10H) ;

13

C NMR (500 MHz, CDCl3): (mixture of rotamers)  158.8, 158.6, 158.4, 158.1,

157.9, 157.8, 157.77, 157.73, 142.5, 142.49, 142.45, 142.41, 142.32, 142.24, 142.04, 138.10,
138.0, 137.59, 137.51, 130.36, 130.31, 130.18, 130.08, 119.76, 119.45, 117.5, 115.6, 104.3,
102.5, 102.47, 102.41, 50.01, 48.12, 47.9, 46.0, 46.0, 43.7, 42.3, 37.2, 37.0, 36.97, 33.80, 32.65,
32.49, 28.16, 26.90, 26.23, 25.4, 25.4, 25.2, 25.1, 24.4, 24.3, 24.3, 24.2; HRMS calculated for
C42H47N9O12 ([M+H]+), 870.3422, found 870.3420.
5.4.2.7:

1-hydroxy-N-(3-(1-hydroxy-6-oxo-1,6-dihydropyridine-2-

carboxamido)propyl)-N-(4-(1-hydroxy-N-(3-(1-hydroxy-N-(4-isothiocyanatophenethyl)-2oxo-1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2-dihydropyridine-3carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (p-SCN-Bn-HOPO, 10):
NEt3 (0.0012 g, 0.012 mmol) was added to a solution of 8 (0.01 g, 0.011 mmol) in (8:2)
acetonitrile and water (1 mL). Next, Di-2-Pyridyl thionocarbonate (0.011 g, 0.05 mmol) was
added at room temperature and stirred vigorously for 1 h. The crude reaction solution was
directly purified by HPLC on a preparative C18 column (Waters Symmetry C18 Prep Column,
100Å, 5 µm, 19 mm X 100 mm) using a gradient of 5-75% MeCN in water (both containing
0.1% TFA) with an initial hold at 5% MeCN for 1.33 mins and then a ramp to 75% MeCN over
30 minutes. The product peak was collected from 15.01-15.5 min and the eluted solution was
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lyophilized to recover the product as a white solid. The purified ligand was collected in multiple
small batches with an approximate combined yield of 32%.
The purified sample was confirmed by HPLC on a analytical C18 column (Waters
Symmetry C18 Prep Column, 100Å, 5 µm, 4.6 mm X 100 mm) at 1 mL/min using a gradient of
5-75% MeCN in water (both containing 0.1% TFA) with an initial hold at 5% MeCN for 1.33
mins and then a ramp to 75% MeCN over 30 minutes followed by a ramp to 95% MeCN over 1
minute and an isocratic hold at 95% MeCN for 5.66 minutes.
1

H NMR (500 MHz, CDCl3): (mixture of rotamers)  7.37-7.31 (m, 7H), 7.12-7.08 (m,

1H), 6.58-6.52 (m, 4H), 6.34-5.81 (m, 4H), 3.62-3.54 (m, 12H) , 3.13-2.83 (m, 11H), 2.01-1.24
(m, 11H) ; 13C NMR (500 MHz, CDCl3): (mixture of rotamers)  161.78, 161.71, 161.54, 161.4,
160.65, 160.61, 157.89, 157.83, 157.78, 157.73, 142.59, 142.48, 142.41, 142.33, 142.31, 142.21,
139.58, 138.49, 138.90, 138.81, 138.17, 138.0, 137.57, 137.50, 134.07, 130.76, 130.74, 130.59,
130.52, 128.89, 128.66, 126.41, 126.32, 119.74, 119.53, 119.43,104.33, 102.50, 102.39, 49.62,
48.11, 47.96, 46.49, 46.01, 45.70, 37.24, 37.01, 36.96, 34.04, 32.83, 32.71, 28.15, 27.12, 26.85,
26.22, 25.46, 25.26, 25.17, 24.36, 24.18 ; HRMS calculated for C43H45N9O12S ([M+H]+),
912.2987, found 912.2987.
5.4.3:

Ligand-antibody conjugation

Trastuzumab (purchased commercially as Herceptin, Genentech, San Francisco, CA) was
purified using pre-packed size exclusion chromatography (SEC) columns (Sephadex G-25 M,
PD-10 Desalting Columns, 50 kDa, GE Healthcare) and centrifugal filter units with a 50,000
molecular weight cutoff (Amicon Ultra 4 Centrifugal Filtration Units, Millipore Corp., Billerica,
MA) and phosphate buffered saline (PBS, pH 7.4) to remove α_α-trehalose dihydrate, Lhistidine, and polysorbate 20 additives. After purification, the antibody was taken up in PBS at
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pH 7.4. Subsequently, ~60 μL of antibody solution (~13 nmol) were diluted to 1 mL with PBS at
pH 7.4. The pH antibody solution was raised to 8.8-9.0 with 0.1 M Na2CO3 before the slow
addition of 5 equivalents of p-SCN-Bn-HOPO or p-SCN-Bn-HOPO in ~12 μL of DMSO. The
reaction was incubated at 37 oC for 1 h and shaken at 300 rpm, followed by SEC and centrifugal
filtration to purify the ligand-antibody conjugate. The final bioconjugates were stored in PBS pH
7.4 at 4 oC.
Chelate number was investigated via MALDI-TOF mass spectrometry analysis
conducted at the University of Alberta. Samples of

89

Zr-DFO-trastuzumab,

89

Zr-HOPO-

trastuzumab, and unmodified trastuzumab were submitted for analysis and the chelate number
was calculated as the difference between the modified and unmodified antibody divided by the
mass of the chelator. Samples were analyzed in triplicate and values were calculated from
averages. When the triplicate MALD-TOF results were examined, the error was determined to be
too large to provide meaningful results (Figure A.5.2). Identical samples gave values that
differed by the masses of entire chelates. This method was determined insufficient for the current
study.
Chelate number was then determined using an isotopic dilution assay. A stock solution of
1 mM ZrCl4 was made up in 1 M oxalic acid. Approximately ~200 µCi of

89

Zr oxalate solution

in 1 M oxalic acid was added to 100 µL of the stock solution. This mixture was then neutralized
to pH 7 with 1 M Na2CO3 to create a ~200 µL Zr working solution of ~500 µM Zr4+. Triplicate
solutions of DFO-Trastuzumab and HOPO-Trastuzumab were prepared containing 300-400
pmol of antibody in 30 µL of PBS. Aliquots of 20, 25, and 30 µL of the Zr working solution
were added to the three ligand-antibody samples for each ligand. The solutions were incubated at
room temperature with gentle mixing overnight. The next day a volume of 50 mM EDTA equal
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to 1/9 of the volume of the reaction mixture was added to each sample and left to incubate for 15
minutes in order to scavenge any nonspecifically bound Zr4+. Samples were then analyzed using
radioITLC to determine the extent of radiolabeling. The average number of chelates per antibody
was calculated as the ratio of bound vs. unbound radioactive 89Zr × the moles of Zr4+ ÷ the moles
of antibody. The experiment was run in duplicate using the same batch of ligand-Trastuzumab
conjugate as the in vivo studies.
5.4.4:
89

Radiolabeling studies

Zr was received after target processing as

89

Zr-oxalate in 1.0 M oxalic acid. This

solution is then neutralized with 1.0 M sodium carbonate to reach pH 6.8-7.2. Both the DFO and
HOPO ligands were labeled at various concentrations in water or saline with the neutralized 89Zr
solution at room temperature for varying lengths of time, typically 10-60 min. Reactions were
monitored via radio-TLC with different stationary phases depending on the nature of the
reaction. 89Zr-ligand complexes required Varian ITLC-SA strips (Agilent Technologies) whereas
89

Zr-ligand-trastuzumab complexes employed Varian ITLC-SG strips (Agilent Technologies),

but both analysis methods used 50 mM EDTA at pH 5 as the mobile phase.

89

Zr complexes

remained at the origin, while free 89Zr was taken up by EDTA in the mobile phase and migrated
along the ITLC strip.
5.4.5:
89

Serum stability studies

Zr-ligand and

89

Zr-ligand-antibody complexes were prepared according to the

radiolabeling protocol as described above. For each 89Zr complex, samples were made consisting
of 900 μL human serum and 100 μL of the 89Zr species and were placed in a heat block at 37 oC
with agitation. Samples were monitored using radio-TLC before being added to the serum and
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then after 1 week of incubation. The stability of the complexes was measured as the percentage
of 89Zr that was retained at the origin of the ITLC strip and therefore still intact.
5.4.6:

Immunoreactivity assay

The immunoreactivity of the

89

Zr-DFO-trastuzumab and

89

Zr-HOPO-trastuzumab

bioconjugates was determined using specific radioactive cellular-binding assays following
procedures derived from Lindmo et al.15,

16

To this end, BT474 cells were suspended in

microcentrifuge tubes at concentrations of 2.5, 2.0, 1.5, 1.25, 1.0, 0.75, and 0.25 ×106 cells/mL
in 500 μL PBS (pH 7.4). Aliquots of either

89

Zr-DFO-trastuzumab or

89

Zr-HOPO-trastuzumab

(50 μL of a stock solution of ~10 μCi in 10 mL of 1% bovine serum albumin in PBS pH 7.4)
were added to each tube (n = 3; final volume: 550 μL), and the samples were incubated on a
mixer for 60 min at room temperature. The treated cells were then pelleted via centrifugation
(600 G for 2 min), aspirated, and washed twice with cold PBS before removing the supernatant
and counting the activity associated with the cell pellet. The activity data were backgroundcorrected and compared with the total number of counts in appropriate control samples.
Immunoreactive fractions were determined by linear regression analysis of a plot of (total/bound)
activity against (1/[normalized cell concentration]). No weighting was applied to the data, and
data were obtained as n = 3.
5.4.7:

PET imaging

PET imaging experiments were conducted on a microPET Focus 120. Female, athymic
nude mice with BT474 xenografts on their right shoulders were administered

89

trastuzumab (9.25-9.99 MBq [250-270 μCi] in 200 μL 0.9% sterile saline) or

Zr-HOPO89

Zr-DFO-

trastuzumab (9.25-9.99 MBq [250-270 μCi] in 200 μL 0.9% sterile saline) via intravenous tail
vein injection (t = 0). Approximately 5 min prior to the acquisition of PET images, mice were
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anesthetized by inhalation of 2% isoflurane (Baxter Healthcare, Deerfield, IL)/oxygen gas
mixture and placed on the scanner bed; anesthesia was maintained using 1% isoflurane/gas
mixture. PET data for each mouse were recorded via static scans at various time points (n=4)
between 6 h and 9 d. An energy window of 350-700 keV and a coincidence timing window of
6 ns were used. Data were sorted into 2D histograms by Fourier rebinning, and transverse images
were reconstructed by filtered back-projection (FBP) into a 128 × 128 × 63 (0.72 × 0.72 ×
1.3 mm3) matrix. The image data were normalized to correct for non-uniformity of response of
the PET, dead-time count losses, positron branching ratio, and physical decay to the time of
injection, but no attenuation, scatter, or partial-volume averaging correction was applied. The
counting rates in the reconstructed images were converted to activity concentrations (percentage
injected dose per gram of tissue, %ID/g) by use of a system calibration factor derived from the
imaging of a mouse-sized water-equivalent phantom containing

89

Zr. Images were analyzed

using ASIPro VM software (Concorde Microsystems).
5.4.8:

Biodistribution

Acute in vivo biodistribution studies were performed in order to compare the uptake of
89

Zr-HOPO-trastuzumab and

89

Zr-DFO-trastuzumab in BT474 tumor-bearing female, athymic

nude mice. Mice were warmed gently with a heat lamp for 5 min before administration of 89ZrHOPO-trastuzumab (0.59-0.67 MBq [16-18 μCi] in 200 μL 0.9% sterile saline) or

89

Zr-DFO-

trastuzumab (0.67-0.74 MBq [18-20 μCi] in 200 μL 0.9% sterile saline) via intravenous tail vein
injection (t = 0). Animals (n = 4 per group) were euthanized by CO2(g) asphyxiation at 1, 3, 5, 7,
9, and 14 d. After asphyxiation, 14 organs were removed, rinsed in water, dried in air for 5 min,
weighed, and assayed for radioactivity on a gamma counter calibrated for

89

Zr. Counts were

converted into activity using a calibration curve generated from known standards. Count data
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were background- and decay-corrected to the time of injection, and the percent injected dose per
gram (%ID/g) for each tissue sample was calculated by normalization to the total activity
injected. The full data set of organs is also included in the appendix with values represented in
%ID without normalization (Table A.5.2).
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS

6.1:

The HOPO journey
This thesis follows an idea from its very inception to its fruition as a successful project

which shows real and significant improvement over the current technology. The project started
from the persistent observation of bone uptake with 89Zr-based immunoPET imaging agents and
the recognition of the chelator, DFO, as the weak link in the modality. The idea of improving the
performance of such agents by developing a better chelator was then paired with a firm
foundation in a basic chemistry to approach the challenge. By taking an in depth look at the
chemistry of Zr and DFO to begin with, we were able to begin forming our hypotheses for
chelator optimization and building our knowledge of the techniques necessary to evaluate these
chelators. Next we looked to existing literature1 to find suitable binding groups and ligand
geometries. Our initial work with catechols and hydroxypyridinones led us rather directly to the
3,4,3-(LI-1,2-HOPO) ligand. The robust stability demonstrated by this HOPO ligand when
radiolabeled with

89

Zr4+ was more than convincing enough to lead us to develop a bifunctional

derivative to allow use with antibodies. Finally, p-SCN-Bn-HOPO proved to be an optimal
bifunctional chelator compared to the “gold standard” DFO. When evaluated as an immunoPET
imaging agent, the
89

89

Zr-HOPO-trastuzumab complex showed dramatically decreased levels of

Zr in the bones of mice, down to background blood levels, compared to 89Zr-DFO-trastuzumab.

This feat is both something to be excited about and something to be proud of.
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6.2:

Future directions

6.2.1:

Translation possibilities

The most rewarding possible outcome of this work would be to see p-SCN-Bn-HOPO be
moved forward into a clinical trial with

89

Zr. Of particular interest is the

89

Zr-J591 clinical trial

currently taking place at Memorial Sloan Kettering Cancer Center.2 The

89

Zr-DFO-huJ591

radioconjugate is being lauded as an excellent imaging agent for the detection of bone metastases
in advanced prostate cancer patients. This could be an ideal application of p-SCN-Bn-HOPO as
it could lower the background signal in the bone by eliminating the release of the 89Zr4+ cation in
vivo. Reduced background signal in the bone tissue could enable improved distinction of osseous
lesions and possibly even allow for the detection of smaller lesions.
6.2.2: Other metals
Another possible avenue for investigation is the application of p-SCN-Bn-HOPO toward
the chelation of other metals, whether radioactive or otherwise for imaging or therapeutic
purposes. As the 3,4,3-(LI-1,2-HOPO) ligand was originally made for the purpose of chelating
actinides1, it follows that the bifunctional ligand p-SCN-Bn-HOPO might also be useful actinides
and lanthanides that have medical applications. Two specific examples of possible nuclides of
interest are actium-225 and thorium-227 which both emit alpha particles suitable for
radioimmunotherapy (RIT). The thermodynamic stability constant of Th-HOPO has been
determined and is comparable to that of Zr-HOPO suggesting that

227

Th might be a good

candidate for evaluation with a p-SCN-Bn-HOPO-antibody system.3 Furthermore, 225Ac is at the
forefront of radioimmunotherapy due to its decay chain containing many other radioactive
daughter nuclides which increase the therapeutic payload of the RIT agent. 4 Despite this, the
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chelation of

225

Ac has not been optimized and would be a ripe area for the further evaluation of

p-SCN-Bn-HOPO.
6.3:

Conclusions
This project demonstrates the power of chemistry to predict and solve problems within

biological applications. From looking at a library of existing ligands, we were able to select a
chelator based on its chemical properties in relation to the metal of interest. We remade the
ligand and proved its potential for Zr4+ before taking that framework and developing it into a
bifunctional chelator for use in our intended area of study. This new molecule was then shown to
outperform the existing chelator quite stunningly in fixing the exact issue we set out to address,
namely reducing accumulation of radioactivity in bone tissue.
These results show that innovation doesn’t have to start from scratch. There is an
enormous volume of existing ligands in the literature that are just waiting to be harnessed for
new applications. With increased collaboration and exchange between different branches of
chemistry and other disciplines, it makes sense to take advantage of established molecules to
solve different problems. Hopefully, this work can serve as an example and encourage others to
pull from different branches of chemical research to help solve a myriad of new and exciting
challenges.
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CHAPTER 2: APPENDIX

Zr-DFO MS report (Figure A.2.1)
NMR comparison of DFO and the Zr-DFO complex (Figure A.2.2)
Radio-ITLC method comparison (Figure A.2.3)
HPLC radiotrace of 89Zr-DFO post-serum study (Figure A.2.4)
Cell binding assay results (Figure A.2.5)
Full biodistribution data (Table A.2.1)
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Figure A.2.1. Non-radioactive Zr-DFO mass spectrometry analysis indicating the different states
a) DFO, b) Zr-DFO, and c) an octa-coordinate Zr(OH)2-DFO similar to that suggested by DFT
calculations. The low resolution mass spectrum was recorded using a Waters Acquity UPLC
with electro-spray ionization (ESI) SQ detector.
a) DFO: [M+H]+ (m/z expected: 561.36, measured: 561.4); [M-H]- (m/z expected: 559.35,
measured: 559.4); [M+Cl]- (m/z expected: 595.32, measured: 595.5); b) Zr-DFO: [M]+ (m/z
expected: 647.23, measured: 647.3); [M+H]2+ (m/z expected: 324.12, measured: 324.4); c)
Zr(OH)2-DFO: [M+H+Cl]- (m/z expected: 717.22, measured: 717.3)
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Figure A.2.2. NMR measurement of DFO (upper panel) and Zr-DFO (lower panel)
demonstrating the structural change of DFO before and after Zr chelation. Significant chemical
shifts changes are observed for protons located the closest to hydroxamate binding groups (Ha,
Hf, Hd, & Hb respectively 2.152.19, 2.52.65, 3.213.27, and 3.673.71).
DFO: 1H-NMR (D2O, 500 MHz) δ: 1.28-1.8 (m, 18H, Hc); 2.15 (s, 3H, Ha); 2.55 (t, 4H, Hf); 2.83
(m, 4H, He; s, 3H, Hh); 3.04 (t, 2H, Hg); 3.21 (t, 4H, Hd); 3.67 (mc, 6H, Hb).
Zr-DFO: 1H-NMR (D2O, 500 MHz) δ: 1.26-1.82 (m, 18H, Hc), 2.19 (s, 3H, Ha); 2.65 (t, 4H, Hf);
2.82 (m, 4H, He), 2.84 (s, 3H, Hh), 3.04 (t, 2H, Hg); 3.27 (t, 4H, Hd); 3.71 (m, 6H, Hb).
In the time since this work was conducted, Ma et. al1 published a similar NMR analysis
comparing DFO and Zr-DFO. Our results are similar to theirs, with a discrepancy in the
assignments of He and Hf with theirs being the opposite of ours. Their study was more in depth
than ours in that they used variable temperature NMR and 2D methods to make individual
assignments, so their results are more likely to be accurate.
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Figure A.2.3. Comparison of radio-ITLC conditions for 89Zr-DFO radiolabeling reaction
monitoring. Conditions evaluated included ITLC-SG, ITLC-SA, and cellulose strips with 50 mM
EDTA at pH 5, 0.5 M citric acid, and Millipore water.
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Figure A.2.3. The radioactive fraction from the SEC analysis was HPLC analyzed and the
retention time of 89Zr-DFO remained unchanged confirming the stability of the 89Zr-DFO
complex even after incubation with serum protein.
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Figure A.2.4. Comparison of 89Zr-DFO-A33 and 89Zr-DFO through a 1 h incubation with
SW1222 human colorectal cancer tumor cells shows the significantly lower affinity of 89Zr-DFO
for the cells as compared to the 89Zr-labeled A33 antibody which actively binds an antigen found
on the SW1222 tumor cells.
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Blood
Heart
Lung
Bone
Kidney
Bladder
Tumor
Muscle

SW1222
1.42 ± 0.35
0.53 ± 0.13
0.79 ± 0.25
0.95 ± 1.05
8.72 ± 1.12
4.61 ± 2.22
1.14 ± 0.42
0.69 ± 0.50

Healthy
3.99 ± 1.44
1.41 ± 0.56
1.47 ± 0.46
1.31 ± 0.49
18.78 ± 13.17
20.68 ± 10.36
n/a
2.4 ± 0.93

Table A.2.1. Full biodistribution data for 89Zr-DFO in healthy and SW1222 tumor-bearing mice.
Data presented as %ID/g. While the values are somewhat higher in heathy mice, the ratios are
quite similar which suggests the same relative distribution.
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CHAPTER 3: APPENDIX

HOPO MS report (Figure A.3.1)
HOPO HPLC chromatogram (Figure A.3.2)
LICAM MS report (Figure A.3.3)
LICAM HPLC chromatogram (Figure A.3.4)
Zr-CMM UV/Vis (Figure A.3.5)
HOPO/Zr-HOPO HPLC chromatogram (Figure A.3.6)
LICAM/Zr-LICAM HPLC chromatograms (Figure A.3.7)
Zr-HOPO MS report (Figure A.3.8)
Zr-LICAM MS report (Figure A.3.9)
LICAM Radiolabeling Trends (Figure A.3.10-11)
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Figure A.3.1. Mass spectrometry analysis of the HOPO ligand showing the expected mass
signals.
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Figures A.3.2. HPLC chromatogram of the HOPO ligand.
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Figures A.3.3. Mass spectrometry analysis of the LICAM ligand showing the expected mass
signals.
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Figures A.3.4. HPLC chromatogram of the LICAM ligand.
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Figure A.3.5. UV/Vis spectra of the catechol methyl monomer (CMM) mixed with different
amounts of ZrCl4. No significant differences can be seen between samples; therefore no
meaningful information can be extrapolated about binding.
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Figure A.3.6. HPLC chromatogram of the HOPO ligand and the non-radioactive Zr-HOPO
complex.

165

Figure A.3.7. HPLC chromatograms of the LICAM ligand alone and a mixture of ZrCl4 and
LICAM. The top trace is over a gradient from 5-95% and the bottom is 50-95% MeCN in water
both spiked with 0.1% TFA. The fact that one method shows the Zr-LICAM coming out slightly
before the LICAM alone while the other shows it eluting slightly after suggests that the small
change might be due to slight changes in the column over time rather than a consistent,
meaningful change in retention time indicative of a change in speciation. This is insufficient to
claim a new Zr-LICAM complex has been formed.
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Figures A.3.8. Mass spectrometry analysis of the Zr-HOPO complex showing the expected mass
signals indicating a 1:1 complex with full deprotonation of the hydroxypyridinone groups.
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865  [M+Cl]-

832  [M-H]-

Figures A.3.9. Mass spectrometry analysis of the Zr-LICAM complex with notable signals
highlighted. Masses suggest the LICAM ligand is not fully deprotonated, losing only 4 protons
from the catechols instead of 8.
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Figures A.3.10. Effects of temperature and pH on the 89Zr radiolabeling of LICAM. The two
graphs show data from two different experiments. The effects are mostly inconsistent. The best
results seem to be from pH 7, but they are still very low. Temperature and time don’t seem to
improve the yields.
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Figures A.3.11. Effects of time and temperature on the 89Zr radiolabeling of LICAM. There is
no significant effect comparing room temperature and 37 oC. There is also no meaningful
improvement in labeling over time.
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CHAPTER 4: APPENDIX

Zr-HOPO HRMS report (Figure A.4.1)
NMR comparison of the HOPO ligand the Zr-HOPO complex (Figure A.4.2)
Experimental Zr-HOPO IR spectra (Figure A.4.3)
Computed Zr-HOPO IR spectra (Figure A.4.4)
Zr-HOPO UV-Vis spectroscopy (Figures A.4.5-6)
Complete Gaussian 09 reference (Ref. 48)
DFT basis set evaluation (Table A.4.1)
DFT structure of Zr(1,2-HOPO)4 (Figure A.4.7)
DFT structure of DFOH2 (Figure A.4.8)
Cartesian coordinates of all optimized structures (gas phase)
Cartesian coordinates of all optimized structures (CPCM,water)
Maximum intensity projection PET images (Figure A.4.9)
Full biodistribution data (Tables A.4.2-3)
Calculated P values (Table A.4.4)
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Figure A.4.1. High resolution mass spectrometry (HRMS) analysis of the Zr-HOPO complex
showing the expected mass signal.
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Figure A.4.2. 1H NMR comparison of the HOPO ligand (top) and the Zr-HOPO complex
(bottom). Spectra were collected on a 500 MHz machine in D2O.
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Figure A.4.3. Experimental Zr-HOPO IR spectra. The purple line is powdered ZrCl4. The red
line is solid HOPO. The blue line is a mixture of solid HOPO and ZrCl4 powder while the green
line is the lyophilized product of the complexation of HOPO and ZrCl4. The three peaks pointed
out in the figure correspond to changes in the spectra as a result of the complexation (from 1630
to 1610, 1564 to 1537, and 1375 to 1360 cm-1). This red-shift is characteristic of a hydroxamate,
or in this case a hydroxypyridinone, binding a metal. Furthermore, similar signals are seen in the
DFT calculated IR spectra associated with a number of highly coupled asymmetric carbonyl
stretches (see Figure A.4.4).
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Figure A.4.4. Computed Zr-HOPO IR spectrum. The spectrum is scaled by 0.992 and with a
resolution of 15 cm-1. The prominent peaks resembling those in the experimental (between 1600
and 1300 cm-1) correspond to various highly coupled asymmetric carbonyl stretches.

175

Figure A.4.5. Zr-HOPO UV-Vis spectroscopy. Solutions of HOPO were prepared with 0.1
equivalent increments of ZrCl4 from 0.0 to 2.0 equivalents in PBS at a pH of 7.4 and allowed to
equilibrate at room temperature for 24 h. The figure above shows a) the full spectrum and b) a
zoomed in section highlighting the peak which undergoes the greatest change. While the peak
does shift slightly lower in absorbance and to slightly lower wavelengths, neither of these
changes shows a consistent stopping point corresponding to a specific ratio of Zr:HOPO.
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Figure A.4.6. Zr-HOPO UV-Vis spectroscopy. The figure above shows a) a profile of the
absorbance at 326 nm, b) a profile of the maximum peak absorbance, and c) a profile of the peak
wavelength all according to the amount of ZrCl4. None of these graphs demonstrate a distinct
end point to the spectral changes. All of the shifts are small and continual over the entire range
from 0.0 to 2.0 equivalents of ZrCl4. There is no notable plateau at the 1:1 stoichiometry
suggested by other experiments. These results are neither negative nor positive; they simply do
not confer any information.
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Basis set

MeOH to MeO-

EtOH to EtO-

cep-121g
381.5
377.5
cep-31g
387.6
384.7
LANL2DZ
389.9
385.5
QZVP
380.0
376.7
cc-pVTZ
385.6
381.6
aug-cc-pVTZ
377.6
374.7
cc-pVQZ
382.1
378.2
aug-cc-pVQZ
377.7
374.9
expt.
381.6 ± 0.7
378.6 ± 0.8
Table A.4.1. Deprotonation enthalpies obtained with B3LYP using different basis sets.

179

Figure A.4.7. Optimized DFT structure of Zr bond by four free 1,2-HOPO groups. The
geometry is a very close match to a previously reported crystal structure of Zr bound by four
hydroxamate groups.35
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Figure A.4.8. Optimized DFT structure of DFOH2 (CPCM). The zwitterionic form was found to
be more stable with the protonated amine tail forming hydrogen bonds with oxygens including a
deprotonated hydroxylamine group.
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Cartesian coordinates of optimized structures (gas phase)
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[ZrDFO(H2O)2]2+ with non hydrogen bonded amine group, III
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6.75832300
7.57596200
5.42157400
5.94419300
3.67457800
4.29393200
3.67046200
2.30889000
4.96526900
3.85207000
4.61732500
-0.26060200
-1.03059300
0.08949800
0.86709300
1.72608600
0.24194700

0.69353800
0.68131900
2.86252300
2.97580000
4.89710000
4.43408600
6.03360300
5.58548000
5.71168000
3.07341800
3.14951300
4.10393400
4.42333200
2.35365700
1.59507800
3.45121800
3.53344600
1.57421500
2.96696500
1.00693900
-0.16214600
0.21085400
-2.24496800
-1.61524300
-1.63452500
-3.23011400
-1.55456600
-3.07072000
-4.22535600
-3.63890800
-2.47999900
-3.70051700
-3.92627700
-2.64698400
-2.81089700
-3.41120900
-0.06962200
-0.31741400
0.40434100

1.77400700
3.33409700
2.64217800
2.90515300
1.36875000
-1.37187100
-0.64620800
-2.33945300
-0.73422700
-2.21994600
-0.56687700
-3.06892600
-1.42665200
-2.50272900
-2.57361500
-0.89731000
0.87014200
0.88978800
0.00796500
-0.84114300
-3.23486000
-3.16968800
-2.99755800
-1.57143800
-0.28312800
-0.83090100
-2.10678500
-2.77490200
-0.55988700
-1.53813600
2.34670700
2.96874400
1.37348100
2.20488600
1.61288900
2.69538200
3.51260300
3.90156600
4.08759100
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[ZrDFO(H2O)2]2+ with hydrogen bonded amine group, IIIa
Zr
N
C
C
C
C
C
N
C
C
C
C
O
N
C
C
C
C
C
N
C
C
C
C
O
N
C
C
C
C
C
N
C
C
O
O
O
O
O
O
H
H
H
H
H
H
H
H
H
H
H
H
H

0.07347200
-0.89282600
-0.89247200
-0.54621200
0.95958300
1.62984200
2.56330600
2.17431300
2.92510600
4.40013100
5.30075900
5.28552900
4.70224700
5.90128500
5.92834400
4.73927300
3.36471100
2.15711700
0.82028400
0.32439600
-0.67750200
-1.49507900
-3.00853400
-3.35827700
-2.48862800
-4.67253100
-5.29222400
-6.27861800
-5.66849400
-4.61898600
-3.99950200
-2.93056100
-2.85991900
-4.05510300
0.77532900
2.28036600
0.81032300
-0.97021600
-1.68349300
-1.67819000
0.04913100
-1.34344100
-1.41580900
-1.90550300
-0.20531400
-1.01359000
-1.06863900
1.00539600
1.55790400
0.85505000
2.22379600
3.60936600
2.53553900

-0.92732700
0.00719600
-0.24855200
-1.70477500
-2.12057200
-2.84551300
-1.94448400
-1.94804000
-1.83318100
-2.20275300
-1.05884900
0.14530400
0.06139600
1.28991000
2.55341800
3.49923900
2.83268400
3.79298200
3.13250700
2.07036500
2.10890700
3.35645100
3.09803400
2.59722600
2.04124100
2.72462600
2.08956800
0.95417400
-0.16756400
-1.05478000
-2.15523700
-1.66455300
-1.74872600
-2.09124900
-1.76363400
-1.47937100
0.74735200
0.97501300
-1.38671400
-1.54763900
0.07560600
-0.75693700
0.86549600
-0.00468500
0.47441600
-1.82573200
-2.41147100
-2.80539700
-1.24467600
-3.27615600
-3.68478700
-2.24919600
-0.89369600

-1.26674700
2.23131500
3.73860200
4.15699500
4.30389100
3.08656300
2.22154000
0.77890200
-0.32477800
-0.39282600
-0.92759800
0.03571800
1.16358900
-0.40841900
0.37791100
0.04573600
0.31563700
0.18318500
0.61103400
-0.31356900
-1.20112400
-1.48581700
-1.24473100
0.17340500
0.93195300
0.52619100
1.71981900
1.31760900
0.42955100
1.15090000
0.25053400
-0.67095800
-2.01385100
-2.88367100
0.57589800
-1.43223800
-0.06639100
-1.81152500
-0.02879600
-2.55659500
1.81563300
1.68959000
1.97362100
4.07743800
4.19302300
5.14451000
3.49348800
5.16008000
4.60215000
2.44324400
3.46871300
2.28484300
2.53787000
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H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
O
H
O
H
H
H

4.75695200
4.47661800
4.96968600
6.32609600
6.37157300
5.90460600
6.88304000
4.85084700
4.80669100
3.37358400
3.22326500
2.30164900
2.06861500
0.02712600
0.94407000
-1.14657900
-1.36275900
-3.35061200
-3.56463600
-5.29197100
-4.47488500
-5.82481600
-6.68856100
-7.13345600
-5.21992000
-6.49255400
-3.81091300
-5.09816300
-4.77168100
-3.51930500
-3.90664900
-4.12339700
-4.99970000
0.34993100
-0.34544200
1.01877500
1.95412300
1.17997000
0.68624600

-2.52703900
-3.05826000
-0.74548200
-1.43908100
1.27396900
2.27797300
3.05362300
4.40107100
3.82934300
2.40610100
1.98329300
4.66584900
4.18227800
3.87862200
2.64554300
4.20367300
3.62343700
2.33008000
4.01693200
3.21803800
1.71988700
2.85853400
0.52233500
1.39875400
0.28326900
-0.80766900
-0.43680100
-1.56386100
-2.64049800
-2.92926800
-1.63057900
-3.17800500
-1.74010000
-3.00396900
-3.21689800
-0.31861000
-0.59866200
-3.50120100
0.20849900

0.58590400
-1.07981100
-1.92661500
-1.03150600
-1.30695300
1.43761100
0.17735000
0.66774000
-1.00317700
1.32865900
-0.36442700
0.83856500
-0.84256000
0.71504400
1.58548400
-0.89089900
-2.54246300
-1.95197100
-1.47018500
-0.10953900
2.34393300
2.29242700
2.24283200
0.78607600
-0.46959100
0.07938500
1.56193300
2.00017300
-0.35660600
0.86212000
-3.86347700
-3.02975200
-2.46077600
-2.37585900
-3.02867700
-3.27477500
-3.34092100
-2.49773900
-4.02364900
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ZrDFO(OH)2, IV
Zr
N
C
C
C
C
C
N
C
C
C
C
O
N
C
C
C
C
C
N
C
C
C
C
O
N
C
C
C
C
C
N
C
C
O
O
O
O
O
O
H
H
H
H
H
H
H
H
H
H
H
H
H

0.38923500
-1.28893100
-0.95999200
-1.19578600
-0.12330900
1.09586700
2.15447900
2.03229500
3.02139900
4.49245500
5.44922600
5.68536300
5.99186600
5.57805400
5.74750600
4.40280200
3.45656500
2.26787600
1.16916400
0.34259300
-0.70510600
-1.44404000
-2.95377400
-3.65790500
-3.04133900
-5.02029800
-5.87544200
-6.63886700
-5.74339000
-4.84382300
-3.95631700
-2.75537300
-2.46489900
-3.50944000
0.70271600
2.69011600
0.79582800
-1.13627000
-1.66877800
-1.27042900
-0.37684400
-1.66760000
-1.93178800
-1.56029500
0.09034600
-2.19069900
-1.19700100
-0.61548200
0.24127700
0.73276500
1.61501200
3.16436300
2.07258500

0.30749800
0.80555000
1.99042200
3.35709900
4.44556500
4.52315500
3.37934500
2.37997000
1.69574700
2.08630600
1.19945000
-0.15986600
-0.22606100
-1.27941200
-2.65847400
-3.39640200
-2.63784400
-3.51292000
-2.70501400
-1.87248000
-2.24647300
-3.55634900
-3.40330300
-2.33689500
-1.56236100
-2.25342200
-1.17638300
-0.41818700
0.18649900
1.36928700
1.93274900
1.11571300
0.42013300
0.22349000
1.98902500
0.71529500
-0.52659100
-1.44489800
1.33290400
-0.06161700
0.29869700
1.09850700
0.10960400
1.91556200
1.88001200
3.73551100
3.18835300
5.43013000
4.32696700
4.56929800
5.47229100
3.80154800
2.86071200

1.25615500
-1.94847600
-2.84091000
-2.12724800
-2.45209700
-1.47764000
-1.57499200
-0.48834700
0.12344300
-0.08361100
0.75331000
0.07247300
-1.16272500
0.87466800
0.36204100
0.10796200
-0.86184900
-1.33971900
-2.09020200
-1.18689600
-0.42092900
-0.70940200
-0.41496300
-1.28026900
-2.08237300
-1.08524800
-1.63648800
-0.51369300
0.60344200
0.15579800
1.30245100
1.59251200
2.71791100
3.81494800
-0.17321500
0.91470600
-0.97521400
0.50439900
0.69038600
2.87364300
-1.66675600
-1.01020400
-2.34654400
-3.75638300
-3.12626600
-2.40870400
-1.04642500
-2.42256200
-3.48771700
-0.44395300
-1.68452600
-1.51908000
-2.54373100
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H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
O
H
O
H

4.77220000
4.62732100
5.06054900
6.42424100
5.22962000
6.31091600
6.36046200
4.65061600
3.88086000
4.02842200
3.06772200
2.63516400
1.80464300
0.51272700
1.62179600
-1.29059400
-1.04304400
-3.07904000
-3.45839400
-5.45483000
-5.21627200
-6.59956200
-7.23925900
-7.36478500
-5.11144400
-6.40378000
-4.19092200
-5.47831200
-4.54905000
-3.57907400
-3.11871400
-3.67204700
-4.47525400
0.88658700
0.42339500
1.32747100
2.30351700

1.98778700
3.14108300
1.07734600
1.70606400
-1.15552700
-2.57481500
-3.22966000
-4.39536600
-3.56718900
-2.28979200
-1.74287000
-4.30526600
-4.01747000
-3.38483100
-2.00737400
-3.86549000
-4.34984000
-3.10567200
-4.37113500
-2.92319300
-0.51239600
-1.60549700
0.37596400
-1.10900100
-0.60669700
0.53290900
1.07000500
2.19047200
2.03561500
2.92704000
-0.53097800
1.15352200
-0.11251300
1.51136900
1.49627800
-1.40627200
-1.36323200

-1.14071400
0.19849500
1.76942900
0.81397100
1.81778700
-0.57335300
1.07938500
-0.29384400
1.06582100
-1.73523400
-0.36589300
-2.01411800
-0.47752700
-2.65032500
-2.80351800
-1.74825800
-0.06193800
0.63417400
-0.55113100
-0.45675900
-2.20231000
-2.34694400
-0.98855900
-0.05066200
1.02890200
1.41702300
-0.67400900
-0.21465100
2.22072400
1.03135300
4.50153900
4.37911600
3.42349600
2.82176700
3.68413500
1.85676700
1.90980200
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Zr(1,2-HOPO)4
C
C
C
C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
H
Zr
C
C
C
C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
H
C
C
C
C
C
N
H
H
H
O
O
C
O
N

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

2.24941700
1.93531200
0.70521100
-0.20909300
0.10008500
1.32269100
0.47417800
2.66970700
-1.15660700
1.53776700
-0.65240300
3.58799100
4.35293000
3.89616200
3.20014600
5.16794800
5.00070300
5.64539800
5.82567800
0.00024700
-3.76927600
-4.35757100
-3.73352600
-2.52289000
-1.91903800
-2.57530300
-4.19991200
-5.29031100
-2.01273400
-1.91753000
-0.78734200
-4.46670400
-5.56922900
-3.86610100
-2.97609300
-4.45096700
-4.59600000
-3.79288200
-5.41621500
-2.24951800
-1.93520100
-0.70477700
0.20964600
-0.09973200
-1.32264600
-0.47357800
-2.66969700
1.15740700
-1.53794600
0.65282000
-3.58846200
-4.35352200
-3.89702500

2.76647900
3.38461000
3.10123300
2.20183500
1.56785000
1.88257200
3.58678500
4.07093900
1.95811900
1.22363600
0.70931900
3.09567200
3.92955900
2.47007500
1.82903800
2.72338600
3.30461800
1.77231600
3.29187700
-0.25688200
-2.68057000
-3.61145600
-3.93222100
-3.32718500
-2.38053400
-2.09369000
-4.65446700
-4.05883700
-3.54663400
-1.15042300
-1.73139900
-2.37001900
-2.95951200
-1.47884300
-1.07317900
-1.14598200
-0.06154900
-1.48200600
-1.64861300
2.76404200
3.38189300
3.09871100
2.19981600
1.56615600
1.88068500
3.58402600
4.06782900
1.95627700
1.22209100
0.70809600
3.09287400
3.92638800
2.46719500

-2.47700200
-3.69591300
-4.34706500
-3.78364100
-2.54304300
-1.94069200
-5.29149800
-4.09947400
-4.25032300
-0.71964500
-1.89204600
-1.81784800
-2.40260700
-0.63933700
-0.25550000
0.06082600
0.97814400
0.32546200
-0.60018600
-0.00029000
-0.33573300
0.53382200
1.76854700
2.13493700
1.25669100
0.05662900
2.43333900
0.21253900
3.06591600
-0.74256200
1.44902000
-1.65879000
-1.90591600
-2.50786500
-2.20774500
-3.81802700
-3.90645500
-4.63060600
-3.90976600
2.47881300
3.69780900
4.34844100
3.78439900
2.54368200
1.94186400
5.29295600
4.10185900
4.25067300
0.72067000
1.89213200
1.82024300
2.40536400
0.64189800

M
M
M
M
H
H
M
M
M
H
H
M
M
M
M
M
M
M
M
H
M
M
M
M
H
H
M
M
M
H
H
M
M
M
M
M
M
M
M
M
M
M
M
H
H
M
M
M
H
H
M
M
M
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H
C
H
H
H
C
C
C
C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
H

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

-3.20078900
-5.16933800
-5.00499400
-5.63946000
-5.83208000
3.76933900
4.35767200
3.73399500
2.52369300
1.91981100
2.57573300
4.20040300
5.29013000
2.01380300
1.91803700
0.78836900
4.46630900
5.56858200
3.86540800
2.97592600
4.44972900
4.60839000
3.78417900
5.40834500

1.82682500
2.72023400
3.31324400
1.76888300
3.27677200
-2.68139600
-3.61167300
-3.93113300
-3.32538100
-2.37932800
-2.09373200
-4.65293500
-4.05966500
-3.54384200
-1.15085200
-1.72969500
-2.37234700
-2.96239400
-1.48211800
-1.07548700
-1.15071100
-0.06782000
-1.47500600
-1.66484400

0.25735400
-0.05740100
-0.96773500
-0.33360400
0.60880100
0.33399100
-0.53618700
-1.77143700
-2.13774000
-1.25886900
-0.05832500
-2.43669600
-0.21493700
-3.06909800
0.74138700
-1.45103300
1.65764300
1.90459700
2.50749400
2.20711300
3.81826800
3.90308000
4.62944100
3.91550800

M
M
M
M
M
M
M
M
M
H
H
M
M
M
H
H
M
M
M
M
M
M
M
M
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3,4,3-(LI-1,2-HOPO)H4
C
C
C
C
C
N
H
H
H
O
O
C
O
N
C
H
H
C
C
C
C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
C
C
C
C
C
N
H
H
H
O
O
C
O
N
C
H
H
C

-2.20811500
-1.22503700
-0.58246300
-0.93253500
-1.96329400
-2.53951000
0.20110000
-0.97313000
-0.43625400
-3.56324600
-2.43205600
-2.95586100
-3.65749600
-2.77181300
-1.92854100
-2.30765200
-2.08473700
8.37401600
8.45381600
9.72641000
10.91171500
10.88193500
9.57253800
9.76362000
7.52123200
11.88541200
9.60573900
11.84844300
6.99909900
5.97266500
6.91774300
7.77104000
5.60386500
5.77285300
4.97869100
2.20837300
1.22536300
0.58301200
0.93322100
1.96387900
2.53989100
-0.20048500
0.97333800
0.43712200
3.56354400
2.43273100
2.95600900
3.65785500
2.77169500
3.47597500
2.85276900
3.54726600
-8.37429900

2.82795000
3.31664700
4.56188200
5.31722900
4.86100600
3.60492500
4.92436100
2.74338400
6.25060200
3.15601200
5.40416500
1.53242200
1.48638600
0.44123700
0.44143100
-0.36069000
1.37569200
-3.08409600
-3.62065400
-3.79793000
-3.44478200
-2.88545000
-2.74428700
-4.21789500
-3.88871600
-3.57042400
-2.18350100
-2.49763100
-2.91148600
-3.25918200
-2.40051200
-2.12452900
-2.22704200
-2.24128100
-3.08837500
2.82808700
3.31696000
4.56230400
5.31757200
4.86113800
3.60497900
4.92493600
2.74376800
6.25104400
3.15584400
5.40418800
1.53250000
1.48651300
0.44124300
-0.82113900
-1.66066600
-0.85536300
-3.08372400

2.11987900
2.98040600
2.68518300
1.56809700
0.66874100
1.03134500
3.34529300
3.86461000
1.33167900
0.13498700
-0.40169100
2.42931100
3.48869100
1.60654700
0.37596800
-0.26923600
-0.17106900
0.79645900
2.08251200
2.71216900
2.07132700
0.74144000
0.18812900
3.71419300
2.56325700
2.53125700
-1.13144000
-0.01510800
0.15658200
0.82497100
-1.11278300
-1.58820500
-1.77147900
-2.85559000
-1.50632700
-2.11979000
-2.98029200
-2.68503500
-1.56793900
-0.66857000
-1.03123000
-3.34514100
-3.86450700
-1.33152700
-0.13489100
0.40187200
-2.42927000
-3.48850400
-1.60665200
-1.97760500
-1.64183100
-3.06985100
-0.79654800
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C
C
C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
H
H
H
H

-8.45407700
-9.72666400
-10.91198600
-10.88223200
-9.57283900
-9.76385300
-7.52148100
-11.88567900
-9.60606900
-11.84876400
-6.99938500
-5.97294100
-6.91802300
-7.77131700
-5.60413600
-4.97899800
-5.77313400
4.89192500
5.48467600
4.81862000
1.92840800
2.30750600
2.08459800
0.41527000
0.26750100
0.06196800
-0.41539900
-0.06210100
-0.26761600
-3.47613800
-3.54736500
-2.85299900
-4.89212400
-4.81886600
-5.48480000
-10.60632800
-3.60440700
3.60483100
10.60598900

-3.62007300
-3.79732400
-3.44436200
-2.88525500
-2.74408800
-4.21712400
-3.88800000
-3.56999200
-2.18353300
-2.49765000
-2.91113000
-3.25871100
-2.40028800
-2.12443900
-2.22687100
-3.08824400
-2.24106800
-0.91264400
-0.04675200
-0.88653800
0.44144700
-0.36067300
1.37570900
0.22615200
-0.71760300
1.03182200
0.22614600
1.03181600
-0.71760900
-0.82112500
-0.85540000
-1.66067000
-0.91251800
-0.88640100
-0.04659000
-2.06118500
3.93956500
3.93933900
-2.06107200

-2.08269000
-2.71236800
-2.07145700
-0.74147600
-0.18815300
-3.71446200
-2.56348700
-2.53140000
1.13151200
0.01515300
-0.15665900
-0.82509700
1.11275400
1.58825400
1.77145000
1.50633200
2.85555900
-1.34894600
-1.66896200
-0.25428300
-0.37608100
0.26913400
0.17095400
-0.65722100
-1.20292900
-1.31675000
0.65709900
1.31663000
1.20280500
1.97748800
3.06973600
1.64163300
1.34889600
0.25423300
1.66895600
1.24773000
-0.49926300
0.49941200
-1.24763700
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3,3,3-(LI-1,2-HOPO)H4
C
C
C
C
C
N
H
H
H
O
O
C
O
N
C
H
H
C
C
C
C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
C
C
C
C
C
N
H
H
H
O
O
C
O
N
C
H
H
C

-0.51872700
0.20588700
1.39704500
1.84357600
1.11000400
-0.05292700
1.96004300
-0.16088800
2.73983700
-0.77635200
1.33874000
-1.85412300
-2.80343100
-1.96184000
-0.84127800
-1.07941200
0.05195200
7.26148800
8.20989200
9.58384300
10.01449500
9.07251500
7.72463900
10.30452500
7.85443100
11.05054200
6.83588800
9.26133600
5.80531800
5.51038200
4.87203600
5.16609000
3.45240400
3.42329600
2.98078800
-0.79677000
-2.18041300
-2.72179900
-1.90666600
-0.46924200
-0.01571600
-3.80246000
-2.83054900
-2.30707900
1.41152400
0.44965500
-0.13294200
-0.25915000
0.53721200
1.24918600
0.67402600
1.25194500
-5.85367100

5.01900300
5.91439900
6.51138600
6.23587100
5.32981900
4.77034400
7.20175700
6.15846100
6.68420500
3.86873400
4.95883000
4.43682900
5.24977300
3.07133400
2.11046800
1.46817600
2.68100800
-0.75510800
0.01608600
-0.38250100
-1.53857200
-2.36965900
-1.89793100
0.23432600
0.91036000
-1.85798100
-2.76328400
-3.46293600
-0.29739300
0.77385400
-1.04613900
-1.89888700
-0.62629400
0.45812400
-1.11936200
-2.22321600
-2.30999800
-2.73641700
-3.08323200
-3.02001100
-2.57516400
-2.79516900
-2.05968100
-3.41425100
-2.51450400
-3.30407600
-1.88553600
-2.70731600
-0.68410900
-0.43154300
-0.91292600
0.65112700
-1.97899200

0.50295100
1.28802900
0.75973000
-0.53120800
-1.38405600
-0.77095400
1.38323400
2.27780300
-0.94488500
-1.61713000
-2.59338100
0.95928800
1.18882900
1.14323300
0.93267900
0.07635000
0.66551200
-1.00392000
-0.32988600
-0.31394700
-0.96099200
-1.67073400
-1.63722800
0.21705900
0.16669000
-0.96027800
-2.35694500
-2.32385900
-0.99915100
-0.37741900
-1.66753200
-2.13270900
-1.69651100
-1.86136800
-2.55572000
2.34523100
2.49057000
3.74826700
4.82460900
4.70455400
3.42690100
3.85426600
1.66031700
5.77646500
3.30781100
5.55985200
1.01222500
0.05163900
0.88595500
-0.40310900
-1.20065600
-0.58071900
-1.51177100
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C
C
C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
H
H
H
H

-5.26993400
-5.71677200
-6.73467500
-7.36911100
-6.86192100
-5.24490600
-4.47513000
-7.08659100
-7.52758700
-8.31384400
-5.35236200
-4.47753800
-5.84202300
-6.55091300
-5.34110200
-5.27027600
-6.08650900
2.70268400
3.25180300
2.68101900
0.69400500
0.91282300
1.58585900
-0.53356400
-0.32412600
-1.40248200
-3.31196200
-3.93056700
-3.22287000
-3.94988300
-3.30775000
-4.04368000
1.68348800
-0.23719800
-8.17878800
7.49244700

-3.24078000
-4.14696900
-3.80369700
-2.50957200
-1.66863900
-5.12311300
-3.49108300
-4.47568900
-0.39850600
-2.00323100
-1.03239200
-1.45800800
0.24487300
0.52599000
1.19876300
0.66625600
1.99595200
-0.97559600
-0.53556900
-2.06294200
0.31109400
-0.21179500
0.90471300
1.24694800
1.90762200
0.63483500
2.52436900
3.37291300
1.84328900
1.78188500
0.95009000
2.46955800
-2.87274600
3.94727000
-0.51851800
-3.46959300

-1.63189000
-2.64631700
-3.53231400
-3.44885300
-2.41261000
-2.72251800
-0.94037000
-4.30689900
-2.37746500
-4.16091500
-0.42885600
0.39137900
-0.37893300
-1.04932900
0.63809800
1.59488100
0.74238300
-0.38193900
0.45973800
-0.23841500
1.98905600
2.92439100
1.75283000
2.18448700
3.03903400
2.45440100
1.46699400
1.77140500
2.32279300
0.26277700
-0.05018800
-0.58767100
4.21111300
-2.46619400
-3.14635100
-2.67192500
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DFOH2
N
C
C
C
C
C
N
C
C
C
C
O
N
C
C
C
C
C
N
C
C
C
C
O
N
C
C
C
C
C
N
C
C
O
O
O
O
O
O
H
H
H
H
H
H
H
H
H
H
H
H
H
H

-0.75175200
0.02321200
0.41235100
1.58064800
1.50597100
2.56836300
2.47273700
3.47046100
4.91149200
6.00974500
6.28800100
7.37457300
5.31316200
5.47288900
4.31775300
2.95073800
1.74983300
0.35918200
0.24166600
0.13921100
0.09692500
-1.05522700
-2.43501200
-2.80622200
-3.27149800
-4.60929500
-5.78956500
-5.81694700
-6.04327000
-6.00647300
-4.67311900
-4.44689000
-5.59057800
1.16401500
3.22560300
0.37162900
0.09807900
-3.64840700
-3.33544000
-0.42711100
-1.76842500
-0.50678800
-0.59912600
0.91807700
0.68682900
-0.48103400
2.54306900
1.56822100
0.51141600
1.63670300
2.42599400
3.57582800
4.99937800

2.00718300
3.22952100
4.11088700
3.49536200
3.83320900
3.09307000
1.61862500
0.70831100
1.26779800
0.16294200
-0.45776900
-0.21895200
-1.28240700
-1.97037800
-2.97558100
-2.29310000
-3.24289900
-2.59330400
-1.20210200
-0.87588800
-1.93765000
-1.67495900
-2.01913500
-1.65805000
-2.76024900
-3.24727900
-2.30466500
-0.94275100
-1.07754400
0.27282100
0.93609500
2.29976900
3.16408800
1.11640900
-0.53966400
-0.22709600
0.38795500
0.19821200
2.83624600
1.63761300
2.19016400
1.13142100
3.78561800
2.87831000
5.11379200
4.24005600
3.83525600
2.40368700
3.56800000
4.91461200
3.34888600
3.40268800
1.89960900

-1.81725700
-2.25505600
-1.03877900
-0.20417600
1.30841100
2.16836200
2.02121400
1.75973400
1.65211700
1.63288800
0.24757700
-0.37484700
-0.25740100
-1.56027300
-1.78926200
-2.08197400
-1.83162900
-2.08411100
-1.54689300
-0.25113700
0.85176300
1.87010600
1.30379800
0.13631500
2.10708700
1.67774200
2.04926800
1.29829600
-0.23070600
-0.98940400
-0.91512700
-0.80641000
-0.25837700
2.34130600
1.61776000
-2.56180300
0.15196400
-1.62100300
-1.11200600
-0.89102500
-1.74567000
-2.38355300
-2.96554400
-2.78234300
-1.39746400
-0.40879200
-0.62006500
-0.31380400
1.68948400
1.47318600
3.22907400
1.87356200
0.75612500
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H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H

5.09691100
5.74028300
6.95792600
4.45271800
5.50692300
6.44493200
4.58962500
4.23315400
2.92887300
2.83255200
1.82378800
1.80858000
-0.44507400
0.18287900
0.01886500
1.04898000
-1.04565300
-0.86642900
-2.93722100
-4.56365600
-4.76363300
-6.72372300
-5.76632200
-4.87837000
-6.62231100
-5.28646400
-7.02589500
-6.75016600
-6.23970300
-6.39002400
-6.02712000
-5.17239800
0.73540600
-3.23137000

1.92095000
-0.62535200
0.60886800
-1.37325300
-1.22762300
-2.48145300
-3.63826200
-3.61860500
-1.92072700
-1.40709200
-4.13144100
-3.61175300
-3.22211300
-2.46086100
-2.95181500
-1.85540500
-0.61170400
-2.24713400
-3.02521200
-3.40410900
-4.22602100
-2.85407900
-2.12057600
-0.40237700
-0.32751000
-1.73695800
-1.53645900
0.96142600
0.10899900
3.27974200
2.74734100
4.14891700
0.79107500
-0.42887800

2.51571800
2.34680600
1.94900900
0.28480700
-2.37214600
-1.56404300
-2.62477900
-0.89746500
-3.11592500
-1.44519500
-2.48009600
-0.79565600
-1.67858800
-3.15351600
0.45063400
1.39558000
2.13917700
2.78805700
3.02611800
0.59541600
2.15104400
1.84563800
3.13459900
1.48047900
1.73271900
-0.66886300
-0.42565100
-0.57579900
-2.05193100
-1.00233400
0.65617000
-0.04196900
1.44886300
-0.95549300
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Cartesian coordinates of optimized structures (CPCM, water)
Zr[3,4,3-(LI-1,2-HOPO)], I, CPCM
C
C
C
C
C
N
H
H
H
O
O
C
O
N
C
H
H
C
C
C
C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
C
C
C
C
C
N
H
H
H
O
O
C
O
N
C
H

-1.11977300
-0.54350100
0.46292500
0.86883700
0.28220700
-0.67476900
0.91371800
-0.88782100
1.62152900
-1.22269400
0.54884600
-2.34416500
-3.31691400
-2.39029400
-1.28229900
-1.74809000
-0.60697700
4.30599000
5.16545100
4.72732000
3.42961300
2.55093000
3.03354300
5.40253500
6.15775400
3.06062100
2.12410300
1.29816700
4.78889500
6.00862200
3.92637700
2.99517800
4.34596400
5.13137200
4.79635000
1.73472900
2.07466000
1.62424400
0.93392500
0.62140700
0.91808000
1.86774600
2.72780600
0.65019900
0.34671200
0.08514500
2.53428600
3.79456700
1.95923300
2.86671500
2.38824200

1.68752700
2.10061100
1.30306000
0.08875700
-0.33139200
0.50305800
1.63648500
3.01873500
-0.54287500
0.01694800
-1.43101900
2.41534800
2.57314100
2.91150700
2.84992900
2.57264100
2.03927400
-1.40039000
-2.39192400
-3.74112500
-4.09517300
-3.09092400
-1.78808300
-4.49931800
-2.09483000
-5.11196500
-0.88143300
-3.27462300
0.04454200
0.28791800
1.02436300
0.73737400
2.44993100
2.57820100
2.68252200
0.75944800
0.45123000
-0.76617000
-1.70920000
-1.40716600
-0.12355900
-0.98801400
1.12330000
-2.68070200
0.20951200
-2.22257800
1.80759700
1.56130000
2.90745500
3.83364800
4.81323000

-2.92473200
-4.13392300
-4.74769100
-4.17484000
-2.94805000
-2.37379700
-5.67753700
-4.59398600
-4.63198700
-1.17526300
-2.25910400
-2.36902000
-3.20204000
-1.10131800
-0.09819400
0.85281700
-0.35863500
-1.07411800
-1.56773400
-1.65895700
-1.26765500
-0.77146400
-0.67827000
-2.04321000
-1.88093300
-1.33612000
-0.10246200
-0.37806700
-1.02468600
-1.36479400
-0.65698000
-0.35193800
-0.62420300
0.13210700
-1.59764100
3.20579600
4.52894000
5.11299300
4.34014000
2.98370700
2.51923700
6.14761500
5.07297400
4.72843600
1.27194500
2.09271100
2.43333600
2.35706000
1.87306400
1.11713900
1.11469200
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H
C
C
C
C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
Zr

3.80651900
-4.51496700
-5.41342900
-4.93765100
-3.56526500
-2.65442000
-3.15744700
-5.64349500
-6.47112700
-3.16665000
-2.17443000
-1.33834500
-5.06652300
-6.33958900
-4.20596600
-3.21088700
-4.67769100
-3.98131600
-5.65026400
3.16902300
2.25589100
3.42612400
0.58833800
-0.04413800
0.68976300
-0.11177400
0.47456200
-1.03329300
-0.51025300
0.36849500
-1.14261600
-3.62057300
-3.93379100
-3.32221500
-4.83051800
-5.11308300
-5.66817900
-0.06953100

3.92412700
-1.80233700
-2.84881100
-4.12335300
-4.33809800
-3.27582100
-2.06461900
-4.92579000
-2.64308700
-5.28614500
-1.12413000
-3.32071200
-0.41701700
-0.29432700
0.63502900
0.42367800
2.03303100
2.55312600
1.99242700
3.42968100
3.05530400
4.36605500
3.34229500
2.45026700
3.69012900
4.47044900
5.39700000
4.66954800
4.19187300
4.19188700
5.02740200
3.66720000
4.28620000
4.33483600
2.80264400
2.09931700
3.50636100
-1.52930400

1.67466000
0.60774500
0.35331500
-0.05300100
-0.23879800
0.01034600
0.47697800
-0.24261300
0.45297600
-0.58064200
0.82671700
-0.17386600
0.91751100
1.06514200
0.96388400
0.86983100
1.11617700
1.78354400
1.61317200
-0.36085600
-0.84140000
-0.87439300
2.34341900
2.35432000
3.38082000
1.54368400
1.59469100
2.11225900
0.06567600
-0.58962100
-0.26311100
-0.68855200
-1.53564200
0.12597500
-0.23589500
-1.02864100
-0.12318100
-0.06471100
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Zr[3,3,3-(LI-1,2-HOPO)], II, CPCM
C
C
C
C
C
N
H
H
H
O
O
C
O
N
C
C
C
C
C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
C
C
C
C
C
N
H
H
H
O
O
C
O
N
C
H
H
C
C
C

-0.79686800
-0.14014800
0.81158800
1.08829200
0.42378100
-0.48664500
1.32387000
-0.38067200
1.80169700
-1.12634900
0.58147300
-1.96646800
-2.87077300
-2.03433700
-1.00829000
4.28015500
5.17773800
4.76975500
3.46375000
2.54473900
3.00554100
5.47532700
6.17337600
3.11993600
2.07059500
1.27586700
4.71619000
5.93534300
3.81265300
2.88251600
4.17766700
4.97620300
4.59841100
1.48890800
1.76584000
1.33263200
0.72037200
0.46788100
0.75018600
1.52859300
2.35882000
0.45417500
0.24909700
0.00110400
2.29895900
3.56677600
1.74134800
2.66859700
2.19422000
3.60255200
-4.57876800
-5.51419700
-5.08281700

1.79162900
2.18645500
1.31922000
0.05785900
-0.34267300
0.55189100
1.63778000
3.14702700
-0.62339800
0.07714400
-1.47335100
2.61594000
2.91851300
3.04358400
2.72146500
-1.37388700
-2.36255700
-3.72346400
-4.09251100
-3.09146100
-1.77898200
-4.48028200
-2.05598300
-5.11912700
-0.87204200
-3.28226700
0.08800900
0.35325100
1.05865100
0.75986600
2.49773900
2.70774100
2.67809100
0.92885200
0.68536900
-0.52900100
-1.52938000
-1.29057900
-0.01576100
-0.70327700
1.40349900
-2.49509200
0.25250900
-2.15127700
1.95703700
1.73508900
2.99888600
3.89671000
4.88166800
3.98872600
-1.62021900
-2.59906200
-3.86403900

-2.83027500
-4.00420400
-4.61011400
-4.06200900
-2.86906300
-2.30797600
-5.51287100
-4.44281800
-4.51095200
-1.15151100
-2.19602500
-2.28951200
-3.15830200
-0.99361400
0.05132200
-0.87970800
-1.30567800
-1.36128100
-1.01165600
-0.58682200
-0.51169000
-1.68963500
-1.59865400
-1.06101800
0.01890300
-0.24591800
-0.88733200
-1.21134700
-0.59872300
-0.30233700
-0.67576100
0.04862300
-1.67364900
3.25044700
4.60180600
5.20496300
4.43526600
3.05479100
2.55994100
6.25860400
5.15586400
4.84945800
1.27457600
2.16272000
2.45762500
2.45880800
1.78044800
1.01291200
0.99116500
1.57785500
0.40339900
0.03924000
-0.44191800

202

C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
C
H
H
C
H
H
C
C
H
H
C
H
H
Zr
H
H
H
H

-3.71612900
-2.76759900
-3.23049500
-5.81718600
-6.56442400
-3.34853700
-2.21962700
-1.44981200
-5.06974000
-6.33779300
-4.15100500
-3.16914400
-4.52868700
-3.83461800
-5.52993800
2.97668000
2.07214700
3.21919400
0.36513500
-0.17216200
0.49080600
-0.47551700
-3.25600200
-3.48111100
-2.99670000
-4.53441300
-4.77164400
-5.35172500
-0.09754700
0.09390400
-1.30190000
-0.17716300
-1.44297200

-4.13149100
-3.13605800
-1.94107100
-4.61548400
-2.34786200
-5.07000300
-1.08189400
-3.22837200
-0.22652400
-0.04038700
0.76856300
0.49400500
2.19193700
2.64262500
2.21209400
3.45758200
3.05075800
4.38100200
3.52018400
2.76082500
4.39952500
3.94241300
3.82666900
4.50655400
4.43317300
2.99871200
2.32582700
3.73221100
-1.52700200
4.60905900
4.53469800
2.21574100
2.00717800

-0.59670300
-0.23606200
0.30719700
-0.71402600
0.11133100
-0.99504300
0.77740900
-0.38038800
0.77127600
0.88876100
0.88404900
0.81612700
1.05031800
1.76882400
1.48811700
-0.45206900
-0.92237800
-0.99529100
2.07413200
2.65083300
2.72133700
0.83882800
-0.60421800
-1.43169800
0.26515700
-0.28931000
-1.12249200
-0.23251900
-0.01249400
0.17968700
1.24892000
-0.43438600
0.75293800

203

[ZrDFO(H2O)2]2+ with non hydrogen bonded amine group, III, CPCM
Zr
N
C
C
C
C
C
N
C
C
C
C
O
N
C
C
C
C
C
N
C
C
C
C
O
N
C
C
C
C
C
N
C
C
O
O
O
O
O
O
H
H
H
H
H
H
H
H
H
H
H
H
H

0.29537800
-8.15471000
-7.38446300
-6.32197900
-5.55838200
-4.48329500
-3.74740700
-2.63834700
-2.60973300
-3.82720200
-3.56264100
-3.34975400
-3.89548400
-2.57099500
-2.19489200
-0.68719500
-0.25908900
1.24844600
1.72777200
1.65363100
2.53827200
3.85751800
5.09412200
5.18681300
4.78711300
5.70441900
5.80577300
5.91042200
4.74208600
3.35880400
2.21144700
1.81843500
2.15011500
3.00813400
-1.44636900
-1.45959700
0.47362300
2.20836200
0.98482200
1.67012100
-8.88112500
-7.52977400
-8.61031000
-8.13062900
-6.93446500
-6.80839800
-5.61040300
-6.27541300
-5.07820000
-3.75239600
-4.95505500
-4.43835200
-3.28564100

-0.31543800
-5.01405300
-3.76034900
-3.37389400
-2.09129800
-1.68000800
-0.38893000
-0.02408000
0.85526000
1.64161300
3.16056300
3.87892700
3.44932900
4.99991100
5.80238700
5.66224200
4.20137500
4.07316600
2.61235300
1.78057300
1.66199900
2.41520800
1.47186400
0.69607300
1.21290900
-0.56277500
-1.46962600
-2.94927600
-3.45664600
-3.49344900
-3.96268400
-2.92784100
-2.77761400
-3.75429400
-0.78813500
0.97267100
0.99178200
0.83461900
-1.89759700
-1.70958700
-5.24501300
-5.82230300
-4.87376400
-2.97152600
-3.99063000
-3.20643900
-4.20295500
-1.26648400
-2.25894800
-2.49170800
-1.51349400
0.45573500
-0.52062300

1.16681300
-1.65216500
-2.08030900
-1.03226200
-1.45883600
-0.41826700
-0.85561600
0.06624700
1.07405700
1.53519700
1.69805700
0.35503700
-0.72906300
0.39181700
-0.79983700
-1.14489200
-1.43869100
-1.77308200
-1.97520500
-0.73604100
0.25869500
0.29847500
0.24960400
-1.07490600
-2.18431700
-1.01173500
-2.18529300
-1.73489000
-0.84237900
-1.54356900
-0.60877100
0.38986900
1.68053900
2.45317500
-0.12727100
1.72124300
-0.58195100
1.23962200
-0.14750300
2.29452100
-2.33645900
-1.57151400
-0.74509400
-2.20919500
-3.04969700
-0.06016700
-0.90598500
-1.59199400
-2.43509600
-0.29902500
0.56071400
-0.91665500
-1.83976600

204

H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
O
H
H
O
H
H

-4.66996200
-4.10558800
-2.70843200
-4.44304800
-2.15708700
-2.81399400
-2.43842400
-0.48282000
-0.08684700
-0.85319400
-0.48867900
1.47123000
1.84843600
2.76187500
1.10091400
3.91014700
3.88535300
5.08456800
5.99431000
6.03881600
4.92343900
6.68690600
5.98226400
6.85506000
4.68023000
4.98969900
3.09779600
3.39366200
2.49133100
1.30533900
3.90341100
2.44508100
3.31412500
-1.04210300
-1.79404300
-0.75630000
0.40828600
1.08472600
-0.29463000

1.47630500
1.23561600
3.33616700
3.60531200
5.26621900
5.45912300
6.85409800
6.30028000
6.06106500
3.80460600
3.57750400
4.61323400
4.54674300
2.57832600
2.09420800
3.13909300
2.97199400
0.77811300
2.09363500
-0.90403000
-1.30317600
-1.20488400
-3.56637800
-3.08535000
-2.83360900
-4.47270200
-2.50981200
-4.19500100
-4.87149900
-4.17426600
-3.23298900
-4.09484900
-4.61802800
-1.89677400
-2.30502300
-2.42380800
0.33028200
0.04595400
0.87558800

0.86334900
2.51728900
2.36024100
2.18204500
1.27935300
-1.63367800
-0.60240900
-2.01857000
-0.31177600
-2.27727600
-0.56453100
-2.70602900
-0.98186900
-2.32836200
-2.70726200
-0.51549600
1.24300100
1.09689700
0.34744300
-0.11724700
-2.81300900
-2.78710100
-2.64244500
-1.18613800
0.06141700
-0.49920600
-1.95587500
-2.39027700
-0.06863600
-1.18470900
2.81064700
3.32929000
1.86318500
2.25505600
1.78753600
3.02378600
3.33421000
3.97408600
3.73122600
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[ZrDFO(H2O)2]2+ with hydrogen bonded amine group, IIIa, CPCM
Zr
N
C
C
C
C
C
N
C
C
C
C
O
N
C
C
C
C
C
N
C
C
C
C
O
N
C
C
C
C
C
N
C
C
O
O
O
O
O
O
H
H
H
H
H
H
H
H
H
H
H
H
H

0.09593700
-1.23474300
-1.05209400
-0.39117200
1.07274400
1.40367100
2.51062700
2.14088800
2.94319600
4.43563100
5.29107600
5.54115500
5.64298200
5.68305300
5.91353300
4.62748600
3.45376800
2.19046600
0.97960300
0.36472900
-0.65286500
-1.36834900
-2.90634700
-3.51517700
-2.78294200
-4.86971400
-5.65543500
-6.51113400
-5.70246900
-4.80863500
-4.03089200
-2.88184700
-2.73986600
-3.86073200
0.74471800
2.35645600
0.87187000
-1.01425400
-1.70240800
-1.55489100
-0.33200500
-1.68779800
-1.81141600
-2.04658700
-0.44947800
-0.42222800
-1.02229100
1.78188400
1.23044900
0.49877200
1.74119800
2.68990800
3.44686700

-0.90110900
0.18668800
0.02372800
-1.33147000
-1.48431600
-2.93651300
-3.02668400
-2.27480500
-1.85243800
-2.15918900
-1.16062500
0.16232700
0.19610400
1.27741700
2.64446000
3.51744700
2.87046300
3.76378700
3.03699400
2.01353500
2.13705200
3.45542500
3.29020500
2.69444700
2.32005400
2.56645500
1.84928400
0.71491100
-0.35562400
-1.25661900
-2.34208200
-1.81054300
-1.68891800
-1.99669600
-2.12284800
-1.24031100
0.67988700
1.04848400
-1.54342500
-1.30782900
0.29000900
-0.63109300
1.01440400
0.09598300
0.87242700
-1.44906600
-2.13153900
-1.16350800
-0.81293300
-3.41436800
-3.54392100
-4.07582800
-2.59722200

-1.06389700
2.32465400
3.82895800
4.16965400
3.64369200
3.18761500
2.11129800
0.86456500
-0.12427500
-0.13330800
-0.94775300
-0.20353300
1.07932400
-0.97993000
-0.44456700
-0.45993900
0.31717300
0.39723800
1.03821700
0.14449800
-0.71725600
-0.96233000
-1.01857600
0.26354000
1.25498100
0.26643100
1.30311300
0.67344100
-0.11034000
0.78257500
-0.00664400
-0.79347000
-2.12193500
-3.09336800
0.60540400
-1.13743800
0.27861400
-1.37111100
-0.03037900
-2.56231500
1.83250200
1.89286200
2.08203000
4.27835500
4.16750500
5.26115400
3.75427200
4.42017700
2.79134100
2.79581200
4.03925500
1.84313400
2.48271400
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H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
O
H
O
H
H
H

4.81387300
4.54565800
4.84456600
6.27141900
5.56151700
6.28573500
6.69811200
4.88318700
4.32346400
3.78095700
3.19097200
2.40174100
1.90621700
0.19960700
1.28116400
-1.09004700
-1.03074700
-3.18877800
-3.35865100
-5.37598100
-4.94641900
-6.31287200
-7.08084200
-7.24987000
-5.08436100
-6.41315900
-4.09590400
-5.43956500
-4.69289100
-3.60191800
-3.56684900
-4.03192400
-4.79631500
0.48348200
-0.11465900
0.94682300
1.87673400
1.32648900
0.46760200

-2.22299800
-3.16007000
-0.97162500
-1.62531000
1.18299700
2.53662300
3.11777900
4.49493100
3.70310200
2.62876000
1.91936500
4.65383000
4.12330500
3.75056300
2.49978900
4.19024700
3.84663100
2.64531200
4.27167100
2.90149700
1.45876600
2.56327000
0.23694600
1.16960600
0.14297500
-0.99620300
-0.65426800
-1.78641200
-2.86822200
-3.08064600
-1.64017000
-3.07936100
-1.51562100
-2.87358900
-3.13169500
-0.10890200
-0.27168400
-3.36155600
0.41052000

0.88977200
-0.57562100
-1.92848400
-1.12215200
-1.98273000
0.57879700
-1.04737800
-0.02214900
-1.50217100
1.34062100
-0.16240500
1.00884100
-0.60281500
1.31714200
1.94297200
-0.20493000
-1.93151800
-1.85937600
-1.20759700
-0.54754600
2.03749600
1.81642100
1.48503400
-0.00435100
-0.87115600
-0.65478100
1.36008600
1.51201100
-0.70149700
0.67910400
-4.08233000
-3.14399000
-2.79713100
-2.23591000
-2.96146600
-3.00379200
-3.24683400
-2.26200800
-3.67354700
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ZrDFO(OH)2, IV, CPCM
Zr
N
C
C
C
C
C
N
C
C
C
C
O
N
C
C
C
C
C
N
C
C
C
C
O
N
C
C
C
C
C
N
C
C
O
O
O
O
O
O
H
H
H
H
H
H
H
H
H
H
H
H
H

-0.19003800
1.15924900
1.28625000
1.17770100
-0.18405400
-1.19014800
-2.08922800
-1.95581400
-2.89358500
-4.35426400
-5.36571300
-5.68593200
-5.87599400
-5.79307300
-6.08387400
-4.81850300
-3.66928500
-2.45196800
-1.22151900
-0.52168800
0.54068900
1.24393200
2.78433800
3.36396800
2.61648900
4.72241900
5.50210700
6.43668900
5.70950700
4.83429200
4.10626400
2.93699400
2.77970300
3.92024700
-0.60865400
-2.47987000
-0.99782600
0.97096800
1.76495700
1.59485500
0.18606400
1.62911900
1.59356000
2.27334100
0.53280600
1.92285800
1.50969700
0.06390600
-0.68589500
-0.64034400
-1.84421100
-3.14242100
-1.81445100

-0.46726400
-0.65663700
-1.49762200
-3.03804200
-3.74692800
-3.94678500
-2.71084300
-2.23114500
-1.79178400
-2.23342500
-1.26177800
-0.04272100
-0.17492600
1.16223000
2.44538800
3.32867800
2.59064700
3.49484600
2.69175700
1.95361700
2.33081200
3.66499400
3.53207600
2.55110900
1.85783900
2.44783900
1.43143200
0.63389300
-0.10291400
-1.29971000
-2.01688300
-1.26450200
-0.69394400
-0.62282300
-1.95796100
-1.06355800
0.63161700
1.49858600
-1.32670100
-0.21635500
-0.51653900
-1.08557400
0.27316400
-1.25921400
-1.13518600
-3.47813900
-3.29440400
-4.74947200
-3.22600400
-4.23174300
-4.79263900
-2.93598500
-1.86573200

1.46791600
-2.01812900
-3.28188000
-3.06642700
-3.37789200
-2.20241500
-1.89069400
-0.48876300
0.37439300
0.26642700
0.92457400
0.04524500
-1.22205400
0.68003300
-0.01057100
-0.19833000
-0.93007600
-1.25240400
-1.75628300
-0.66988600
0.05586600
-0.16098100
-0.11120500
-1.14696100
-1.93417000
-1.15022500
-1.90053200
-0.94844400
0.21103800
-0.24616100
0.92131400
1.45387500
2.66238500
3.66382400
-0.11767200
1.38694200
-0.40299600
0.98154500
0.63803900
2.96869700
-1.70303600
-1.19547300
-2.14646600
-3.68907200
-3.98848400
-3.74367800
-2.04999200
-3.75682300
-4.20941400
-1.29716900
-2.45456900
-2.07124100
-2.53655100
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H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
O
H
O
H

-4.63499900
-4.42294800
-5.01589400
-6.30827100
-5.59856300
-6.52107200
-6.83641100
-5.12079300
-4.46462200
-4.04880400
-3.33358800
-2.72431800
-2.15742600
-0.50149100
-1.52452900
0.93393200
0.93589200
3.10307100
3.23107200
5.23927000
4.78677800
6.10310700
7.00067100
7.17533300
5.09115800
6.46858700
4.09152800
5.47242600
4.79695600
3.71197800
3.63707300
4.09938300
4.85075700
-0.33366200
0.29281000
-1.11186900
-2.00801400

-2.40512300
-3.20422400
-0.94915500
-1.80800800
1.19876200
2.19926100
2.98504500
4.22405300
3.67658200
2.16104300
1.74880100
4.22036300
4.07638100
3.35619100
1.93612000
4.11993300
4.34846900
3.19680200
4.52215600
3.04294400
0.77645700
1.92925800
-0.08755500
1.32991400
0.61734100
-0.47317800
-0.98130600
-2.04930600
-2.20371700
-2.98309700
0.07138100
-1.61023100
-0.28190600
-2.11374700
-2.14752400
0.83771800
0.63861200

-0.77531500
0.77801000
1.91268300
1.06803600
1.67477100
-0.98301800
0.57743700
-0.76400300
0.78496200
-1.87051900
-0.31261400
-2.03400300
-0.36590400
-2.24121900
-2.48930700
-1.10375300
0.64219900
0.88324800
-0.26864800
-0.51021500
-2.40424900
-2.67325900
-1.55931400
-0.52138700
0.76674900
0.91736300
-0.98896500
-0.73830200
1.74961400
0.58508700
4.45788100
4.10867300
3.20196000
2.80329500
3.55369100
2.82302700
3.15853200
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3,4,3-(LI-1,2-HOPO)H4, CPCM
C
C
C
C
C
N
H
H
H
O
O
C
O
N
C
H
H
C
C
C
C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
C
C
C
C
C
N
H
H
H
O
O
C
O
N
C
H
H
C

-1.63787300
-0.36246600
0.40445300
-0.10086600
-1.41805600
-2.10981000
1.40029500
0.02856700
0.47201000
-3.41694100
-2.04376600
-2.59426400
-3.35936000
-2.57673900
-1.68970000
-2.28791800
-1.40104600
8.98027700
9.32743300
10.65212200
11.62653400
11.31150900
9.97901700
10.89792600
8.56552200
12.63681000
9.71345000
12.08209700
7.55677200
6.72881700
7.21316600
7.91074900
5.84932500
5.43364000
5.95226700
1.63804700
0.36275300
-0.40426600
0.10084900
1.41791800
2.10977300
-1.40002000
-0.02811100
-0.47210100
3.41678100
2.04343700
2.59452200
3.35974700
2.57691100
3.51289500
3.59854900
3.05973200
-8.98046200

-3.85791800
-4.17890200
-5.16251800
-5.80530400
-5.49385700
-4.51800900
-5.40942700
-3.68341800
-6.55004100
-4.18068800
-5.98078500
-2.92198100
-3.42833300
-1.60024500
-1.01009000
-0.27583800
-1.79334900
-1.19216800
-2.06891200
-2.06939300
-1.20053500
-0.28045600
-0.34168100
-2.76058200
-2.74040100
-1.18519100
0.59386200
0.59553000
-1.22122100
-2.05631000
-0.38230800
0.26302500
-0.34965100
-1.36218300
-0.05033300
3.85807300
4.17906000
5.16281400
5.80574400
5.49430100
4.51829200
5.40972000
3.68347400
6.55059200
4.18097200
5.98134400
2.92200000
3.42820700
1.60030700
0.67569300
1.00570000
-0.32059300
1.19204200

-0.60821300
-1.06558700
-0.36156800
0.76908400
1.26250300
0.50727600
-0.71834300
-1.94577200
1.31038600
0.98284200
2.29209200
-1.34023300
-2.24119000
-1.01968500
0.03197300
0.58416700
0.73868500
-0.32575500
-1.35543300
-1.89165100
-1.40432500
-0.34394300
0.13229600
-2.69220100
-1.72789200
-1.79728400
1.18299700
0.23037900
0.22244400
-0.29719400
1.23533000
1.59307200
1.81481400
1.78299400
2.86370200
0.60895900
1.06665600
0.36294000
-0.76772300
-1.26146300
-0.50653700
0.71996300
1.94685800
-1.30879300
-0.98244100
-2.29111500
1.34070000
2.24162800
1.01998600
1.73186000
2.77205500
1.72411100
0.32487500
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C
C
C
C
N
H
H
H
O
O
C
O
N
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
H
H
H
H

-9.32785900
-10.65262500
-11.62686900
-11.31159000
-9.97903000
-10.89862300
-8.56608100
-12.63720500
-9.71314200
-12.08201900
-7.55689000
-6.72905600
-7.21309800
-7.91058200
-5.84918700
-5.43357900
-5.95198200
4.91343400
4.81693800
5.35724100
1.68973000
1.40104800
2.28786200
0.42466400
-0.17451000
0.72067400
-0.42461000
0.17457000
-0.72059300
-3.51268600
-3.59819100
-3.05958400
-4.91331300
-4.81698200
-5.35703500
-3.50561700
-10.60355100
3.50530900
10.60397200

2.06911000
2.06963100
1.20049200
0.28005100
0.34125500
2.76107900
2.74082600
1.18518600
-0.59467000
-0.59620100
1.22109300
2.05632400
0.38203400
-0.26342600
0.34938400
1.36195100
0.04988800
0.63772000
0.32733200
1.64104800
1.01031200
1.79366000
0.27609200
0.33364100
1.08947700
-0.42275400
-0.33343300
-1.08928500
0.42295000
-0.67575500
-1.00588000
0.32055900
-0.63780200
-0.32726400
-1.64117000
-4.76919900
-1.05408300
4.76961600
1.05308500

1.35419500
1.89022500
1.40306600
0.34307000
-0.13299300
2.69049100
1.72651600
1.79587400
-1.18326700
-0.23105100
-0.22315400
0.29644700
-1.23585400
-1.59355700
-1.81517000
-1.78346600
-2.86402200
1.06485500
0.01643100
1.07929300
-0.03163900
-0.73824200
-0.58396800
0.55761600
1.08428500
1.29820900
-0.55724600
-1.08388500
-1.29786200
-1.73176900
-2.77193800
-1.72407100
-1.06494700
-0.01655300
-1.07930500
1.78868500
-1.27769000
-1.78820500
1.27741800
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3,3,3-(LI-1,2-HOPO)H4, CPCM
C
C
C
C
C
N
H
H
H
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O
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N
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C
N
H
H
H
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O
C
O
N
H
C
H
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C
C
C
C
C
N
H
H
H
O
O
C
O
N
C
H
H
C

-0.96116800
0.19362600
1.16164800
0.96877000
-0.21745500
-1.12149300
2.06307700
0.34113600
1.69504600
-2.30129400
-0.56015300
-2.12518300
-3.06190900
-2.11072900
-1.02768400
-1.51149400
-0.52397700
8.06955500
8.13559200
9.25064000
10.29478200
10.26805800
9.13068900
9.27851600
7.31982700
11.14909400
9.15189500
11.14486000
6.85984900
5.97108600
6.75638200
7.48823000
5.59731600
5.95718400
5.25661300
0.96157000
-0.19334300
-1.16123900
-0.96811200
0.21829900
1.12216400
-2.06279600
-0.34104700
-1.69432200
2.30216300
0.56118600
2.12545300
3.06211200
2.11098500
3.25995900
2.88830800
3.59312300
-8.07017200

-3.59363300
-3.80111100
-4.75251600
-5.47578000
-5.28177000
-4.32811100
-4.91139900
-3.24588300
-6.19830900
-4.10445800
-5.85559000
-2.71426700
-3.26259800
-1.39629200
-0.75441800
-0.05976700
-1.51820300
-0.85444400
-1.61203600
-1.48503600
-0.60586800
0.19279600
0.00810700
-2.08511500
-2.29013600
-0.49355300
0.81752400
1.05480500
-1.01481500
-1.88512900
-0.24367100
0.43207700
-0.32613000
-0.04131900
-1.36595200
3.59393100
3.80136900
4.75287800
5.47631400
5.28244600
4.32861400
4.91167400
3.24599100
6.19887900
4.10516400
5.85629800
2.71444100
3.26262200
1.39654400
0.53511700
-0.49093600
0.86292500
0.85394000

-1.48149300
-2.23137200
-1.77336500
-0.59589200
0.19831300
-0.32482200
-2.35825900
-3.14945900
-0.24054200
0.45372600
1.31268600
-1.92638600
-2.61518000
-1.58810200
-0.78040000
-0.08376700
-0.18118400
1.51869600
2.68971400
3.57438900
3.29452400
2.09778700
1.27330300
4.47891800
2.90142900
3.95250000
0.09310800
1.67523900
0.60341000
0.92849600
-0.51144500
-0.70909900
-1.43215700
-2.42704200
-1.47242400
-1.48196200
-2.23167500
-1.77362600
-0.59629300
0.19765300
-0.32546900
-2.35834400
-3.14964100
-0.24088400
0.45282800
1.31195900
-1.92694800
-2.61595200
-1.58837300
-2.00839400
-2.09361000
-2.99802200
1.51797700
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C
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C
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N
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
C
H
H
H
H
H
H

-8.13654900
-9.25182300
-10.29585700
-10.26879800
-9.13120200
-9.27995800
-7.32088000
-11.15033300
-9.15203600
-11.14542000
-6.86027300
-5.97162300
-6.75649200
-7.48820200
-5.59723700
-5.25666300
-5.95685100
4.43295100
4.80021100
4.07923300
1.02790400
1.51161900
0.52430800
0.00003900
0.51704400
-0.51706000
-3.25974900
-3.59278500
-2.88817900
-4.43284600
-4.07924800
-4.80004500
-10.01636300
-2.17056100
2.17175900
10.01622300

1.61146400
1.48435900
0.60516800
-0.19341700
-0.00865500
2.08438000
2.28960200
0.49276300
-0.81798100
-1.05549200
1.01448700
1.88479800
0.24344500
-0.43240600
0.32610500
1.36597300
0.04132700
0.60430800
1.63578800
0.30518300
0.75491400
0.06030700
1.51887000
0.00026800
-0.71891900
0.71950700
-0.53501400
-0.86293700
0.49106300
-0.60421500
-0.30498900
-1.63571500
-1.32102800
-4.73735900
4.73849400
1.32051800

2.68901600
3.57339600
3.29319800
2.09640800
1.27225800
4.47795500
2.90097900
3.95094500
0.09199400
1.67364000
0.60298600
0.92838300
-0.51191200
-0.70973200
-1.43236600
-1.47248100
-2.42735200
-0.99434600
-0.92451000
0.00079600
-0.78052700
-0.08378500
-0.18143700
-1.66463700
-2.31139600
-2.31126400
-2.00829600
-2.99793100
-2.09356300
-0.99437100
0.00078300
-0.92450500
0.20226300
1.21894200
1.21775400
0.20372300
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DFOH2, CPCM
N
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-2.21171500
-2.32889200
-0.95665800
-1.07442800
-0.89500300
-2.00182200
-1.97851300
-3.05025200
-4.46600700
-5.52624200
-5.29597200
-4.76358500
-5.73330100
-5.72239500
-4.56871000
-3.20274000
-1.99366400
-0.63746300
-0.45251900
-0.15539600
0.24806000
1.60581200
2.81716200
2.89392400
3.79741100
5.06199700
6.28366800
6.19538500
6.31736900
5.95704100
4.52330800
3.98162000
4.94963600
-0.68007900
-2.87492800
-0.78274900
-0.22235800
3.62279800
2.71571800
-1.48075700
-1.93632900
-3.12044300
-2.83524200
-2.98341600
-0.52491000
-0.25890200
-0.29201500
-2.03604000
0.06856500
-0.83310700
-1.88051600
-2.99388400
-4.49540400

1.03373600
2.54685100
3.24086700
4.55132200
4.39421900
3.67462900
2.18104800
1.32872600
1.89064400
0.76923400
-0.21255200
0.16833200
-1.48766100
-2.59117100
-3.61015400
-3.10285700
-3.95202800
-3.52346300
-2.03591200
-1.26454600
-1.86656000
-1.31338300
-1.80799600
-1.61978200
-2.44911000
-2.95686400
-2.04636600
-0.61196700
-0.56146300
0.81994400
1.17067700
2.28895200
3.26339700
1.63111300
0.08980100
-1.44345400
0.06229100
0.32022500
2.50843000
0.65255600
0.71658500
0.60128300
2.89812000
2.74593100
3.46849400
2.55545600
5.24765900
5.04601800
3.91074100
5.40597300
3.94305400
4.00905000
2.51381600

1.95342200
1.85768100
1.66407600
0.82508200
-0.71563500
-1.53369800
-1.44946300
-1.63267800
-1.41253700
-1.31415900
-0.15128000
0.96028800
-0.35233700
0.64703500
0.41810400
0.95056300
0.47648200
1.10963600
1.13880100
0.08238300
-1.26472400
-1.80482900
-1.01227900
0.26699100
-1.69852700
-1.10160200
-1.41475100
-0.82295200
0.72386500
1.32916100
1.12755900
0.53696600
-0.13953600
-1.78272500
-1.92028200
2.38425800
0.18564000
1.87080300
0.53422700
1.30306600
2.88497900
1.70638000
2.76185000
1.01121600
2.64805200
1.16623200
1.16042100
1.03838800
-0.92173800
-1.14435200
-2.59395400
-1.21676500
-0.51344200
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-4.72503100
-5.58560900
-6.50630400
-6.12125400
-5.65003400
-6.69109700
-4.83701300
-4.50333000
-3.23634500
-3.05189200
-2.15046900
-1.92379700
0.19995500
-0.59311100
0.28339600
-0.52612000
1.60167000
1.70432800
3.67469500
4.90264900
5.23854100
7.18118100
6.39939400
5.24669400
6.99595400
5.67780200
7.35031000
6.56250800
6.14665100
5.62529500
5.55821200
4.35499000
-0.44614300
3.31045700

2.54452500
0.21525900
1.24168400
-1.71209700
-2.14498800
-3.09932600
-4.55134000
-3.83381800
-3.08051100
-2.06657700
-5.01325200
-3.89086700
-4.00160500
-3.81727300
-2.95752500
-1.58854500
-0.21793100
-1.59370900
-2.57384000
-3.05249300
-3.95901300
-2.55562000
-1.98245200
-0.15037200
0.00155500
-1.32258000
-0.79236700
1.60979500
0.82141200
3.72184800
2.76579000
4.04759800
0.97108300
-0.40675900

-2.25657500
-2.25651700
-1.15496500
-1.26273100
1.64425800
0.56940800
0.92169300
-0.65818800
2.05029600
0.62215100
0.72527800
-0.61990900
0.58915400
2.16143400
-1.23028600
-1.99148000
-1.75118700
-2.85872700
-2.69806800
-0.02457200
-1.50963000
-1.03036400
-2.50717800
-1.13393100
-1.26391000
1.18885500
1.02415500
0.87799800
2.41080400
0.59221000
-0.90212500
-0.61266500
-1.01107800
1.23404200
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Figure A.4.9. Maximum intensity projection PET images
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10 min
Zr-HOPO

Zr-DFO

1h
Zr-HOPO

Zr-DFO

4h
Zr-HOPO

12 h
Zr-DFO

Zr-HOPO

Zr-DFO

24 h
Zr-HOPO

Zr-DFO

Blood

3.24 ± 0.66 5.11 ± 0.90 0.17 ± 0.10 0.10 ± 0.04 0.05 ± 0.04 0.03 ± 0.01 0.02 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.02 ± 0.02

Heart

1.57 ± 0.22 2.17 ± 0.62 0.12 ± 0.06 0.06 ± 0.02 0.06 ± 0.01 0.03 ± 0.01 0.06 ± 0.01 0.02 ± 0.00 0.07 ± 0.01 0.02 ± 0.01

Lung

1.07 ± 0.17 2.16 ± 1.08 0.17 ± 0.09 0.14 ± 0.04 0.08 ± 0.01 0.04 ± 0.02 0.06 ± 0.01 0.02 ± 0.01 0.09 ± 0.05 0.04 ± 0.01

Gall
6.61 ± 2.87 1.57 ± 0.25 6.94 ± 3.38 0.47 ± 0.14 1.00 ± 0.41 0.26 ± 0.15 2.45 ± 1.02 0.16 ± 0.14 1.15 ± 0.59 0.23 ± 0.21
Bladder
Liver

3.29 ± 0.75 0.88 ± 0.49 0.22 ± 0.09 0.24 ± 0.07 0.13 ± 0.01 0.12 ± 0.03 0.09 ± 0.02 0.06 ± 0.02 0.06 ± 0.03 0.11 ± 0.02

Spleen 0.31 ± 0.04 0.37 ± 0.22 0.09 ± 0.03 0.06 ± 0.02 0.06 ± 0.01 0.03 ± 0.01 0.05 ± 0.01 0.02 ± 0.01 0.06 ± 0.01 0.02 ± 0.01
Stomach 1.22 ± 0.39 0.62 ± 0.28 0.30 ± 0.15 1.10 ± 0.51 0.50 ± 0.74 0.06 ± 0.02 0.01 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.01 ± 0.01
Large
0.26 ± 0.15 0.43 ± 0.13 0.09 ± 0.06 0.02 ± 0.01 7.17 ± 2.15 0.62 ± 0.55 0.10 ± 0.03 0.07 ± 0.05 0.03 ± 0.02 0.02 ± 0.01
Intestine
Small
5.99 ± 1.18 0.94 ± 0.16 1.11 ± 0.35 0.35 ± 0.17 0.12 ± 0.13 0.04 ± 0.02 0.02 ± 0.01 0.01 ± 0.01 0.02 ± 0.00 0.02 ± 0.01
Intestine
Kidney 9.46 ± 2.71 14.44 ± 5.88 1.05 ± 0.51 1.39 ± 0.55 0.40 ± 0.14 1.10 ± 0.44 0.53 ± 0.23 0.36 ± 0.13 0.51 ± 0.29 1.12 ± 0.33
Bladder 2.04 ± 1.06 2.50 ± 0.48 0.73 ± 0.36 2.47 ± 1.30 0.58 ± 0.27 1.22 ± 0.77 0.54 ± 0.26 0.69 ± 0.31 0.28 ± 0.14 0.56 ± 0.41
Muscle 0.36 ± 0.06 0.73 ± 0.56 0.10 ± 0.03 0.02 ± 0.01 0.09 ± 0.06 0.01 ± 0.01 0.06 ± 0.01 0.01 ± 0.00 0.06 ± 0.01 0.01 ± 0.00
Bone

1.04 ± 0.44 0.43 ± 0.10 0.29 ± 0.09 0.07 ± 0.04 0.23 ± 0.12 0.04 ± 0.02 0.25 ± 0.07 0.03 ± 0.01 0.17 ± 0.03 0.06 ± 0.01

Tail

4.25 ± 1.46 5.13 ± 2.92 0.81 ± 0.34 0.26 ± 0.05 0.29 ± 0.18 0.14 ± 0.08 0.11 ± 0.04 0.13 ± 0.05 0.05 ± 0.01 0.08 ± 0.02

Table A.4.2. Full biodistribution data including all tissues collected. All values expressed as
%ID/g.
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10 min
Zr-HOPO

Zr-DFO

1h
Zr-HOPO

Zr-DFO

4h
Zr-HOPO

12 h
Zr-DFO

Zr-HOPO

Zr-DFO

24 h
Zr-HOPO

Zr-DFO

Blood

1.28 ± 0.39 2.71 ± 0.94 0.08 ± 0.03 0.04 ± 0.01 0.03 ± 0.01 0.01 ± 0.01 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.01

Heart

0.27 ± 0.02 0.33 ± 0.10 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00

Lung 0.13 ± 0.04
Gall 0.34 ± 0.29
Bladder
Liver 1.20 ± 0.09
Spleen 0.04 ± 0.01

0.30 ± 0.21 0.03 ± 0.01 0.02 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
0.13 ± 0.09 0.10 ± 0.16 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00
0.31 ± 0.10 0.10 ± 0.01 0.12 ± 0.02 0.04 ± 0.01 0.05 ± 0.02 0.04 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.05 ± 0.02
0.07 ± 0.02 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00

Stomach 0.67 ± 0.68 0.22 ± 0.10
Large 0.23 ± 0.11 0.41 ± 0.13
Intestine
Small 2.18 ± 1.25 0.43 ± 0.13
Intestine
Kidney 2.78 ± 1.57 6.11 ± 2.87

0.16 ± 0.08 0.66 ± 0.26 0.45 ± 0.50 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
1.05 ± 1.93 0.02 ± 0.00 6.53 ± 1.86 1.37 ± 1.58 0.11 ± 0.02 0.07 ± 0.04 0.04 ± 0.01 0.02 ± 0.01
0.77 ± 0.33 0.19 ± 0.13 0.35 ± 0.62 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
0.40 ± 0.20 0.57 ± 0.18 0.16 ± 0.07 0.44 ± 0.17 0.21 ± 0.10 0.14 ± 0.05 0.21 ± 0.12 0.46 ± 0.16

Bladder 0.08 ± 0.09 0.07 ± 0.04 0.01 ± 0.01 0.05 ± 0.03 0.01 ± 0.00 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.01 0.01 ± 0.00 0.01 ± 0.01
Muscle 0.04 ± 0.01 0.10 ± 0.10 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00
Bone

0.05 ± 0.04 0.02 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00

Tail

2.55 ± 0.95 1.74 ± 0.72 0.27 ± 0.05 0.12 ± 0.03 0.14 ± 0.07 0.07 ± 0.03 0.05 ± 0.01 0.07 ± 0.03 0.03 ± 0.01 0.04 ± 0.01

Table A.4.3. Biodistribution data without normalization. All values expressed as %ID.
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Blood
Heart
Lung
Gall Bladder
Liver
Spleen
Stomach
Large Intestine
Small Intestine
Kidney
Bladder
Muscle
Bone
Tail

10 min
0.01529
0.11823
0.09260
0.01283
0.00169
0.57396
0.14010
0.12945
0.03807
0.11012
0.46929
0.24602
0.03801
0.60666

1h
0.25713
0.16419
0.63237
0.01075
0.70805
0.19204
0.02319
0.04036
0.00781
0.39845
0.04248
0.00310
0.00481
0.02000

4h
0.27915
0.00164
0.00928
0.01512
0.63334
0.00677
0.18904
0.00384
0.30326
0.02181
0.17054
0.03876
0.01486
0.15382

12 h
n/a
0.00013
0.00042
0.00447
0.08529
0.00144
0.13398
0.37090
0.11353
0.24716
0.49863
0.00003
0.00090
0.47791

24 h
0.35592
0.00011
0.14603
0.02669
0.02658
0.00015
0.20703
0.34642
1.00000
0.03458
0.24675
0.00036
0.00088
0.03349

Table A.4.4. Calculated P values for the comparison of 89Zr-HOPO and 89Zr-DFO
biodistribution data. Multiple unpaired t tests were carried out using GraphPad Prism. Significant
values are shown in bold (P < 0.05).
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CHAPTER 5: APPENDIX

p-SCN-BN-HOPO synthetic scheme (Figure 5.3)
Compound 4 1H NMR (Figure A.5.1)
Compound 4 13C NMR (Figure A.5.2)
Compound 5 1H NMR (Figure A.5.3)
Compound 5 13C NMR (Figure A.5.4)
Compound 7 1H NMR (Figure A.5.5)
Compound 7 13C NMR (Figure A.5.6)
Compound 8 1H NMR (Figure A.5.7)
Compound 8 13C NMR (Figure A.5.8)
Compound 9 1H NMR (Figure A.5.9)
Compound 9 13C NMR (Figure A.5.10)
Compound 9 crude prep HPLC (Figure A.5.11)
Compound 9 pure analytical HPLC (Figure A.5.12)
Compound 10 1H NMR (Figure A.5.13)
Compound 10 13C NMR (Figure A.5.14)
Compound 10 HRMS (Figure A.5.15)
Compound 10 crude prep HPLC (Figure A.5.16)
Compound 10 pure analytical HPLC (Figure A.5.17)
Compounds 9 and 10 IR comparison (Figure A.5.18)
MALDI-TOF data (Table A.5.1)
Biodistribution data as %ID (Table A.5.2)
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Figure 5.3. Synthetic scheme for p-SCN-BN-HOPO. Reproduced here for reference for the
following characterization data.
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Figure A.5.1. Proton NMR of compound 4: (N1, N4, N9 – Tri-tert-butoxycarbonyl)-1,12-diamino-4,9-diazadodecane.
1

H-NMR (CDCl3, 400 MHz): δ 3.07-3.21 (m, 10H), 2.68 (t, 2H), 2.08 (bs, 2H), 1.59-1.70 (m,
4H), 1.41-1.46 (m, 31H).
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Figure A.5.2. Carbon NMR of compound 4: (N1, N4, N9 – Tri-tert-butoxycarbonyl)-1,12-diamino-4,9-diazadodecane.
13

C-NMR (CDCl3, 100 MHz): δ 156.04, 155.55, 79.48, 78.88, 46.80, 43.79, 38.76, 37.35, 32.46,
30.9, 28.42.

223

Figure A.5.3. Proton NMR of compound 5: tert-butyl(4-((tert-butoxycarbonyl)(3-((4nitrophenethyl)amino)propyl)amino)butyl)(3-((tert butoxycarbonyl)amino)propyl)carbamate.
H NMR (500 MHz, CDCl3): (mixture of rotamers)  8.10-8.09 (d, 2H), 7.36 (d, 2H), 3.28-2.58
(m, 20H), 1.80 (bs, 2H), 1.58 (bs, 2H), 1.38-1.36 (m, 27H).
1
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Figure A.5.4. Carbon NMR of compound 5: tert-butyl(4-((tert-butoxycarbonyl)(3-((4nitrophenethyl)amino)propyl)amino)butyl)(3-((tert butoxycarbonyl)amino)propyl)carbamate.
C NMR (500 MHz, CDCl3): (mixture of rotamers)  156.1, 155.9, 129.8, 123.9, 79.3, 78.7,
78.3, 49.85, 49.83, 49.80, 49.76, 49.72, 47.1, 47.0, 46.94, 46.91, 46.89, 46.86, 46.77, 46.72,
46.67, 46.60, 46.52, 46.46, 46.41, 46.38, 46.33, 46.27, 46.26, 46.23, 46.20, 45.69, 45.66, 44.28,
44.20, 43.88, 43.83, 43.78, 43.52, 43.47, 43.40, 43.38, 43.32, 37.76, 37.68, 37.64, 37.60, 37.56,
37.51, 37.48, 37.38, 34.45, 34.40, 34.15, 28.45
13
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Figure A.5.5. Proton NMR of compound 7: 1-(benzyloxy)-N-(3-(1-(benzyloxy)-6-oxo-1,6dihydropyridine-2-carboxamido)propyl)-N-(4-(1-(benzyloxy)-N-(3-(1-(benzyloxy)-N-(4nitrophenethyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2-dihydropyridine3-carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide.
H NMR (600 MHz, CDCl3): (mixture of rotamers)  8.16-7.25 (m, 20H), 7.19-4.86 (m, 16H),
3.82-2.06 (m, 25H), 1.84-0.63 (m, 8H)
1
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Figure A.5.6. Carbon NMR of compound 7: 1-(benzyloxy)-N-(3-(1-(benzyloxy)-6-oxo-1,6dihydropyridine-2-carboxamido)propyl)-N-(4-(1-(benzyloxy)-N-(3-(1-(benzyloxy)-N-(4nitrophenethyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2-dihydropyridine3-carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide.
13

C NMR (600 MHz, CDCl3): (mixture of rotamers)

longer scan in progress to improve

resolution
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Figure A.5.7. Proton NMR of compound 8: N-(4-(N-(3-(N-(4-aminophenethyl)-1-(benzyloxy)2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-1-(benzyloxy)-2-oxo-1,2-dihydropyridine-3carboxamido)butyl)-1-(benzyloxy)-N-(3-(1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2carboxamido)propyl)-6-oxo-1,6-dihydropyridine-2-carboxamide.
H NMR (600 MHz, DMSO-d6): (mixture of rotamers)  8.70-8.64 (m, 1H), 7.44-7.33 (m, 27H),
6.93-6.89 (m, 1H), 6.89-6.80 (m, 3H), 6.64-6.62 (m, 4H) , 6.31-6.10 (m, 4H), 5.38-5.26 (m, 5H),
5.04-4.99 (m, 3H), 3.60-3.55 (m, 18H), 3.16-3.13 (m, 14H), 1.76-1.21 (m, 10H)
1
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Figure A.5.8. Carbon NMR of compound 8: N-(4-(N-(3-(N-(4-aminophenethyl)-1-(benzyloxy)2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-1-(benzyloxy)-2-oxo-1,2-dihydropyridine-3carboxamido)butyl)-1-(benzyloxy)-N-(3-(1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2carboxamido)propyl)-6-oxo-1,6-dihydropyridine-2-carboxamide.
C NMR (600 MHz, DMSO-d6): (mixture of rotamers)  158.77, 158.70, 158.28, 158.25,
158.18, 158.14, 155.63, 155.30, 155.27, 155.09, 155.06, 155.03, 141.89, 141.63, 141.60, 140.70,
140.59, 140.51, 136.82, 136.77, 136.64, 131.65, 161.41, 131.38, 131.35, 127.49, 127.44, 127.38,
127.29, 126.97, 126.87, 126.27, 126.23, 126.20, 120.31, 120.35, 119.75, 117.81, 115.46, 113.1,
101.62, 100.26, 100.1, 76.16, 76.10, 59.81, 52.71, 45.56, 45.49, 43.71, 43.47, 43.31, 41.3, 39.83,
39.65, 34.51, 34.45, 34.18, 34.11, 31.09, 29.71, 25.62, 24.36, 23.29, 22.73, 22.54, 22.43, 21.75,
21.38, 21.29
13
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Figure A.5.9. Proton NMR of compound 9: 4-(11,15-bis(1-hydroxy-2-oxo-1,2-dihydropyridine3-carbonyl)-1-(1-hydroxy-6-oxo-1,6-dihydropyridin-2-yl)-6-(1-hydroxy-6-oxo-1,6dihydropyridine-2-carbonyl)-1-oxo-2,6,11,15-tetraazaheptadecan-17-yl)benzenaminium
chloride.
H NMR (500 MHz, CDCl3): (mixture of rotamers)  7.44-7.28 (m, 5H), 7.20-7.16 (dd, J1, J2=6
Hz, 1H), 7.08-7.01 (m, 2H), 6.54-6.53 (m, 4H), 6.33-6.32 (m, 3H) , 6.18-6.21 (m, 0.5H), 5.745.67 (m, 0.5H), 3.65-3.51 (m, 4H), 3.51-3.16 (m, 8H), 3.12-2.70 (m, 11H), 1.91-1.38 (m, 10H)
1
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Figure A.5.10. Carbon NMR of compound 9: 4-(11,15-bis(1-hydroxy-2-oxo-1,2dihydropyridine-3-carbonyl)-1-(1-hydroxy-6-oxo-1,6-dihydropyridin-2-yl)-6-(1-hydroxy-6-oxo1,6-dihydropyridine-2-carbonyl)-1-oxo-2,6,11,15-tetraazaheptadecan-17-yl)benzenaminium
chloride.
C NMR (500 MHz, CDCl3): (mixture of rotamers)  158.8, 158.6, 158.4, 158.1, 157.9, 157.8,
157.77, 157.73, 142.5, 142.49, 142.45, 142.41, 142.32, 142.24, 142.04, 138.10, 138.0, 137.59,
137.51, 130.36, 130.31, 130.18, 130.08, 119.76, 119.45, 117.5, 115.6, 104.3, 102.5, 102.47,
102.41, 50.01, 48.12, 47.9, 46.0, 46.0, 43.7, 42.3, 37.2, 37.0, 36.97, 33.80, 32.65, 32.49, 28.16,
26.90, 26.23, 25.4, 25.4, 25.2, 25.1, 24.4, 24.3, 24.3, 24.2
13
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Figure A.5.11. Crude compound 9 HPLC chromatogram. The crude product was purified by
HPLC on a preparative C18 column (Waters Symmetry C18 Prep Column, 100Å, 5 µm, 19 mm X
100 mm) at 17.059 mL/min using a gradient of 10-23% MeCN in water (both containing 0.1%
TFA) with an initial hold at 10% MeCN for 1.33 mins and then a ramp to 23% MeCN over 20
minutes. The product peak was collected from 6.45-8.26 min and the eluted solution was lyophilized
to recover the product as an off white solid.
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Figure A.5.12. Purified compound 9 HPLC chromatogram. The purified sample was confirmed
by HPLC on a analytical C18 column (Waters Symmetry C18 Prep Column, 100Å, 5 µm, 4.6 mm
X 100 mm) at 1 mL/min using a gradient of 10-30% MeCN in water (both containing 0.1% TFA)
with an initial hold at 10% MeCN for 1.33 mins and then a ramp to 30% MeCN over 30 minutes
followed by a ramp to 95% MeCN over 1 minute and an isocratic hold at 95% MeCN for 5.66
minutes.
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Figure A.5.13. Proton NMR of compound 10: 1-hydroxy-N-(3-(1-hydroxy-6-oxo-1,6dihydropyridine-2-carboxamido)propyl)-N-(4-(1-hydroxy-N-(3-(1-hydroxy-N-(4isothiocyanatophenethyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2dihydropyridine-3-carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (p-SCN-BnHOPO).
H NMR (500 MHz, CDCl3): (mixture of rotamers)  7.37-7.31 (m, 7H), 7.12-7.08 (m, 1H),
6.58-6.52 (m, 4H), 6.34-5.81 (m, 4H), 3.62-3.54 (m, 12H) , 3.13-2.83 (m, 11H), 2.01-1.24 (m,
11H)
1
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Figure A.5.14. Carbon NMR of compound 10: 1-hydroxy-N-(3-(1-hydroxy-6-oxo-1,6dihydropyridine-2-carboxamido)propyl)-N-(4-(1-hydroxy-N-(3-(1-hydroxy-N-(4isothiocyanatophenethyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2dihydropyridine-3-carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (p-SCN-BnHOPO).
C NMR (500 MHz, CDCl3): (mixture of rotamers)  161.78, 161.71, 161.54, 161.4, 160.65,
160.61, 157.89, 157.83, 157.78, 157.73, 142.59, 142.48, 142.41, 142.33, 142.31, 142.21, 139.58,
138.49, 138.90, 138.81, 138.17, 138.0, 137.57, 137.50, 134.07, 130.76, 130.74, 130.59, 130.52,
128.89, 128.66, 126.41, 126.32, 119.74, 119.53, 119.43,104.33, 102.50, 102.39, 49.62, 48.11,
47.96, 46.49, 46.01, 45.70, 37.24, 37.01, 36.96, 34.04, 32.83, 32.71, 28.15, 27.12, 26.85, 26.22,
25.46, 25.26, 25.17, 24.36, 24.18
13
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Figure A.5.15. HRMS spectra of compound 10: 1-hydroxy-N-(3-(1-hydroxy-6-oxo-1,6dihydropyridine-2-carboxamido)propyl)-N-(4-(1-hydroxy-N-(3-(1-hydroxy-N-(4isothiocyanatophenethyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2dihydropyridine-3-carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (p-SCN-BnHOPO).

236

4
3.5

Absorbance (AU)

3
2.5
2
1.5
1
0.5
0
0

5

10

15

20

25

Retention Time (min)

Figure A.5.16. Crude compound 10 HPLC chromatogram. The crude reaction solution was
directly purified by HPLC on a preparative C18 column ( Waters Symmetry C18 Prep Column,
100Å, 5 µm, 19 mm X 100 mm) using a gradient of 5-75% MeCN in water (both containing 0.1%
TFA) with an initial hold at 5% MeCN for 1.33 mins and then a ramp to 75% MeCN over 30
minutes. The product peak was collected from 15.01-15.5 min and the eluted solution was
lyophilized to recover the product as a white solid.
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Figure A.5.17. Purified compound 10 HPLC chromatogram. The purified sample was confirmed
by HPLC on a analytical C18 column (Waters Symmetry C18 Prep Column, 100Å, 5 µm, 4.6 mm
X 100 mm) at 1 mL/min using a gradient of 5-75% MeCN in water (both containing 0.1% TFA)
with an initial hold at 5% MeCN for 1.33 mins and then a ramp to 75% MeCN over 30 minutes
followed by a ramp to 95% MeCN over 1 minute and an isocratic hold at 95% MeCN for 5.66
minutes.
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Figure A.5.18. Comparison of infrared spectra for compounds 9 and 10. The blue spectrum is
from compound 9 and the red spectrum is from compound 10. The major difference between the
compounds is the formation of the isothiocyanate group from the amine and this change can be
seen in the appearance of the corresponding band at ~2,100-2,200 cm-1.
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Trastuzumab

DFO-Trastuzumab

HOPO-Trastuzumab

1

147995.6

147912.7

150494.7

2

147637.3

147933.3

149203.8

3

147740.2

147949.1

149101.9

Average

147791.0333

147931.7

149600.1333

Std Dev

184.4796556

18.25267104

776.3910376

Differences

140.6666667

1809.1

Chelator Mass

750

911

Chelate Number

0.187555556

1.985839737

Table A.5.1. MALDI-TOF data for determination of chelate number. Mass values shown in
amu. These data were found unusable due to the large inconsistencies in the measured mass
values for the antibody constructs with respect to the masses of the individual chelators.
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Table A.5.2. Biodistibution data with values expressed as %ID.
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